Studies in the synthesis of azasteroids. by Chaudhri, Farhat
        
University of Bath
PHD








If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 11. May. 2021
(ij
STUDIES IN THE SYNTHESIS OF
AZASTEROIDS
Submitted by 
FARHAT CHAUDHRI, M.Sc. 
for the degree of Ph.D. 
of the University of Bath 
1982
COPYRIGHT
Attention is drawn to the fact that copyright of this thesis 
rests with its author. This copy of the thesis has been 
supplied on condition that anyone who consults it is understood 
to recognise that its copyright rests with its author and that 
no quotation from the thesis and no information derived from it 
may be published without the prior written consent of the author.
This thesis may not be consulted, photocopied or lent to 
other libraries without the permission of the author for 
two years from the date of acceptance of the thesis.
ProQuest Number: U641809
All rights reserved
INFORMATION TO ALL USERS  
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest.
ProQuest U641809
Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States Code.
Microform Edition ©  ProQuest LLC.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
UNIVERSITY OF BATH 
LIBRARY
% 1 8 MAY 1982
(ii)
Science is the great antidote to the 




I would like to thank Professor R.T. Parfitt for his advice, 
encouragement and invaluable discussions throughout the course 
of this work.
I thank the Science Research Council and Organon 
Laboratories for financial assistance for a period of 
two years and also Bath University.
My thanks are due to the technical staff at Bath University 
and Organon Laboratories for the recording of spectra, etc.
I wish also to thank the members of the academic staff 
of the Department of Pharmacy at Bath University, especially 
Drs. G.H. Dewar, C.Upton and D. Harcourt, and Drs. D. Savage 
and J. Redpath from Organon Laboratories.
I thank the typists Mrs. T. Evans and Mrs. J. Harbutt 
for typing of the manuscript.
(iv)
SYNOPSIS
This project involved the synthesis of azasteroids with 
potential GABA (y-aminobutyric acid)-mimetic activity.
Several methods leading to the formation of azasteroids 
were employed.
The Diels-Alder reaction of isoquinoline-derived dienes 
with suit^le dienophiles furnished several adducts, some of 
which were tested for biological activity. An unusual double 
Diels-Alder reaction was observed for some cases i.e. one 
equivalent of the diene reacted with two equivalents of dieno- 
phile to give a "di-adduct". A possible mechanism for this 
reaction is discussed in Chapter Five.
Many diaza-steroid intermediates were prepared from 
quinazoline derivatives. These, together with their mechanistic 
features are discussed in Chapter Six.
The condensation reaction of hydroxy-naphthaldehydes 
with guanidine afforded benzoquinazolines. Reaction of a 
benzo[f]quinazoline with chloroacetyl chloride, followed 
by cyclization resulted in the formation of a tri-azasteroid.
These reactions are discussed in Chapter Seven.
The experimental details of the syntheses of 'aza-steroids' 
and their intermediates, fron isoquinoline-, quinazoline-, 
and naphthalene-derivatives are given in Chapters Nine, Ten 
and Eleven, respectively.
(V)
Results obtained for the biological activity tests of 
some 'aza-steroids', are discussed in Chapter Eight. Potential 
future studies are also mentioned in Chapter Eight.
Concise reviews of y-aminobutyric acid, azasteroids, 
isoquinolines and quinazolines, pertinent to this project 
together with background material are given in Part One of 
the thesis. Chapters One, Two, Three and Four, respectively.
A large number of references, necessary for the reviews 
contained in Part One, are provided.
(Vi)
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I N T R O D U C T I O N  
OBJECTIVES AND RATIONALE
It has been known for some time that the guanidinium
moeity^^^ plays a decisive role in the blocking of sodium
channels^^^ and thus preventing the conduction of the nerve
impulse. Compounds such as Tetrodotoxin (380) and Saxitoxin
529(See Chapter 4, p.116 ) are potent neurotoxins.
The aim of this project was to investigate synthetic
methods leading to the formation of steroid-type molecules
containing the amidinium or guanidinium groups, with potential
28GABA-mimetic activity. y-Aminobutyric acid (GABA) is a 
central inhibitory neurotransmitter (See Chapter 1). The 
design of a suitable GABA-mimetic drug must be aimed at obtaining 
a compound which is less basic than guanidine but more basic 
than GABA itself. Since GABA is a weaker base than guanidine, 
it binds relatively weakly to the receptor site and thus is 
an ideal competitor to calcium ions for the receptor site.
Binding affinity of the receptor site is influenced by the 
basicity of the molecule, i.e. the more basic a molecule, the 
greater will be its binding force to the receptor site.
-<„ > "̂2 > - C >  A "
Increasing basicity 
 >
Increase in binding strength
The 'steroid* skeleton was employed as a rigid framework, into 
which were incorporated the appropriate functional groups.
Theoretically, the quinazoline nucleus is an ideal starting 
point for the synthesis of 'steroidal' structures with potential 
GABA-mimetic activity. The two nitrogen atoms are arranged in such 
a manner that they need not be replaced, nor is there a necessity 
to introduce any further nitrogen atoms during the completion 
of the synthesis. Synthetic methods were extended to involve 
the benzo [f ] quinazolines as, precursors to the desired 
products. Reports by Caromna^^^ and others of syntheses of 
azasteroid - intermediates from isoquinoline derivatives (for 
example, see below), prompted the investigation into synthetic 
methods leading to azasteroids with potential pharmacological 
activity, from isoquinoline derived intermediates. Several 
steroid-type compounds were synthesized, some of which were 




C H A P T E R  O N E  
REVIEW OF Y-AMINOBUTYRIC ACID
1. V-Aminobutyric acid as a neurotransmitter
Y-Aminobutyric acid (GABA)(1) is now widely accepted as a 
principal central nervous system (CNS) inhibitory transmitter. 
Although the role of GABA in brain function is hot fully under­
stood, it is however realised that GABA participates in human 
motor co-ordination, endocrine function and higher integrative 
cortical function. Thus, disorders such as Huntington's Chorea, 
Parkinsonism, epilepsy, spasticity and schizophrenia probably 
arise due to a malfunction of the GABA system. A large number 
of drugs, including the barbiturates, benzodiazepines, diphenyl 
hydantoins and some antipsychotic neuroleptics, have been shown 
to facilitate GABA neurotransmission.
1.1 History
GABA was identified as an important brain constituent only
relatively recently, owing to the fact that it is not found in
1,2any significant amount in other tissues. Its functional role
3,4as an inhibitory transmitter became apparent when Elliott et al. 
identified GABA as the active agent in brain extracts which had a 
unique inhibitory action on crayfish stretch-receptors.^ The 
powerful inhibitory effect of GABA on crustacean stretch-receptors 
and muscle was later shown to be indistinguishable from synaptic 
i n h i b i t i o n . W i t h  the further evidence obtained by demonstrat­
ing that GABA is selectively released by stimulating inhibitory






























nerve fibres, it became probable that GABA is an inhibitory
otransmitter in crustaceans.
Hayashi, in 1955, first noted the inhibitory effect
produced by GABA on mammalian cortical neurones. A depressant
9 10action was also observed by Purpura ejk and Curtis et al..
but neither group believed that GABA could be responsible for the
natural inhibition of central neurones. However, further tests
on the cerebral and cerebellar cortex revealed such a powerful
inhibitory effect that GABA could not be ignored as a putative
inhibitory transmitter.^^ Intracellular recording and studies
12on membrane resistance, later demonstrated a remarkable 
similarity between the effects produced by synaptic inhibition 
and by GABA. In both cases, there was a hyperpolarisation, with 
a similar reversal level, and a great decrease in membrane 
resistance, attributable chiefly to an increase in chloride ion
permeability.
1.2 Metabolism of GABA
Hie production of GABA from glutamic acid is mediated by a 
highly specific enzyme, glutamic decarboxylase (GAD), which 
requires pyridoxal phosphate as coenzyme, and is inhibited by 
semicarbazide and hydroxylamine. GAD is also inhibited by 
chloride ions, so that an increase in the chloride ion content in 
inhibitory cells, resulting from intense activity, could sub­
stantially reduce the rate of production of GABA.
6.
GABA-cimino-transferase (GABA-T) is another important enzyme 
involved. By reversible transamination with a-oxoglutarate, it 
converts GABA to succinic semialdehyde, which, in the presence of 
an appropriate dehydrogenase, is oxidised to succinic acid. 
Succinic acid is required by the tricarboxylic acid (TCA) cycle, 
and so GABA is conveniently removed by this route (see Scheme 1).
An alternative pathway leading to the production of GABA is 
via the oxidative decarboxylation of arginine resulting in 
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1,3 Structure of GABA
GABA is a flexible molecule, X-ray crystallography 
indicates that GABA in the solid state, exists in a partially 
folded conformation,16 while proton magnetic resonance studies^? 
favour extended conformations for GABA in solution. There is 
also evidence for extended conformations of GABA under in vivo 
conditions,^® This amino acid exists as a zwitterion at 
neutral pH and pK values of 4,03 and 10,27 at
1,4 Localization of GABA in Brain
GABA occurs in mammals in appreciable amounts only in the CNS, 
with the highest levels in the substantia nigra and globus 
pallidus, GABA is too powerful an inhibitor to be freely dis­
tributed in the extracellular space of the brain. When GABA is 
injected inside neurones, it does not alter their excitability,^® 
therefore it could be stored within cells. In fact, most of the 
GABA in the brain is probably actively stored in an intracellular 
compartment. Fluid left in contact with the surface of the brain 
contains at most only treices of GABA, Slices of cerebral cortex 
absorb GABA, even against a very high concentration gradient.
This active process requires the expenditure of energy, and is 
therefore blocked by metabolic inhibitors.
While it is generally accepted that systemically administered 
GABA does not raise levels in the brain, subcutaneous injection 
of large doses (60 pmole/g) increases the brain levels in mice,^^
10.
The concentration of GABA in the brain can be altered by a 
variety of drugs, many of which inhibit GABA-metabolizing 
enzymes.
Although GABA itself is not incorporated into protein, it 
does stimulate protein synthesis in cell free extracts of 
immature rat brain.
Histochemical methods can be used for the localization of 
GABA^^ in the brain. Use has also been made of the distribution 
of radiolabelled thiosemicarbazide as an indicator of GABA meta­
bolism.^®
1.5 GABA as a Neurotransmitter
Increasing evidence has been obtained to suggest that amino 
acids are involved in chemical synaptic transmission, by subjecting 
the amino acids to the criteria established for neurotransmitters 
such as acetylcholine (ACh) and the catecholamines:-
i) their concentration relative to other regions of the nervous 
system must be high; 
ii) the enzyme(s) involved in their synthesis must show a high 
activity;
iii) the nerve endings must possess a selective high affinity 
uptake mechanism.
All those presynaptic characteristics would then diminish or 
disappear when the terminals degenerate following a lesion of the
11.
afferent neuron or axon. Also, the transmitter substance should 
be released from the nerve terminals, either through the effect 
of high concentration or drugs such as veratridine, or through 
electrical stimulation.
Evidence for GABA as a neurotransmitter
The evidence for certain amino acids as synaptic transmitters 
includes information about :-
I the synthesis and storage within presynaptic nerve cells,
II the release from presynaptic terminals,
III the interaction with receptors on the postsynaptic neurones 
and the consequent transient alterations in ionic permeab­
ility of the subsynaptic membrane,
IV the ability of certain substances to antagonise both amino 
acid- and synaptically-induced postsynaptic effects, 
and V the processes associated with the inactivation and removal 
of amino acids from the synaptic environment.
Experimental difficulties abound in all aspects of these invest­
igations, since lists of criteria for transmitter identification 
were originally drawn up on the basis of experience regarding the 
transmitter function of acetylcholine at vertebrate neuromuscular 
and ganglionic synapses.
1.5.1 I Synthesis and Storage in Presynaptic Terminals
Consideration of GABA as a central transmitter originated 
from its presence in vertebrate brain tissue,^4 and studies of the
12.
gross distribution of GABA, GAD and GABA-T have been of prime 
significance in establishing the importance of this amino acid. 
More specific and detailed information has been provided using 
microdissection and microanalytical techniques; such investig­
ations providing, for example, a measure of the amounts of GABA 
cind GAD within synaptic t e r m i n a l s . I n  both the spinal cord 
and cuneate nucleus depletion of GABA by the administration of 
agents which inhibit GAD, leads to a reduction of GABA-mediated 
inhibitions. The convulscint effects produced by these agents 
may also be related to the reduced amount of GABA available for 
synaptic release in these and other regions. Cytochemical 
techniques, including autoradiographical localization of labelled 
GABA within synaptic terminals after in vivo or in vitro uptake, 
are being employed. Also, the immunohistochemical visualization 
of GAD has been an indicator of synaptic sites of GABA synthesis.
1.5.2 II Synaptic Release of GABA
Owing to the large number of problems involved in demonstrat­
ing in vivo the synaptic release of any central transmitter, very 
few studies have shown that impulses in a putative gabergic path­
way release GABA.®® Although a Ca®"'‘-dependent release of GABA 
can be induced in vitro from tissue slices or synaptosomes, by 
electrical 'stimulation* or increased concentration, this 
release is difficult to relate to that occurring synaptically 
in vivo, except where the degeneration of a pathway does or does
13,
not influence the release in vitro from slices prepared from
27the relevant region of the CNS.
1.5.3 III Postsynaptic Action of GABA
Microelectrophoretic methods have established two central 
actions of GABA and close analogues:-
a) hvperpolarization of neurones produced by an increase in 
membrane permeability to Cl“ (and possibly also K^) which 
appears identical to the permeability increase induced at
OQinhibitory synapses, and also by 'glycine-like* amino acids, 
and
b) depolarization of primary afferent terminals which, although 
also associated with an increased permeability to Cl”, is not 
produced by 'glycine-like* amino acids.®®
These : effects establish a relationship between GABA and post­
synaptic (hyperpolarizing) inhibition, and also between GABA and 
presynaptic inhibition. The former required additional use of 
specific antagonists of the action of GABA,to exclude the involve­
ment of 'glycine-like* amino acids as transmitters.
Under in vitro conditions, GABA binds in a sodium-independent 
manner to synaptic membrane fractions of mammalian brain at sites 
which ccin be distinguished by substrate specificity from those 
associated with the sodium-dependent membrane transport of this 
and related amino acids.
14.
1,5.4 IV Postsynaptic Antagonists of G ABA
Since the pcstsynaptic effects of * glycine-like* and 
*GABA-like* amino acids appear identical, specific antagonists 
of these two classes of inhibitory amino acid have been required 
to distinguish glycine- from GABA-raediated synaptic processes.
Inhibitions sensitive to low strychnine concentrations are 
regarded as being mediated by a * glycine-like * amino acid; 
whereas (+)-bicuculline methochloride, (+)-bicuculline and 
picrotoxin block both the hyperpolarizing effect of *GABA-like* 
amino acids on neurones and the depolarization of primary 
afferent terminals. Thus, GABA can be accepted as the most 
probable transmitter when a synaptic process can be suppressed 
or reduced by bicuculline, but is not affected by strychnine.
1.5.5 V Inactivation and Removal of Synaptically Released GABA
In view of the predominantly intracellular location of GABA- 
metabolizing enzymes, the factors involved in the removal of 
synaptically released GABA from the extracellular environment 
appear to be diffusion and carrier-mediated cellular uptake into 
neurones, terminals and glial cells. There is no evidence to 
suggest that GABA is inactivated enzymically in the extracellular 
synaptic environment. Uptake by synaptic terminals could 
provide a supply of transmitter for re-use. Both low- and high- 
affinity transport mechanisms have been identified;^® the former 
is significant when subsynaptic concentrations of GABA are
15.
relatively high immediately after synaptic release, whereas
the latter is most important for maintaining very low esxtra-
cellular concentrations of the amino acid.
Under in vitro conditions a number of compounds inhibit
GABA uptELke, and the receptor sites differ from those associated
31with the postsynaptic action of GABA, Also, these substances, 
particularly (+)-2,4-diamihobutyric acid, (-)-nipecotic acid, 
guvacine and arecaidine, selectively enhance and prolong the 
effects of micro-electrophoretic GABA in vivo.
An important characteristic of GABA-mediated inhibitions is 
the enhancement and prolongation by anaesthetics, particularly 
by the barbiturates which also similarly influence the effect of 
micro-electrophoretic GABA but not that of glycine.
1.6 Mechanism of GABA Action
GABA produces an increase in membrane permeability to 
chloride ions which can be measured as an increase in membrane 
conductance. It is in this manner that this naturally occurring 
transmitter can counteract the depolarizing action of excitatory 
processes, to maintain the polarization of a cell at an equilibrium 
level near that of its resting value, acting essentially as a 
chemical voltage clamp. GABA can exert a hyperpolarizing 
(inhibitory) effect via this mechanism. However, when the intra­
cellular chloride ion concentration is high, GABA can produce a 
decrease in membrane potential (depolarization), a mechanism 
involved in presynaptic inhibition (see Figure 1).
16.
Much evidence suggests that GABA-anionophore complexes
exist in some excitable membranes which function in such a
manner that, when GABA or a suitable agonist attaches to the
GABA recognition site, anion channels are opened for a period
during which GABA is attached to such sites. Recent work
suggests that convulsants such as picrotoxin, bicuculline,
penicillin and pentylenetetrazole, and the anticonvulsants such
as diphenylhydantoin, diazepam and phenobarbitone, decrease or
32 33increase, respectively, the efficacy of GABA synapses. *
GABA acts on its receptor in the extended form^l*^^ (gee 
Figure 2). The atoms which protrude from the surface and might 
be the first ones to hit a membrane surface that would be 
approached by the faces of the molecules, are shaded. This is 
the surface of GABA, a receptor site would recognise. Figure 3 
shows a comparison of "binding site" faces for GABA and two of 
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Figure 3
GABA Muscimol Imidazoleacetic acid
18.
Figure 4

















GABA appears to be involved in the development of certain 
neurological and psychiatric disorders such as Huntington's 
Chorea, Parkinson's disease and schizophrenia. These diseases 
may be treated by pharmacological manipulation of the GABA 
mediated synaptic mechanisms by employing agents which spec­
ifically interact with or increase neurotransmitter function.
Hie 'active conformations' of GABA with respect to its pre- 
and post-synaptic receptors can be elucidated via structure- 
activity studies on compounds of semirigid structure which mimic 
the activity of GABA on its receptors. Such compounds are of 
great pharmacological interest and may be model compounds for the 
development of therapeutically useful GABA agonists. Muscimol 
(5-amino-methyl-3-isox2izolol)^^*^^and trans-ACA (trans-4-amino- 
crotonic acid)^® are powerful GABA agonists with respect to 
bicuculline-sensitive GABA receptors. Both muscimol and trans- 
ACA have a lower conformational mobility thcin GABA, as shown by 
the rotational freedom round carbon-carbon single bonds (see 
Figure 4), Whereas trans-ACA is a potent inhibitor of GABA 
uptake®® and also a substrate for GABA-T muscimol is an almost 
specific GABA agonist, being only a weak inhibitor of GABA uptake/*^ 
Using microelectrophoretic techniques, a series of isoxazole 
derivatives related to muscimol have been tested as GABA agonists 
on single neurones by Krogsgaard-Larsen et al,,^®*^^ using the 
procedure described by Enna and Snyder,^® (Tables 1 and 2 show 
the potency of muscimol analogue^as inhibitors of H-GABA binding.
20.
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—4stated as % inhibition when tested at concentrations of 10 M; 
and as depressants of neuronal firing compared to that of GABA.)
It has recently been shown that unilateral injection of GABA 
into the caudal part of substantia nigra, induces contralateral 
turning in rats. This effect can be mimicked by small amounts 
of three GABA-ergic drugs:- muscimol, baclofen, and imidazole­
acetic acid^^ (see Table 4),
1.8 GABA Inhibitors
There are four main types of GABA inhibitors:-
(i) Inhibitors of GABA synthesis;
(ii) ” " *' degradation;
(iii) *’ ” ” uptake;
(iv) ” ” ” release.
1.8.1 Inhibitors of GABA Synthesis
The main metabolic pathway of GABA synthesis involves the 
decarboxylation of L-glutamate catalysed by glutamate decarboxy­
lase (GAD), a pyridoxal phosphate-dependent enzyme which is 
localized in nerve terminals. 3-Mercaptopropionic acid, a
potent competitive inhibitor'^® of GAD, produces convulsions due
46to a decreased GAD activity and reduced GABA levels in rats.
Many endogenous factors can inhibit GAD, Zinc ions are potent 
inhibitors; since zinc is one of the richest divalent metals in
22
Table 231
Isoguvacine and Related Amino Acids as GABA Agonists
Compound Formula % Inhibition Rel, Potency
OH
Isoguvacine r 1 ° 91±6 ( + )
Piperidine-4- 
carboxylic acid r 87±3 (+)
N-Methyl GABA ? I 0 18±1 (O)
Table 331
Cyclic Amino Acids as Inhibitors of GABA Uptake

















































brain, it may be involved in the regulation of cerebral excita­
bility. Sulfhydryl agents such as glutathione and cysteine could 
also be important in modulating GAD activity. Folic acid is a weak 
competitive inhibitor of GAD and this may be associated with some 
forms of epilepsy where folate levels increase. Huntington's Chorea
is associated with a decrease in GAD activity in the basal ganglia.
48Many structural analogues of glutamate inhibit GAD.
1.8.2 Inhibitors of GABA Degradation
GABA is metabolised to succinate by transamination to succinic
semialdehyde catalysed by GABA-transaminase (GABA-T), ajid subsequent
oxidation catalysed by succinic semialdehyde dehydrogenase (SSAD).
Selective inhibition of either enzyme generally leads to increased
levels of GABA accompanied by an anticonvulsant action. Amino-
oxyacetic acid (AOAA) is a potent competitive inhibitor of GABA-T,
and is one of the most widely used agents for increasing the levels 
49 50of GABA in brain. * AOAA is a carbonyl-trapping agent which is
a quite potent competitive inhibitor of GAD.^^*^^ Ethanolamine-o-
sulphate (EOS) is an active-site directed irreversible inhibitor of
G A B A - T . L i k e  AOAA, EOS is a weak inhibitor of GABA uptake,
but unlike AOAA it does not inhibit GAD. Sodium Di-n-Propylacetate
(DPA, sodium valproate) is a competitive inhibitor of GABA-T^^ but
54has a more potent action on SSAD. DPA has been used clinically
in the treatment of epilepsy. Systemic administration of DPA
53protects against seizures and increases brain levels of GABA.
Consideration of the mechanism of GABA-T action, led to the 
synthesis of Y-acetylenic GABA (GAG, 4-aminohex-5-ynoic acid) as a
25,
catalytic inhibitor of GABA-T, GAG binds to the active-site of 
GABA-T and causes a subsequent time-dependent irreversible 
inhibition. The active-site catalytic inhibitor of GABA-T was 
discovered in a culture filtrate of streptomyces toyocaemis and 
was characterised as (-)-5-aminocyclohexa-l,3-diene-l-carboxylic 
acid (Gabaculline) GabacuMne is a weak inhibitor of GAD
cind a moderately potent inhibitor of GABA uptake.
1,8.3 Inhibitors of GABA Uptake
GABA is transported by structurally specific sodium-dependent
uptake systems. Autoradiographic studies show that GABA is taken
up mainly by nerve terminals and glial cells with L-2,4-diamino-
butyric acid and g-alanine,^^ being relatively selective substrates
for the neuronal and glial uptake systems respectively, in the
57cerebral cortex and cerebellum. The neurotoxic Eimino acid,
L-2,4-diaminobutyric acid (DABA), found in various species of
Lathyrus and Vicia, is a substrate-competitive inhibitor of the
57neuronal uptake of GABA. DABA has a weak depressant action on
the firing of neurons and potentiates the action of electrophoret-
58ically administered GABA on these neurons. D-DABA is much
less potent that L-DABA as an inhibitor of sodium-dependent GABA 
uptake, but is equipotent as a weak inhibitor of sodium-independent 
binding of GABA to synaptic membranes.
Nipecotic acid, like DABA, is a substrate-competitive inhibitor 
of the neuronal uptake of GABA.^^*®^ Arecaidine and Guvacine, 
structurally related to nipecotic acid, are also inhibitors of the
26.
62neuronal uptake of GABA, The conformationally restricted
analogue of GABA, cis-3-aminocyclohexanecarboxylic acid is also 
a competitive inhibitor of GABA uptake, but is more selective 
for neuronal compared to glial uptake of GABA than either DABA 
or nipecotic acid.^^
73A number of centrally active drugs including butyrophenones, 
phenothiazines,^^ and benzodiazepines^^ inhibit GABA uptake in 
vitro. Various drugs inhibit GABA uptake in a relatively non­
specific manner, including p-chloromercuriphenylsulphonate,
chloropromazine, (imipramine), (haloperidol), dibutyryl cyclic
69AMP and the protoveratrines.
1.8.4 Inhibitors of GABA Release
Many drugs act on the synaptic release of GABA. Imi- 
71 72pramine, * haloperidol, chlorpromazine, eind diazepam, inhibit 
the calcium-stimulated release of radioactive GABA from synapto- 
somes,^^ while pentobarbitone inhibits this release of GABA at the 
level of the 'late* calcium ionophores.
In both the spinal cord and cerebellum, tetanus toxin appears 
to block the synaptic release of GABA,®®
1.9 GABA Antagonists
Dating from 1970, a variety of substances have been shown to 
antagonize the postsynaptic action of GABA and to reduce certain 
inhibitions in all areas of the CNS, Membrane binding studies
27.
suggest that some of these substances, e.g. bicuculline,
74compete with GABA for postsynaptic receptors, while others,
75e.g. picrotoxin, may interfere with GABA-activated ionophores.
Three series of compounds antagonise the postsynaptic 
effects of GABA:-
(i) Bicuculline and related compounds;
(ii) Picrotoxin and related compounds;
(iii) Penicillins, e.g. Benzyl penicillin (see Figure 5).
1.9.1 Bicuculline. a convulsant phthalide ispquinoline alkaloid^® is a
37relatively specific GABA antagonist. The structurally related
compounds corlumine and bicucine methyl ester are similar in
77potency to bicuculline as convulsants and as GABA antagonists. 
Quaternisation of the heterocyclic nitrogen atom in bicuculline
78produces more active compounds, for example N-methyl bicuculline. 
Bicuculline methiodide is a more powerful convulsant than 
bicuculline hydrochloride.^® Bicuculline methochloride,^^ which 
is about 100 times more soluble in water than bicuculline hydro­
chloride, and is more active electrophoretically as a selective 
GABA antagonist, is less effective than bicuculline when adminis­
tered systemically, owing to its quaternary structure.
28.
1,9,2 Picrotoxin is an equimolar mixture of picrotoxinin and picrotin, 
the former being about 50 times more active than the latter as a 
c o n v u l s a n t Picrotoxin reversibly, but not consistently, 
antagonizes the action of GABA in many areas of the CNS, 
Picrotoxin does not influence the binding of GABA to synaptic 
membranes. With respect to crayfish muscle, it appears that 
picrotoxin acts on the membrane molecule(s) responsible for con­
trolling the GABA-induced chloride flux, the GABA-ionophores, or
75on the link between receptors and ionophores.
1.9.3 Benzyl Penicillin®^ is a specific but less effective GABA
antagonist than bicuculline. Recent studies on crab neuro­
muscular junction indicate that benzylpenicillin antagonises 
GABA-induced chloride conductance increases by a weaker com­
petitive inhibition, which may be receptor antagonism, and a 
more powerful non-competitive inhibition, which may be ionophore 
blockade.®^
831.9.4 Other GABA Antagonists include bicyclic phosphates; tubocurarine
84 85 86and nicotine; * certain caprolactarn derivatives jand naloxone. 87
29.
1.10 Conclusion
GABA is considered to be the major central inhibitory 
transmitter on the basis of its involvement at virtually all 
levels of the mammalian neuroaxis.
The most fully documented case for an amino acid trans­
mitter, and indeed for any central transmitter, is that for 
GABA, released at terminals of Purkinje cell axons to inhibit 
Deiters* neurones. Evidence is available to confirm that GABA 
is an inhibitory transmitter in the cerebral, cerebellar, and 
hVppoceimpal cortices, released by basket-type cells. GABA 
also appears to be an inhibitory transmitter in the substantia 
nigra (which contains the highest levels of this amino acid in 
the brain), in the retina, olfactory lobe, thalamic relay nuclei, 
dorsal column nuclei and the spinal cord.
Defects of GABA-mediated synaptic transmission underlie 
many neurological disorders, such as epilepsy, various extra- 
pyramidal syndromes, and psychiatric disturbances. The use of 
agents, based on knowledge of the synthesis, action and inacti­
vation of GABA, may be clinically beneficial. Although the 
actions of substances found to be therapeutically effective, such 
as the benzodiazepines, barbiturates, butyrophenones and some 
anticonvulsants, are probably related to gabergic synapses, the 
development of these has not yet been based on an understanding 
of the molecular aspects of gabergic transmission. It will thus 
be important to study the different types of GABA receptors in 
various regions of the human brain, both normal and diseased. 
Major problems which limit such a chemotherapeutic approach are
30.
blood-brain barriers to agents acting at GABA receptors and 
the clinically undesirable modification of gabergic transmission 
at relatively normal synapses by an agent required to act 









Introduction to steroids 
History
A white, crystalline, unsaponifiable substance was isolated from
human gall-stones, about 200 years ago, which in 1816 was named
cholesterine (Greek: Chole-bile; Stereos-solid). In 1859 when the
presence of a secondary alcohol was detected, the more descriptive
name - cholesterol became generally accepted. Preparation of the
dibromide of the substance indicated the presence of a double bond.
In 1888, the empirical formula for cholesterol was confirmed as CgyH^^O,
Diels* discovery that cholesterol was converted to the hydro-
carbon(9A) by selenium dehydrogenation, and* X^ray crystallographic
89measurements by Bernal lead to the elucidation of the correct 











Substances of considerable medicinal importance are found amongst
the steroids, occurring naturally in both plants and animals. These
include the sex hormones, such as oestroneC12), androsteroneC13), and
progesteroneC14); the adrenocortical hormones such as.cortisoneC15);
the antirachitic vitamin, vitamin DgClG); and, the cardiac glycosides
(sugar derivatives of steroids) such as digitoxigeninC17).
The plant steroids®® can be divided into four major groups
sterols, sapogenins, cardiac aglycones,®^ and, alkaloids.®® , The
glycoside,solanine,of the alkaloid solanidineClS) occurs in potato
97sprouts. The important sapogenin, diosgenin(19) isolated from
Dioscorea. and cholesterol(lO) have been useful starting materials for
the synthesis of cortical and sex hormones. More recently, Hardman 
152et al. have extracted diosgenin from Fenugreek.
Insect hormones such as ecdysone(20) are also based on the 
steroidal structure. The bile-acids occurring as conjugates with 
amino acids, for example, glycocholic acid (R'CONH-CHg'CO2H) contain 
steroid fragments such as cholic acid(21) linked as the amide to glycine,
2.1.3 Structure
The steroids are a group of substances possessing a tetracyclic 
backbone(llA), containing four or more fused rings as in the chrysene 
(lis) ring system. One or more of the rings A, B, C, and D may be 
larger or smaller than 6-membered, but usually, rings A, B, and C are
6-membered, and ring D is 5-membèred. Heteroatoms may appear anywhere 





























(19) OHHO Cholic Acid(21)
(22) Gonane R =R =H
(24) Oestrane R*=H; R*'=CH
(25) Androstane R*=r "=CHo
HO
34.
The hydrocarbon lacking both methyl groups and a side-chain is 
named Gonane(22), whilst the saturated hydrocarbon which lacks a 
methyl group at C-lO and the side-chain at C-17 is named oestrane(24).
CH
CH





53“Cholestane. Cis-fused A/B 
(27)
The two naturally occurring A/B ring fusions are:-
(a) *Cis* fusion of the bile-acids, for example cholic acid(21); and
(b) *Trans * fusion of for example androsterone(lS),
(In older texts, the term 'coprostane* is often used to describe the
35.
cis-fusion of 56-cholestane. Trans-fusion is indicated by the term 
*choiestane*.) See structures (26) and (27),
Unfortunately, in a thesis of this type, much of the earlier work 
on naturally occurring steroids (their isolation, biosynthesis, and 
total synthesis) has to be omitted. However, for a thorough invest­
igation of the subject the reader is referred to the excellent texts 
by Fieser,^® Djerassi,Shoppee,^^ and Akhrem and Titov.
2.1,4 Biosynthesis of steroids
Although a great deal of work has been done in this field to 
elucidate the biosynthetic pathways of the various naturally occurring 
steroids in plants and animals, only one pathway will be discussed here 
in order to show the reader the practical applications of this type of 
study. Modification of the natural hormones has lead to the production 
of many drugs which include the oral contraceptives and the anabolic 
steroids.
2.1.4.1 Biosynthesis of the Sex Hormones
The sex hormones are synthesised in the body from cholesterol(10), 
which is readily(converted)to the hormones in a stepwise manner as shown 
in Scheme 2.
2.2 Synthetic methods leading to the formation of azasteroids
Over the last 20 years, synthetic methods resulting in the formation 
of a great number of heterosteroidal structures have been reported. If 
one considers the basic steroid skeleton (28), then theoretically it is 
possible to synthesise an infinite variety of heterosteroids (where 




Biosynthesis of progesterone.. testosteroneCandrogen) and 
oestrone(oestrogen) from cholesterol, in man.
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The main objective in these types of syntheses is to obtain compounds 
with enhanced pharmacological activities. However, a great deal of 
research in this field has provided invaluable information concerning 
novel synthetic routes and reaction mechanisms as applied to organic 
chemistry, and has not been of purely academic interest.
The preparation of azasteroids embraces two distinct approaches
(i) modification of an existing steroid nucleus either by processes 
involving ring cleavage, nitrogen insertion and ring closure, 
or else by application of the Schmidt reaction to an appropriate 
ketone or of the Beckmann rearrangement of the derived oxime; 
or
(ii) total synthesis procedures starting with the aza analogues of 
the precursors of the steroidal skeleton.
Total synthesis represents a difficult task since the steroid 
molecule contains numerous asymmetric centres. Even in the un­
substituted hydrocarbon gonane(22), there are six asymmetric 
centres (C-5, 8, 9, 10, 13 and 14) which give rise to 64 isomers. 
CholesteroK10) with 8 such centres can have up to 256 stereo­
isomers.
Azasteroids are compounds in which nitrogen forms an integral part 
of the steroid nucleus, with or without alteration of ring size, and 
compounds in which nitrogen appears in one or more side-chain
2.2.1 Naturally occurring azasteroids
(Also see Chapter 3, p.84 , isoquinoline alkaloids.)
Among the naturally occurring h e t e r o s t e r o i d s , t h e  more 
prominent are the extranuclear azasteroids. These include alkaloids 
present in Solanum. Veratrum. Holarrhena. and Buxus.
The Solanum alkaloids can be divided into two classes:-
(i) the nitrogen analogues of sapogenins, e.g. solasodine(29) and
tomatidine(30). Solasodine is similar in structure to diosgenin 
(19), except -NH is substituted for O in ring F.
2.2.1.2
38.
(ii) steroids containing a condensed ring system and tertiary
nitrogen, e.g. solanidine(31) and demissidine(32). Solanidine 
was first isolated from the toxic leaves of the black nightshade 
(S. nigrum). The alkamines - rubijervine (12a-hydroxy- 
solanidine) and isorubijervine (18-hydroxysolanidine) have been 
isolated from the rhizomes of Veratrum album.
Large doses of some Solanum alkaloids in animal tests produce 
parenchymatous nephritis and haemoglobinuria, followed by nervous 
paralysis and cardiac arrest.
Alkaloids such as veratramine(33) and jervine(34), extracted from 
the Veratrum plants are not regarded as classical steroids, since they 
contain a 5-membered C ring and a 6-membered D ring. Several alkaloid 
esters of germine(35) have been found in the rhizomes of V. album and 
V. viride.
Many species of Holarrhena contain esters or glycosides of
alkamines called the Kurchi alkaloids which include holarrhimine(36),
conarrhimine(37), and conkurchine(38). The bark of the kurchi shrub
has been used as a remedy for eunoebic dysentery in India.
Ten years ago,^^^»^®® the active steroid alkaloidal components from
the Columbian arrow poison frog - Phyllobates aurotaenia were separated
107and some of which were characterised as batrachotoxinin A(39),
batrachotoxin(40), and homobatrachotoxin(41), Batrachotoxin^^^ is an
active cardiotoxin, affecting neuromuscular preparations both pre- and
post-synaptically, nerve axons, superior cervical ganglion, and Purkinje
fibres in the heart, due to the selective and irreversible increase in
108membrane permeability to sodium ions.
Azasteroids with nuclear nitrogen have been isolated by Schopf and
102Braun from the venom produced by the parotid and skin glands of the 
103Salamanders. Sajnandarine(42) is a central nervous system convulsant.
100The related ketone samandarone(43) has also been isolated.
Azasteroids such as A25822B(44) with high antifungal activity have
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2.3 Syntheses of azasteroids
Many azasteroids of purely synthetic origin have been prepared by 
total or partial synthesis. Modified steroids have attracted a great 
deal of attention for three main reasons
(i) their preparation is a stimulating challenge to the organic
chemist, often involving development of new and generally useful 
reactions;
(ii) the investigations of reaction mechanism and stereochemistry 
based upon the steroidal framework, provide significant and 
interesting chemical problems; and
(iii) biological properties of modified steroids are of great interest.
2.3.1 Aza analogues of the naturally occurring steroids
Many genuine hetero analogues of naturally occurring hormones have 
been synthesised, including:
2-azaoestradio1 3-methyl ether 17-acetate(45), (+)-2-aza-
oestradiol 3-methyl ether,(l)-6-azaoestradiol 3-methyl ether(46),
IIP IIPIIQ c(+)-6-azaoestradiol, (±)-6-azaoestrone, * (±)-6-azaquilenin
(47),^^^ (t)-8-azaoestradiol(48), (±)-8-azaoestrone,^^^*^^^
16-azaoestrone methyl e t h e r ( 4 9 ) , (+)_i0_azatoestrone,
17-azaprogesterone(50), and, 4-azaoestradiol 17-acetate.
2.3.1.1
2.3.1.2
111PappO and Chorvat synthesised a number of 2-aza steroids 
following the discovery of a favourable anabolic:androgenic ratio in
17a-methyl-2-oxa-50i-androstan-3-one. Several other 2-aza steroids
120have been synthesised by Kashman and Kaufman.
Several synthetic methods for the preparation of 4-heterosteroids
have been established by extensive research in the decade 1960-1970.The
4-Aza-androstan^(51A) which has been synthesised from 17#-isopentyloxy-
1214-androsten-3-one; is reported to have high antimicrobial activity. 





observed. The synthesis of 3-deoxy-4-azaoestradiol(52) has been 
achieved^^^ by ozonolysis of 19-nortestosterone, DIBAL reduction of the 
resultant mixture of enol-lactones to a keto-aldehyde followed by 
hydroxylamine cyclisation.
Bridgehead 5-aza steroids (55) and (56) have been s y n t h e s i s e d ^ ^ ^  
from the corresponding oximes (53) and (54).
7-Cyano-6-azacholestane(57) has been obtained^^^ from cholest-5- 
ene, and 6-aza-3-t-butoxycholestane(59) was prepared by reduction of 
the amide(58).
Engel^^®*^^^ has successfully prepared the ll-azapregnanes(61) 
and (62). Compound (61) possessing the unnatural 9g-H configuration 
was obtained via the azido acetate(6 0 ) . ll-Azaoestrogens (64) and 
(65) were obtained by Badanova and Pivnitskic^^® from the seco-acid(63),
2 .3.1.6
129Counsell et al. reported the synthesis of the 17a-epimer of 
20,25-diazacholesterol(66), in continuation of earlier work on the 
hypocholesteromic activity of various side-chain aza- and dieiza-
130cholestanes. 25-Azalanostane(67) was also prepared by Counsell ^  al. 
Neither the diaza-compound (66) nor the aza-compound (67) possess sig­
nificant biological activity.
2.3.2 Partial syntheses of nuclear azasteroids
Insertion of nitrogen atom(s) into the steroid nucleus
Many steroidal analogues containing a nitrogen atom in one of the 
rings A, B, C, or D have been prepared owing to their importance as 
synthetic intermediates and because of their enhanced biological activity. 


































































































erisation purposes. Systematic work in this field began in the 
early 1940’s and the largest portion of azasteroids have been 
synthesised in the last twenty years. Several nitrogen analogues of 
biologically active naturally occurring steroids were found to retain
some or all their activity.
2.3.2.1 Ring A modified azasteroids
Cooper and Moore^^l synthesised 2-oxo-3-aza-A-nor-cholestane(68).
Whilst working on the synthesis of salamander alkaloids, Rao and 
Weiler^^^ achieved regioselective Beckmann fragmentation between C-2 
and C-3, by making use of the 2-OAc group of 2g,17#-diacetoxy-5&- 
androstan-3-one to obtain the cyanoaldehyde(69), which was converted 
into N-benzoyl-3-aza-A-homo-5g-androstane(70) by reduction with diborane 
followed by cyclisation with one equivalent of benzoic anhydride in 
pyridine.
133Barton et al. prepared 4-aza-A-homo steroids(71) via modified 
Beckmann reaction involving p-toluenesuIphonyl chloride/pyridine 
induced rearrangement of nitrone(72). Neumann and Buchecker^^^ 
obtained the steroidal pyrazole(73) by treating 2-diazocholestan-3-one 
with dimethyl acetylenedicarboxylate.
In view of the biological activity displayed by several tetrazoles,
the tetrazolo steroid(74) was synthesised from (25R)-spirost-4-en-3-one 
135by Singh ^  al. via BF^-HNg treatment, followed by degradation of the 
spiro structure.
Starting from A-nortestosterone, Levine^^® accomplished the 
incorporation of a g-lEictam ring into a steroid molecule. The removal 
of a carbon atom from ring A by oxidation (NalOg, KMnO^), followed by 
introduction of a nitrogen atom by C-5 oximation and subsequent Beckmann 
rearrangement to produce a B-homo ring, and finally removal of the amide 
oxygen and dicyclohexylcarbodiimide (DCC) ring closure of the amino 
acid(75) furnished the B-lactam androstane(76a). The pregnane analogue 
(76b) was similarly prepared.
47.
2.3.2.2 Ring B modified azasteroids
Aza-B-homo steroids have been extensively studied and are usually
prepared via Beckmann and Schmidt reactions of 6- and 7-oximes.
138Suginome and Takahashi synthesised 6-aza-B-homo-5a-cholestan-7-one 
and 7-aza-B-homo-5a-choiestan-6-one and the corresponding 53-derivatives 
via photo-Beckmann rearrangement of 50c- and s3-cholestan-6-one oximes.
As the migration of the carbon centre proceeds, configuration is 
retained via the oxaziridine intermediate. The p h o t o l y s i s o f  
3a,5-cyclo-5a-cholestan-6-one oxime gave, amongst other products, (77) 
and (78), in low yields owing to unfavourable conformational factors. 
Khuong-Huh Eind Pancrazi^'^ studied the decomposition of 6g-azido-3a,-5a- 
cyclopregnane in order to investigate the eventual insertion of a nitrene
intermediate - generated by photolysis of an azido steroid - into an
angular methyl group. Detection of the 7-aza-B-homo steroids(79a) and 
(79b) among the products, indicated a preferential migration of the less
strained C - 6 -----C-7 bond. Both the 6- and 7-aza-B-homopregnanes,
(80a) and (80b), were formed in the absence of strain, as observed in 
the photolysis of 6$-azido-5a-pregnane^^^ in cyclohexane.
Mitsuhashi et al,^^^ obtained the lactams (81) and (82) from
cholesta-3,5-dien-7-one via hydrolysis of the aziridine ring in (83) and
subsequent Schmidt reaction.
The unusual dimeric triazolosteroids(84) have been prepared by 
reacting 7a-azido-A^-steroids with a mixture of lead tetraacetate and 
trimethylsilyl azide ((CH2)g"SiN2) and subsequent catalytic (Pd/C) 
hydrogenation,
2.3.2.3 Ring D modified azasteroids
The 17a-aza-D-homo steroids (85a) and (85b)^^^*^^^can be obtained
in low yields by photo-Beckmann rearrangement of androsterone oxime.
146Singh et al. report the thermal cyclisation of azidonitriles,
shown in (86), in the synthesis of bis-tetrazolo steroid(87). The
product was formed on treatment of 4-androst.en e-3,17-dione with
HNg-BFg complex.
18-Nor-17a-aza-D-homoandrostane(88) has been synthesised by 
147Diatta et al. by ozonolysis of the unsaturated nitrile obtained via 

































The synthesis of bisonium steroids was suggested owing to the 
neuromuscular-blbcking potency in several steroidal quaternary ammonium 
analogues. Singh et al. report the synthesis of compound (89) from 
17a-£Lza-D-homoandrost-4-ene-3,17-dione via potassium permangajiate- 
sodium iodate (KMnO^-NalOg) oxidation, formation of the N-benzyl-lactam, 
débenzylation and sodium-pentcinol reduction. Reaction of the bis-amine 
with formaldehyde/formic acid followed by methyl iodide quaternisation 
yielded the product (89), which showed biological activity comparable to 
tubocurarine.
2.3.2.5
The first examples of azasteroids in which a carbon atom common to 
two rings of the steroid nucleus is replaced by a nitrogen atom, were 
prepared by Meltzer e^ al.. a n d  Meyers et al.^ ^
A new type of Eizasteroid, 17-azaprogesterone in which thé C. atom 
bearing the steroid side-chain has been replaced by a nitrogen atom, has 
been synthesised by Rakhit and Gut.^^^
2.3.3 Total syntheses of nuclear ctnd side-chain azasteroids
A steroid molecule can be constructed by steirting with a one- or 
two-ring moiety and attaching chains to it which are capable of under­
going cyclization. In this manner, the molecule is built up until the 
four rings are attached to each other in the required chrysene-type 
orientation.
Several different routes may be employed, including;-
(i) Cyclization of a polyolefin --- ^ ABCD
(ii) A3 --- > ABC  ^ ABCD
(iii) A3 + D --- > ABD  ) ABCD e.g. Torgov synthesis
(iv) A3 + D  ^ ABCD e.g. Diels-Alder reaction
2.3.3.1
50.
(v) A + C --- ^ AC  > ABC ---  ̂ABCD
(vi) A + CD  --> ACD — ^  ABCD
(vii) A + D --- » AD  > ABCD
(viii) BC --- ^ ABC  ABCD
(ix) BC -- > BCD  ^ ABCD
(x) B + D --- > BD  ABCD
(xi) CD --  ̂BCD ----> ABCD
Some of the above mentioned routes are discussed in the following
section, but for further details the reader is referred to the text by
270Blickenstaff, Ghosh and Wolf.'
Several new methods for the total synthesis of azasteroids have
154been developed by Huisman e^ al. Approaches involving enamine
reactions have been described by Huisman and Pcindit for the synthesis 
of 13,14-diaza-^^^*^^^ and 11,13-diaza-^^*^ steroidal systems. (See 
Scheme 3^ The starting material for the 13,14-diaza-D-homosteroid(95) 
was 6-methoxy-2-tetralone(90). Alkylation of its pyrrolidine enamine 
resulted in the formation of the ot-keto ester(91), which on treatment 
with perhydropyridazine in boiling xylene yielded the 13,14-diazasteroid 
(92). Similarly, condensation of (91) with hydrazine hydrate afforded 
the intermediate (93) which on LiAlH^ reduction gave the tricyclic 
hydrazine(94).
1 57Pandit et al.. in an alternative approach, synthesised 11,13- 
dieizasteroids utilising the morpholine enamine of 6-methoxy-l-tetralone 
(96). Acylation of the enamine with the acid chloride of monomethyl 
succinate, followed by acid hydrolysis, yielded the diketo acid(97). 
Estérification of the acid (97), and subsequent heating with guanidine 
carbonate in 2-ethoxyethanol afforded the tricyclic system (98).
Catalytic reduction of the latter in an acidic medium yielded the
ll,13-diazasteroid(99). Treatment of the diketo acid(97) with hydrazine 
hydrate led to the formation of the hydrazine salt of (100) which was 
isolable in the zwitterion form by careful adjustment of its 
aqueous solution to pH 3.5. Estérification of the acid (100), followed 
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2 .3.3.2 Wilkins^®® employed a versatile approach based on the 'Diels-Alder*
type cycloaddition between an imine and a diene, for the synthesis of 
several a z a s t e r o i d s ^ ^ ® ( s e e  Scheme 4). Condensation of the 
ethyl biscarbamate( 103) (R = R = R = Et) with the diene (102) in the 
present of BFg-etherate, yielded the tricyclic ester(104) (R = R* = Et). 
Owing to the difficulties encountered during the hydrolysis of the 
CELrbamate group, further experiments were carried out with the corres­
ponding benzyl biscarbamate(103) (R = r” = Bz.; R* = Me) and the adduct 
(104) (R = Bz.; R* = Me) was isolated as crystals by chromatography.
The adduct (104), on treatment with acetic acid, can be isomerised to its
8,9-dehydro-isomer(105) (R = Bz.; R* = Me). Decarbobenzoxylation of 
(104) (R = Bz.; R* = Me) and (105) (R = Bz.; R* = Me), gives on cycliz­
ation of the intermediate y-amino ester, the 8,9-dehydro-13-azaoestrone 
(106). The ester (104) (R = Bz.; R* = Me) can also be converted into 
the 13-azaoestrone(107), by hydrogenolysis of the benzyl ester and catalytic 
hydrogenation of the 9,11-double bond, followed by cyclization.
Treatment of the diene(102)^®® with the imino ester(108) leads to 
a mixture of tricyclic isomeric adducts (109) and (110). Alkaline 
hydrolysis of the mixture containing (109) and (110) yields the dihydro- 
benzoquinoline acids, which on separation followed by estérification give 
the methyl esters (111) and (113), The 14-aza- (112) and 13-azaequilenin 
(114) systems can be readily obtained from the methyl esters (111) and 
(113) respectively.
. ftCondensation of diene (115) with the biscarbamate(103) (R = R = Bz.; 
R* = Me) yields predominately the 14-azaisomer(116), from which the 14- 
azasteroidal system (117) can be obtained by acid-catalysed cleavage of 
the benzyloxycarbonyl group. Further modifications of this method lead
A
to the synthesis of the tricyclic intermediates (118)^®^ arid (119).1^2
2 .3.3.3
Kessar et al. accomplished the synthesis of the 13-aza compound
(123), (see Scheme 5). The amine (120) (R = H) condenses with 3- 
carbomethoxypropionyl chloride to yield the amide (121), which readily 
undergoes cyclization with phosphorus oxychloride. The basic material
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leads to 13-a,za-18-norequilenin( 123), The product (123) was also
k
synthesised by Birch and Rao via an alternative route^^^ (see Scheme 5a)
Scheme 5a164
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The amine (120) (R = H) has also been employed^®®» for the
synthesis of 13-aza-15-thia-18-norequilenin methyl ether(125). The
ofamine (120) (R = H) reacts with ethyl formate to give the amide.(120)
K
(R = CHO), which on cyclisation forms the dihydrobenz(f)isoquinoline 
(124). The thiazolidone(125) is obtained by reacting the isoquinoline
(124) with mercaptoacetic acid.
The total syntheses of several 6-azaoestrogens have been described 
by Speckamp et al.^^^^ Jones and Wood,^®^”^ and, Schleigh and Popp^^® 
attempted the synthesis of 9-azasteroids. Both groups report the 
successful preparation of the tricyclic intermediate (127), but attempts 
to build up ring D were unsuccessful. When the keto ester(127) is 
treated with hydrazine, the pyrazolone(128) results.
171The synthesis of 14-azasteroids was studied by Poirier ^  al. 
and J o n e s . T h e  former group succeeded in synthesising 3-deoxy-18- 
nor-14-azaequilenin( 126).
Morgan and c o - w o r k e r s , i n  another series of studies, prepared 
the known tricyclic ketone(129), which on condensation with acrylonltrile
57.
in t-butyl alcohol in the presence of potassium hydroxide gives the 
nitrileClSO) (R = CN). Hydrolysis of the nitrile(130) (R = CN) 
furnishes the acid(l30) (R = COgH), which can undergo a modified 
Curtius rearrangement to yield the steroidal imine ether(131) (R = Me). 
When the steroidal imine(l31) (R = Me) is heated in the presence of 
hydrobromic acid, the 15-azaequilenin derivativeC131) (R = H) is obtained.
2.3.3.4
174Morgan et al. also report the synthesis of 15,16-diazasteroids.
The synthesis of several other diazasteroid derivatives have been
reported; for example: 12,14-^^^; 13,16-^^®; 14,16-^^^*^^^; and
15,16-diazasteroids.^^^*
179. Stanovnik et al. have prepared ll-amino-12,13,15,16-tetraaza- 
1,3,5(10),8,11,14,16-gonaheptaen and other tetraazasteroids and a 
pentaazasteroid by em ABC — ^ ABCD route.
2.3.3.5
The Torgov synthesis (AB + D — > ABD — t ABCD) has been employed for 
the preparation of many azasteroids, (see Scheme 6). Condensation of
the vinyl alcohol(132) with the cyclopenta-1,3-dione, followed by 
cyclization affords the azasteroid(134). N-Arylsulphonyl pentaene 
intermediates with tosyl(136)^*^^^»or benzenesulphonyl^^®*sub­
stituents can be synthesised from the requisite allylic alcohols, 
e.g.(l35). Catalytic hydrogenation of the benzenesulphonyl analogous 
gives the CD-trans tetraene,^®^ but with the tosyl analogue(136) a
o 112mixture predominating in the 14 p-isomer(138) results. Hydrogenation
of the 173-hydroxy analogue(137) yields predominantly the oi-isomer(140). 
Oppenauer oxidation of (140) affords (139) which can undergo ring B 
aromatization to give the methyl ether(142) of 6-azaequilenin. Alter­
natively, (142) can be obtained via (143) by detosylation of (140) with 
sodium hydride or by reacting (139) with lithium aluminium hydride 
(LiAlH^) in tetrahydrofuran( IHF). Lithium-ammonia reduction of the
8,9-double bond occurs in 30% yield to give the methyl ether(141) of 
6-azaoestradiol. In the benzenesulphonyl series, however, lithium- 
ammonia reduction of (146) gives the product (143).^®^ 6-Azaoestrone 
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with pyridinium c h l o r i d e . T h e  143-isomers of (141), (142), (143) 
and (144) have also been prepared.
The N-methyl ABD intermediate (148) (R = CHg) was prepared from 
the allylic alcohol(147) and cyclized to give the A^^^^^-steroid(149)
(See Scheme 7.) Reaction of the allylic alcohol(147) (R = H) with 
2-methyl-l,3-cyclopentanedione, followed by acétylation afforded the 
N-acetyl intermediate(148) (R = Ac), which cyclized under conditions 
of ketalization to give the pentaene(lSO) in 50% yield. Lithium 
aluminium hydride reduction of (150) in tetrzihydrofurcin(IHF) resulted 
in a mixture of the deacetylated products (151) and (152), Hydro­
genation of (152) with palladium/charcoal gives a mixture of the 3-methyl 
ether, 17-ketal(153) of 6-azaquilenin.and the corresponding 143-isomer, 
chromatographically separable. The 17-ethyleneketal(154) of azasteroid 
(149) can undergo a Birch reduction in methylamine (the reaction fails 
in ammonia) to give the dihydro product, which on hydrolysis yields the 
diketone(155)
13-Azasteroids can be obtained by replacing the diketone in the 
Torgov synthesis with succinimide (see Scheme 8). Succinimide reacts 
slowly with the allylic alcohol(156) in methanol, but more rapidly as a 
melt containing the potassium salt of succinimide to give the ABD inter- 
mediate(157).185 On treatment with phosphorus oxychloride, the inter- 
mediate(157) undergoes cyclization to yield a tetracyclic steroid 
[probably (iSĵ )], which can be hydrogenated over rhodium/charcoal to the 
methyl ether(161) of 13-aza-8-dehydrooestrone. Alternatively, NaBH^ 
reduction of (157) in ethanol, containing HCl, results in the ether 
(159),^®® which on cyclization gives a one-to-one mixture of (160) ctnd 
(161).
Ŝ tŜ sIs of
The Torgov synthesis can also be applied to/steroids with a pyrazole 
187ring A, The allyl alcohol, prepared from the Schiff's base (162),
(see Scheme 9), reacts with phenylhydrazine to give the corresponding 
hydrazone. The latter, on treatment with p-toluenesulphonic acid, 
undergoes cyclization to yield the pyrazole(163). The allylic alcohol 
obtained by a Grignard reaction on (163) condenses with 2-methyl-l,3- 
cyclopentanedione to give the ABD intermediate, which on p-toluene­
sulphonic acid treatment cyclizes to the diaza-A-nor steroid(164).
Sodium borohydride reduction of (164) affords the 173-hydroxy derivative.
61.
Scheme 8




































Some aza-oxa steroids have also been synthesised via the Torgov 
route (see Scheme 10). Condensation of the isothiouronium salt(165) 
with 2-acetylamino-l,3-cyclopentanedione,followed by cyclization 
of the ABD ir.termediate(166) with p-toluenesulphonic acid leads to the 
steroid (167). Catalytic hydrogenation produces a CD-trans geometry 
as expected, emd sodium borohydride reduction of the oxo group gives 
product (169). Further hydrogenation of (169) results in the 8a~steroid 
(168). Potassium-liquid ammonia reduction of (169) with aniline as the 
proton source affords the normal BC-trans isomer(171). On treatment 
with hydrochloric acid, the isomer (171) undergoes ring closure to give 
the 2-oxazoline(172); the expected N — >0 migration of the acetyl group 
under such conditions, is not observed. Hydrolysis of the amide(l71) 
followed by condensation of the amino alcohol with acetaldehyde in reflux­
ing benzene, afforded the dihydro dérivâtive(170). 13$-Amino-17g-
hydroxy-4-gonen-3-one(173), is obtained by Birch reduction of (171) 
followed by hydrolysis. Under basic conditions, the ABD intermediate 
(166) is unstable and undergoes ring D cleavage to form (174).^®®
The thicizole A-ring steroids (see Scheme 11)^^^*^^^ have also been 
prepared.
An 8-azasteroid(185) has been prepared via alkylation^^^ of 
l,5-dimethoxycyclohexa-l,4-diene with the chloride(183) in liquid 
ammonia, followed by hydrolysis, cyclization with 2N hydrochloric acid, 
and reduction of the 13-double bond (see Scheme 12). Alkylation of 
succinimide or glutarimide (potassium salts) with the bromide(189) 
affords (187) (n = 1 or 2, respectively). Cyclization with poly- 
phosphoric acid, followed by catalytic reduction of the 14-double bond
gave rise to the 1 3 - a z a s t e r o i d ( 1 8 8 ) .192,193,194
8-Azaoestrone has been prepared via the Michael addition of 2-
methyl-1,3-cyclopentanedione to the isoquinoline derivative(190) (see
Scheme 13). Déméthylation of (192) affords 8-azaoestrone.H^*193f 196
The methyl ether of 3-hydroxy-6,8-diaza-D-homo-l,3,5(10),6,13-gona-
197pentaen-17a-one has been prepared by a similar route.
Some 14-azasteroids have been prepared by the addition of 




intermediateC194) (see Scheme 14), Protection of the keto group 
via ethylene ketal formation, catalytic reduction of the pyridine
ring, hydrolysis Of the ketal, and finally, ring closure gave the 
198prototypeC195)•
11,14-Diazasteroids have been synthesised via the intermediate 
formed by Michael addition of diethyl (2-naphthylaraino)raalonate to 
ethyl acrylate (see Scheme 15).^^^
A series of 8-azasteroids have been prepared via enamine ABD 
intermediates. For example, condensation of the isoquinoline 
derivative(199) with cyclopéntanone gives the enamine(200), which can 
undergo cyclization to yield the 12-keto steroid(201), Méthylation 
followed by catalytic hydrogenation affords the methyl ether(202) of 
8-aza-3-hydroxy-l,3,5(10)-oestratrien-12-one•200,201 The 8-azasteroid
(210), (n = 1,2), can be prepared similarly, from the amine ester 
(209).^^
The dihydroisoquinoline(211) (R = H or (X]Hg) reacts with g-diketones
203to give the 8-aza-12-ketosteroids(212) (R = OCH^, R* = Hg),
(R = OCH3, R* = 0)204 and (213) (R = OCH3, R* = Hg, Z = NH),^®^
(R = OCH3, R* = 0, Z = C(CH2)2),203 (R = H, R* = O, Z = C(CH3)2).^04
Ethyl bromoacetate alkylation of the enamine(214), followed by acid
hydrolysis affords the ester(215), which condenses with perhydropyridazine
in boiling xylene to yield the 1 3 , 1 4 - d i a z a s t e r o i d ( 2 1 6 ) , 2 ^ 5  (see Scheme 18), 
The enamine(217) obtained by 1-pyrrolidinocyclopentene addition to 
methyl 3,4-dihydro-l-naphthoate can undergo hydrolysis (of the ester and 
enamine groups) to give (218), which can be cyclized to the azasteroids 
(219) (Z = NH or NCHgPhJ.^OG
Acylation of 1-naphthylamine with 2-carbethoxycyclopentanone at 
180° gives (220) (R = H), which on cyclization followed by reduction of
the 13-double bond with sodium amalgam affords the ll-azasteroid(221)
207 208(R = H), Popp et al, acylated 5-aminoisoquinoline(222) with
2-carboxycyclopentanone, The ABD intermediate was converted to the
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and the intermediate was cyclized with polyphosphoric acid to give
20Rthe 3,ll-diazasteroid(224), (see Scheme 19). .
The ABD intermediates(225) (n = 1,2) have been prepared from the 
Grignard intermediateC228) and eyelopentemone or cyclohexanone res­
pectively, which on standing in solutions of dimethyl azidodiformate 
gave (226).^®»^^® The latter can be hydrolytically decar boxy lated 
by heating with hydrazine hydrate, and the products oxidized to the 
ll,12-diazasteroids(227) Cn = 1,2) (see Scheme 20),
Schiff bases(230) (see Scheme 21), have been prepared from 
a-naphthylamines(229) and 2-formyl- or 2-acetyl-l,3-cyclohexanedione, 
i^ich cyclized in the presence of polyphosphoric acid to give the 
ll-azasteroids(231).^^^*^^^*^^^ Phenylhydrazones(233) of 6-methoxy- 
tetralone(232) can cyclize in refluxing ethanolic hydrochloric acid 
to give the ll-aza-C-nor-D-homosteroids(234). The 6 ,11-diaza analogues 
have been prepared in a similar manner,
215 216Bertin and Perronnet report the synthesis of 10-azasteroids.
Artus et al. have attempted the synthesis of 4,6-diazasteroids.^^^ 
Scheme 22 portrays a unique reaction sequence leading to a 5,10- 
diazasteroid.^^® Pandit and Huisman^^^ have reviewed the synthesis of
heterocyclic steroids via enamines and dienamines. 6,7-Diazasteroids
219 220 221have been prepared * * via CD enamine intermediates (see Scheme 23),
The synthesis of 2,3-dimethoxy-8,ll-diazagona-l,3,5(10),9(ll)- 
tetraene has been reported by Castle et al.^^^
223 2248f13-Diazasteroids can be obtained via the AD intermediate(250) *
(see Scheme 24). Under normal Bischler-Napieralski reaction conditions,
ooe;the intermediate (250) can be cyclized to the dihydroisoquinoline(256). *
226 Acid hydrolysis followed by catalytic hydrogenation furnished the
70.
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diamine(255) (R = R = OMe; R = OMe, R = H), which underwent con­
densation with ethyl 3-ethdxycarbonylpropionimidate hydrochloride^^^
to give 8(14)-dehydro-(257). The diazasteroid(257) can be obtained
224 226directly from (256) via a reductive cyclization procedure. *
Some recent advances in the field of azasteroid synthesis
The four isomeric 3,ll-diamino-50 pregnanes(258) have been prepared 
by Campbell et al♦ The same group^^® also report the synthesis of 
eight, isomeric, steroidal vicinal 2,3-amino alcohols(259). The seven 
possible 3-amino-2-hydroxy eind 2-amino-3-hydroxy isomers of the anti- 
arfhythmic steroid^^® 3a-amino-2 3-hydroxy-50t-androstan-r7-one(259)
(2-OH, S-NHg) have been prepared from 5a-androst-2-en-17-one.
Several new steroidal heterocycles have been synthesised by 
Sykes et al. including androst-4-eno[3,2-f]-(s-triazolo[4,3-b]
pyridazine)(260); the androstano [l7,16-f]-(s-triazolo [4,3-b]pyridazines)
(261) and (262); and, 3-methoxyoestra-l,3,5(10)-trieno[l7,16-f]-(s-
triazolo[4,3-b]pyridazine)(263). Azasteroids (264), (265), (266), (267),
231and (268) have also been prepared by Sykes and Bajwa.
232Junjappa al. report the synthesis of naphthonaphthyridine
derivatives (269) which may be broadly speaking, considered as aza- 
233steroids. They also report the synthesis of novel substituted and 
fused pyrazolo [4,3-c]pyridone and pyrido[4,3-d]pyrimidine derivatives, 
such as (270)234 ^n^ (271).^33
Omar and Ashour235 have synthesised some novel steroidal hydrazones 
containing quinazoline moieties.
236Electrochemical cyclization has afforded compounds of type (272).
Several polyazadithiaateroidal analogues have been prepared by
237Fravolini ^  al. (see Fig^ure 6). The synthesis of thiadiazasteroid
analogues (see Figure 7), has also been reported.23®
Bridgehead nitrogen heterocycles, including the 8,13-diazasteroids 
(283) have been prepared by Scovill and Burckhalter.23®
Lalezari ^  al.24^ report the synthesis of several interesting
polyazasteroids (see Figure 8).
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Yamazaki ejt al. report the successful preparation of 14,17- 
diazasteroids^^^ (288), (289), (290), (291), eind (292); 8,12-diaza- 
D - h o m o s t e r o i d s 2 4 3  (293) and (294); and the 4,8-diazasteroids^'^'^(295)
(see Figure 9),
2.4 Azasteroids - Activity in the central nervous system eind other
biological responses
The broad spectrum of biological activity displayed by the steroids 
generally together with the multiplicity of action exhibited by certain 
individual members, make the steroids one of the most intriguing classes 
of biologically active compounds. The altered physical and chemical 
properties of azasteroids are envisaged to lead to the discovery of new, 
potentially useful drugs.
The azasteroids examined to date have been shown to possess one or 
more of the following activities:- (i) adrenocortical; (ii) anti-mineral 
ocortical; (iii) anabolic; (iv) androgen antagonistic; (v) biosynthetic 
inhibitor; (vi) oestrogenic/anti-oestrogenic; (vii) progestative/anti- 
progestative; (viii) anti-fertility; (ix) catatoxic; (x) cardiac;
(xi) anti-lipemic; (xii) CNS-acting; (xiii) neuromuscular blocking;
(xiv) local anaesthetic; (xv) antimicrobial; and, (xvi) anti-neoplastic.
The reader is referred to the excellent review by Singh, Kapoor find 
Paul^^^ for further details. However, some of the pharmacological 
activities of azasteroids are summarised in Table 5.
The pharmacological activities of some naturally occurring, 
nitrogen containing steroidal molecules has been reviewed in 1962 by 
Martin-Smith et al.^^^ Martin-Smith et have also reviewed
the biological activity present in derivatives of naturally occurring 
steroids possessing nitrogen atoms.
Structure-activity relationships and stereochemical factors 










17 B-Hydroxy-17a-methylandrost- 246,247 
ano- [3,2-c j-pyraizole.
Anabolic activity.
Naturally occurring bisquat- 
ernary steroidal alkaloid- 
malquetine.
Neuromuscular-blocking 
potency equivalent to that 
of (+)-tubocurarine, but 




Progestational activity equal 
to that of progesterone; also 











Oestrogenic activity ten 
times greater than that of 
oestrone.
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Analeptic activity, producing 
convulsions and antagonising 








Analeptic activity, producing 
convulsions and antagonising 
the narcotic effects of 
barbiturates.
Salts of 5a-androstane 260
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(R^ = Ac; R2 = 3-OAc, H;
263,269
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Mono and bisquaternary aza 
steroids.
264,266
CH Neuromuscular blocking, 








PART I (CONTINUED) 84.
C H A P T E R  T H R E E
REVIEW OF ISOQUINOLINES
3.1 History
For many centuries, the dried latex exuded from the seed capsule
of the opium poppy, Papayer somniferum. has been employed to alleviate
pain and also to induce a state of euphoria when injested. The
euphoric and analgesic agent, morphine, was the first nitrogenous base
to be isolated from living organisms, in 1805. The structure of
morphine^^^ was elucidated in 1925, when it was found to be a member
271of the alkaloids based on the isoquinoline nucleus.
Considerable interest in the synthesis of isoquinoline derivatives^^ 
has developed owing to the frequent occurrence of the isoquinoline 
nucleus in alkaloids.
3.1.1
Some recently isolated isoquinoline alkaloids are illustrated in 
Table 6.
3,2 Synthesis
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acid; R = H 290
NH
0-Methylpeyoruvic 




Isoajihalamine; R = H 291,286
HO
Isoanhalidine; R = CH
N-R
Isoajihalonidine; R = H
CH




3,4-Dihydroisoquinolines(296) were first prepared by Bischler





Modification of the reaction by Pictet and Gams,^^^”^ in which the
isoquinoline is obtained directly from 6-hydroxy-6-phenethylamide,




ft= -  CH.
(297)
CH.
Numerous methods of synthesizing isoquinoline derivatives have
275 276been reviewed by Bergstrom and Manske. The Bischler-Napieralski 
277reaction is discussed in depth by Whaley et al.
Optically pure Salsolidines can be prepared by the Bischler- 
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In a novel variation of the Bischler-Napieralski approach, 
w-phenylisonitrosopropiophenone(299) is reduced to an amino alcohol, 
followed by Nrformylation and cyclization, resulting in the formation 





















Fodor et al.^^^ have shown that nitrilium cations(303) are
intermediates in the Bischler-Napieralski cyclization whenever











278The Pictet-Spengler* reaction involves the condensation of 
3-arylethylainine with a carbonyl compound to yield a tetrahydro-
isoquinoline, and may be considered to be a special example of the
279 280Mannich reaction. The reaction* was extended by Decker to
the condensation of substituted phenethylamines with various aldehydes
(see Scheme 27). For further details of this reaction*, the reader




A variety of optically active tetrahydroisoquinolines have been
prepared by this route, some of which are shown in Scheme
The Pictet-Spengler cyclization has also been employed to prepare
the alkaloids 0-methylpeyoxylic and 0-methylpeyoruvic acids from
290mescaline hydrochlorideOlO),
0 O















A study of the synthesis of tetrahydroisoquinolines via the cyclization
of Schiff bases under neutral^^^ or weakly acidic conditions has been
carried out. As expected, a phenolic group ortho or para to the
301 302cyclization site greatly facilitates the reaction. *
3.2.3
Acid-catalysed cyclization of benzalamino-acetal(311) resulting
in the formation of the isoquinoline nucleus(312) was first reported
by Pomeranz281-3 F r i t s c h . 2 8 4 - 5  has since been utilized in the
synthesis of a variety of isoquinolines (see Scheme 29). The reaction


























The Pomeranz-Fritsch cyclization, modified^^^*^^^ by Bobbitt to
obtain 4-hydroxytetrahydroisoquinolines,continues to be a useful 
305-6approach. Substituted isoquinolines have been prepared by
Jackson et al.^^^ ® by cyclization of acetal sulphonamides under 


















Several other reagents have been successfully employed in the 
























3.2.4 Other synthetic routes leading to isoquinolines
Amination of benzopyrylium salts(326), obtained via acylation
of 3,4-dimethoxyphenylpyruvic methyl ester(324) with acetic anhydride
followed by acid-catalysed cyclization, also results in the formation












Ikeda ejt report a novel route to isoquinoline derivatives,








Cyclization of aralkenyl-substituted quaternary ammonium salts 







317Brossi et al. report a facile synthesis of 1,4-dihydro-
isoquinolones and their reduction to the corresponding 1,2,3,4-
tetrahydroisoquinolines (see Scheme 35).
An improved synthesis of l,4-dihydro-3-[2H]-isoquinolone(330)
via a Beckmann rearrangement of 2-indanone oxime(331) is reported by 
318Lyle and Walsh.




Ben Ishai et al. have recently prepared isoquinolones(332), 













OH - ’r ï T f




















For the synthesis of Benzylisoquinolines, Bisbenzylisoquinolines, 
Cularines, Aporphines, Berberines, Benzophenanthridines, and other 
isoquinoline derivatives the reader is referred to the excellent review 
by Shamma.320
The biosynthesis and metabolism of isoquinoline derivatives is 
discussed in detail in the reviews by Shamma^^^ and Mann.^^^
The isoquinoline derivatives, some of which occur naturally, 
possess a wide range of biological activity. A few of the many 
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Bronchodilatory and 326,329,
potent 3-adrenergic. 330
Tr i me t o qui no 1 
OCH3
Antiarrhythmic
CHoO O C H 3
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O C H .
CH_0
*̂ 2 10C H o O
Potent neuromuscular 332,333 
blocking agents
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R = CHg (Laudexinium salt)
R  =  C H 2 * C H 3
Quaternary dimers of tetra- 
hydropapaverine (Bisbenzyl­
isoquinolines)
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ing the translation 
of araino-acyl transfer 
RNA to ribosomal pep­
tide. It also 
inhibits in vitro 
aerobic glycolysis in 
cardiac muscle.
Anticonvulsant,






+)-Bicuculline, R + R = CHg
(+)-Bicuculline methochloride
(+)-Corlumine, R = CH.
Antagonises both the 
depressant effects of 
microiontophoretic- 
ally applied GABA, 





















C H A P T E R  F O U R
REVIEW OF QUINAZOLINES
4,1 Introduction
Although quinazoline itself was first synthesised by Bischler 
and Lang^®^ in 1895 and Gabriel^®® in 1903, preparation of a quina­
zoline derivative(333) was reported by Griess^^? in 1869.
(333)
For an account of the history and early work in the field of
quinazolines, the reader is referred to the reviews by Williamson 
369and Landquist. The chemistry of quinazolines is discussed in
depth by Armarego^^^*^^^ and others.
368
4.2 Synthesis of quinazolines
Quinazolines can be prepared either via a primary route or a 
secondary route.
a) The primary route leading to formation of quinazolines
involves the building up of the quinazoline system from the 
intact carbocyclic ring, for example:-
(i) Niementowski synthesis^^^ (reaction of *0'-aminobenzoic













Reaction of *0*-aminobenzaldéhyde^^^ or 'O'-aminophenyl 













(v) Cyclization of 'O'-amidobenzonitriles with alkaline 
hydrogen p e r o x i d e 3 8 4 - 3 8 9  yield 3,4-dihydro-4- 
oxoquinazolines:-




Cyclization of *0'-amidoacetophenoneoximes with mineral 
acids to yield quinazoline-3-oxidés.



















b) The secondary route leading to quinazoline formation,
involves transformations on the intact skeleton(334),^^^ 
the most important of which are oxidation, reduction,
•c0C3
(334)
the metathesis, addition, and substitution reactions (also 
involving side-chain reactions).
The following section attempts to review modifications of older 
synthetic methods and novel synthetic routes leading to the formation 
of quinazolines and their derivatives, up to the present date.
During the past decade, interest in quinazoline synthesis has increased 
owing to the potent biological activity possessed by the various 
derivatives.
4.2.1.1
400Gotthelf reported the preparation and chemistry of several 
2-alkyl-4-oxodihydroquinazolines from anthranilic acid, in 1901.
2,3-Disubstituted-4-quinazolones, methyl quinazoli n e s , a n d  
quinazoline carboxylic acids"^®^ have been prepared by Bogert et al. 
Several 3-aryl-4-quinazolones were synthesised by Morgan et al.^^*
6,8-Disubstituted quinazolines^^® were(successfully^ prepared in 1947.
103.
422 423The preparation of 4-phenylquinazolines * was reported by 







Condensation of anthranilates with cyclic imidoyl chlorides^^^
affords quinazolines(336) and (337),^^^ (see Scheme 36), 2-Aryl-4-
412 421quinazolones have been prepared by Stephen et al,. and Eaton ejt al.
The preparation of several 4-substituted quinazolines(338) has been





















QuincLzoline and 2-methylquinazolineSreact with aqueous sodium
A.





Several quinazoline derivatives have been prepared from isatoic 
anhydrides(342),^^^*^^^*^^^*^^^ ajid their derivatives.
(342)
4.2.1.4
The thiazolo and thiazino analogues of febrifugine, 2,3-dihydro* 
5 H-thiazolo[2,3-b]quinazolin-5-one(343) and 3,4-dihydro-2H,6H[l,3]- 
thiazino[2,3-b]quinazolin-6-one(344), have been prepared by Payne
et 419 by the reaction of chloroalkyl isothiocyanates
(Cl [CH^]^•N=C=S) on methyl anthranilate.
Ill,
A s ; " "
(343) n = 2
(344) n = 3
Several other sulphur-containing quinazoline derivatives have 




=  CH*CH*R \  /
(346) (a) Rl = = CH,
(b) Rl = pf = H
4.2.1,5
Hie formation of quineizolines from 1,4-benzodiazepines has been 
discussed by Sternbach^^^ et al. Peet et a l . and Bianchi e^ 
Taylor and co-workersreport the preparation of some 
quinazolino[3,2-a][l,4]benzodiazepines(347).





Recently, many quinazoline derivatives containing a fused third 
ring have been prepared (see Figure 11 for some examples). Derivatives 






Z * NH, O
A
(R = H , C H y n C ^ )  NHg
425(353)
( 3 5 2 ^
425(354)





















Busby ^  al.^^^ report the synthesis of 2-chloroquinazoline(366) 










Condensation of *0*-aminobenzonitrile with acetic acid in the 
presence of polyphosphoric acid afforded 2-methyl-4-quinazolone(368).
0
431
^ ^ < ^ 2  CH3.CO2H
P.P.A.
(368)
A general method for the preparation of condensed pyrimidines(369)
from nitriles under acidic conditions is reported by Dave et al.
R*
438
C'A. R = NHg, OH, etc. R = H, Cl, etc.
(369)
2-Arylquinazolin-4-ones and 1,2-diaryl-l,4-dihydroquincLzolin- 
4-ones have been prepared by the thermal decomposition of 3-aryl- 





A novel synthesis of substituted quinazolines(372) is reported 





X « H; CH^; CH
6,8-Disubstituted 2-guanidino-4(3H)-quinazolinones439 (373) have 




X = H; Br; I; Cl. 
Y = H; Br; I; Cl.
A group from Pfizer (U.K.) Ltd, discuss the substituted quinazolines
434(374), (375) and (376).
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(3 7 4 )









00*0CH^*C —  OH 
CH_
(3 7 6 )
4,3 Biological activity in guineizollnes and their derivatives
4.3.1
Few naturally occurring alkaloids possess the quinazoline
370nucleus and only some of these are pharmacologically active.
The vasicine(377) group^^»^®^ exhibits bronchodilater activity,*^^'*^
e v o d i a m i n e s ( 3 7 8 ) 3 5 4 ; 3 5 5  gĵ ow hypotensive activity, and the 
f a b r i f u g i n e s ( 3 7 9 ) 4 5 6 , 4 5 7  g^ow high antimalarial a c t i v i t y .
The most active quinazoline known to date is the 2-iminoperhydro-
q u i n a z o l i n e , 466,467 t e t r o d o t o x i n ( 3 8 0 ) , 463,464 ^hich is a  potent















Many synthetic quinazolines have been tested for various 
biological activities, some of which are found to have specific 
activity. The hypnotic (methaqualone) and the oral diuretic 
(quinethazone), have been marketed and are used clinically with 
considerable success. The biological activities of some














































































PART II. RESULTS AND DISCUSSION
C H A P T E R  F I V E  
SYNTHESIS OF AZASTEROIDS FROM ISOQUINOLINE DERIVATIVES
5.1 Preparation of dienes (384) and (385) from isoquinoline (See 
Scheme 37)
5.1.1 The methiodide (381) obtained in almost quantitative yield by 
reacting isoquinoline with methyl iodide, was oxidized with 










5.1.2 Mercuration (electrophilic substitution) of the isoquinolone
(382) with mercuric acetate, occurred at the 4-position, as 
expected, to afford the acetate (383).
5.1.3 Organomercury compounds are known to undergo palladium-
532'catalysed' vinyl substitutions. The palladium II salt may
sometimes be used in 'catalytic' amounts provided an oxidant
such as copper II chloride or mercury II acetate is present in
order to regenerate the palladium II cation after each reaction 
533cycle for further reaction. In the absence of a suitable
oxidant, stoichiometric amounts of the organomercury compound
534and palladium II salt must be employed.
Reaction of the organomercuric acetate (383) (1 equivalent)
with methyl acrylate (in excess) in the presence of palladium II 
acetate (1 equivalent), dissolved in a polar solvent such as 
acetonitrile, yielded the diene (384). Repetition of the above 
with the ethyl ester of acrylic acid in place of the methyl 
ester, furnished the diene (385). The yields were optimised by 
varying the concentrations of the reactants employed and the 
reaction time. Reactions were followed by thin layer chroma­
tography until complete loss of starting material (383) was 
observed. Finally, the black precipitated palladium was 
separated from the product by filtration through a 'Celite' 
bed (ca. 3 cm. depth) on a sintered funnel. Some product 
which had absorbed onto the filter aid was extracted with 
chloroform. After removal of solvents, frcan the combined 
extracts and filtrates, under reduced pressure, the product 







R = CH,, C^H,
CH^CH'COgR + Pd(OCOCH^)g
CH^CN , 25
H0< OOCH^ + Pdĵ  + Hg(OCOCH^)g
• o .*Note 25 is used to denote average laboratory temperature.
From the above equation it can be noted that the mercury II 
acetate generated by the reaction may oxidize the palladium 
formed at the end of a reaction cycle, to palladium II and so 
enable it to react further. When experiments were repeated 
employing catalytic amounts of palladium II acetate (ca. 0.1 
equivalent), the total time taken for all the starting material
(383) to react was greatly increased (>6 days), thus making 
this modification unfeasible. However, on an industrial 
scale, where expense of starting materials is important, this 




Pd(oœcH3>2 —  
" C H 3
(383) 0
Hg(OœCH^)^
L = CH CN (solvent)
OCOCH,
CH.
( i i i )
C H .
GOOCH,
C H 3( V i )
(V)
( v i i )
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The mechanism of this reaction is outlined in Scheme 38.
The solvated arylpalladium salt (ii) (See Scheme 38) formed
in situ by the exchange reaction of palladium acetate with
535the arylmercuric salt (383), reacts readily with an olefin
(iii) resulting in the formation of pi-bonded olefin complex
(iv). The square planar intermediate (iv) with a co-ordination
number of 4, undergoes rearrangement giving rise to the more
stable sigma-bonded complex (v). Spontaneous elimination of
533ligands (solvent molecules) and hydridopalladium acetate 
results in the formation of the stable trans product (vii).
The nature of the metal-olefin bond can be explained in





this involves a sigma-bond (olefin to metal) and a pi-bond
(metal to olefin) as shown in Figure 13. The sigma-bond
formed between the filled olefin pi orbitals and the empty 
24d5s5p hybrid orbital on palladium results in unfavourable
127,
distribution of negative charge on the metal ion. However, 
this situation is relieved by pi back-donation from the filled 
4d5p hybrid orbital on palladium to the empty olefin antibonding 
pi (ïï*) orbital, thus behaving in a synergistic manner. A 
prerequisite to this type of bonding is that the carbon-carbon 
double bond of the olefin lies perpendicular to the plane con­
taining the metal and other ligand (L) atoms [ Pd. . (Olefin)] . 
The nature of the olefinic double bond (affected by substituents 
on one or both carbon atcans) and the solvating ligands (orbitals 
of which may be involved in the formation of hybridized 
orbitals), plays a vital role in the above mechanism.
Proton magnetic resonance spectroscopy may be used to assign 
the stereo-chemistry of a compound, provided the spectrum 
obtained is not too complex. By this method, the olefinic 
protons of the dienes (384) and (385) shown below, were proven 
to be trans-orientated:-
(384)
67.9[lH,d(J = 15 Hz), Cg-H]; 
06.3[lH,d(J = 15 Hz), C^^-H ] ppm
68.00 [lH,d(J = 16 Hz), Cg-H]; 
66.34 [lH,d(J = 16 Hz), C^^-H] ppm
(385) 0
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A high value for the coupling constant (J = 15 or 16 Hz) is 
an indication of trans orientation of the olefinic protons.
5.2 Formation of suitable dienophiles
Initially, readily available dienophiles (See Figure 14) 
were used in order to investigate the scope and limitations 
of the Diels-Alder reaction. Having established the most 
favourable reaction conditions, several different types of
I 5 A  W  15B
suitable dienophiles (See Figures ) were synthesized, then
X
employed as reactants. Some readily available aza-compounds 
(See Figure 16) were tested speculatively for potential dieno- 
philic activity. Success having been achieved with maleic an­
hydride, led to the use of several analogues of maleic anhydride, 
(See Figure 17) as dienophiles.
Figure 14
C H 2
C H ' C N
C H 2
C H - C 0 2 H
0
0
N - C O 2 C 2 H 5
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V 0
(iii)
N ^ 0 2 C 2 H s
! L c 0 2 C 2 H 5
C O 2 C 2 H 5
The mechanism of action and results of the above “dienophiles” 
will be discussed more fully in the relevant sections in 
Part 5.3.
5.3 The Diels-Alder Reaction
5.3.1 Introduction
The Diels-Alder reaction, one example of a general class
of eyelo-addition reactions, is one of the most useful synthetic
reactions in organic chemistry. It involves the reaction of
541a 1,3 - diene in a 'cisoid' conformation with an olefinic 
or acetylenic dienophile to form an adduct, containing a six- 




A,B,R,R - substituents on diene 









Two new sigma-bonds are formed in the product at the expense
of two pi-bonds in the starting materials. 537 Many Diels-Alder
reactions are accelerated by Lewis acid catalysts (aluminium 
chloride, boron trifluoride, stannic chloride etc.)
A typical Diels-Alder reaction involves an electron-rich 
diene and an electron-deficient dienophile. If a dienophile 
contains one or more activating substituents (electron with­
drawing) (for example -CO-,-COOR, -C=N, or -NOg) in con­
jugation with a double or triple bond, it will react readily 
with a diene, a3 - Unsaturated carbonyl compounds (for 
example :- acrolein, acrylic acid and its esters, maleic 
acid and its anhydride, and acetylenedicarboxylic acid) are 
the most widely used dienophiles in organic synthesis on 
account of their enhanced activity towards dienes.
132,
Many Diels-Alder reactions have been carried out with
nitrogen - containing dienes and/or dienophiles. For further
542details, the reader is referred to the reviews by Hamer ,
544 545 543Arbuzov , Needleman and Cook
The Diels-Alder reaction may be expressed in terms of
546a cyclic flow of electrons, without the necessity to 










In a Diels-Alder reaction, addition of the diene across 
the double bond of the dienophile is usually stereospecific, 
as exemplified by the reaction of methyl trans-crotonate with 
cyclopentadiene (See Figure 19).
Figure 19
Acetone, 30*
C O 2 C H 3
55 % 45 % ICO2CH3 CH3
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In both products, stereospecific addition has occurred across
the crotonic ester bond i.e. the methyl and methyl-ester
functionalities are trans. Addition to the double bond has
therefore been cis (as usual). This implies that the addition
is a concerted process and no free diradical intermediate
capable of rotation about the newly formed single bond, is
. involved. Thus, for any Diels-Alder reaction, the relative
stereochemistry of substituents in both the dienophile and
547the diene is retained in the resulting adduct.
5.3.3 Mechanism of the Diels-Alder reaction
The mechanism of this reaction can be explained by the 
'frontier orbital theory' employing the Woodward-Hoffmann 
rules for pericyclic reactions. The following explanation is 
given for a simplified Diels-Alder reaction i.e. reaction of 
butadiene with maleic anhydride or ethylene. However, this 
theory can be readily extended to explain the reactions 




During the course of the reaction, two new sigma bonds are 
formed simultaneously, and the electrons mobilized in the 
reaction complete a circuit. Most pericyclic reactions are 
little influenced by Coulombic forces: for example, the polarity
134.
of solvent has little or no effect on the rate of Diels-Alder 
reactions. The magnitude of interaction of the frontier 
orbitals of the reactants is the major factor influencing the 
rate of the reaction. For the simplified case, concerning 
unsubstituted reactants butadiene and ethylene, the former 
component has four pi-electrons and the latter two, and these 
are the only electrons involved in this (4 + 2] cycloaddition.
A cycloaddition reaction will occur,provided smooth 
bonding overlap can be achieved between the frontier orbitals 
as the reaction proceeds. For bonding overlap to occur (See 
Figure 20), two factors must be observed:-
1. A pair of frontier orbitals will overlap only if 
they are of like-sign (i.e. both positive or both 
negative).
and 2. Geometrical structure of the molecule must be such 
that it enhances overlapping of frontier orbitals 
i.e. a "symmetry allowed" reaction in which the 
interaction of orbitals presents no energy barrier. 
The Diels-Alder reaction shown in Figure 20 is classified as 
a [ tt4 s  +  tt2 s ] cycloaddition, since the two new sigma-bonds 
are formed on the same side (suprafacial) of the conjugated 
system. The overlapping of the frontier orbitals can proceed 
in either of two ways (A or B) (See Figure 20) for this case.
135.
Figure 20
Overlap of the Frontier Orbitals of a Simple Diels-Alder Reaction
A.
f
HOMO of butadiene (Ŷ ) 
LUMO of ethylene (tt*) .
B.
LUMO of butadiene (Y^*)
HOMO of ethylene (tt) .
development of bonding overlap 
, as reaction proceeds.
N.B. Orbitals are not drawn to scale.
Frontier Orbitals: LUMO (unoccupied molecular orbital of
lowest energy).
HOMO (Filled molecular obital of highest 
energy).
For further details the reader is referred to the excellent
, . 548text by Fleming.
5.3.4 Results
Many Diels-Alder reactions, were carried out, some of which 
are shown in Tables 9 and 10, resulting in the formation of 
nitrogen-containing steroidal molecules. In some cases, a 
novel di-adduct formation was observed.
136,
General procedure:-
To the diene (1 equivalent) dissolved in acetonitrile, 
the dienophile (1-4 equivalents) was added. The resulting 
solution was heated under reflux (12 - 72h). After cooling 
the mother liquor, the precipitated product (in most cases) 
was isolated by filtration, then recrystallized from a suitable 
solvent to afford a pure sample of the adduct.
Table 9
Adducts formed by employing the methyl ester (384) as diene.

















1 3 8 ,
Table 9 (continued)
Product
No.Dienophileemployed Resulting Adduct M.P. yield
(404)164-168 <10%
82%223-225 (398)
















Work by Gillis £t al. and Franzus al^^^ 
suggested the feasibility of employing diethyl azodicarboxylate 
as a dienophile. Reaction of the diene (384) with diethyl 
azodicarboxylate furnished the adduct (404), but unfortunately 
in poor isolable yields, which could not be improved upon.
If the yields had been high, this reaction may have 
presented a synthetic route (see Scheme 39) to 'azasteroids' 
containing the "N-C-N" moiety, required for pharmacological 
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It may also be possible to prepare 'azasteroids' containing 
the "N-C-N" moiety via the use of dienophiles
and (iii) 554 shown in Figure 18. In fact, 4-pheny1-1,2,4-
triazoline-3,5-dione (ii) (Figure 18) is a better dienophile 
than N-phenyl maleimide.
Imidoyl chlorides^^^ were prepared then reacted with 
dienes (384) and (385) in an attempt to obtain adducts of 
type (i) and (ii) (See Figure 21).
Figure 21
r ’c 0 N H 2
R
^ - 0  
'"nh R = CH3 ;
N|H
and/or
(384) R = CH^
(385) R = C H
(11 0
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After several attempts during which, either starting material 
[(384) or (385)] or decomposed products were recovered, this 
synthetic route was abandoned.
A mathematical treatment of molecular orbitals and 
electron density considerations^^^ (if adequate physical 
data available), may be used to postulate the orientation of 
the cycloaddition resulting in products (i) or (ii) (See 
Figure 2l).
Goldstein et and Evnin et al.^^^ reported the
successful use of hydantoins as dienophiles in Diels-Alder 
reactions. This prompted an investigation of hydantoins as 
potential dienophiles in this project. However, preparative 
methods leading to the hydantoins shown in Figure 15B were 
either too lengthy or unsuccessful (See Schemes 40 and 41), 
therefore this approach to potentially useful adducts was 
abandoned.
Scheme 40
H O  
) = N






Ç O 2C 4 H 9
Ç H O H
Ç H O H
C O 2 C 4 H 9
pbCQ.œcHg)^
oxidation
Ç 0 2 C ^ H g
C H O
(Ĉ H3NHOO-NH)2CH-002Ĉ Ĥ
( % )  3^
H  0CeRs'NHCO-Ny^
V 0
HBr , CH COgH
C H o O
N — CfiHs
5.3.6 Pi-adduct formation
In sane of the Diels-Alder reactions carried out, an unusual 
di-adduct formation was observed. However, in the cases where 
a di-adduct was the isolated product, the mono-adduct could not 
be synthesized even if a 1:1 equivalent of reactants was 
employed. This suggested that the two stages of the double 
Diels-Alder reaction occur simultaneously, i.e. as the new 
diene forms, it reacts immediately with a further molecule of
144,
the dienophile (See Scheme 42).
Scheme 42
n - r - R
0
0
I_d 1 (iii)N-R s p o n t a n e o u s







Provided distances x and/or y are sufficiently large, the 
ester function or phenyl group behave as a "claw" to hold 
the second dienophile ( ) in position, thus enabling the
reaction to proceed.
Step (i) shown in Scheme 42 is the rate-determining step, 
indicated by the fact that the mono-adduct (A) formed in each 
case, was not isolable. The mechanism for this reaction is 
not known, but examination of the stereochemistry employing 
"Dreiding" models (See Diagram 1), suggests that the spatial 
arrangement of the atoms in the mono-adduct (A) influences 
the addition of a second molecule of the dienophile to yield 
the di-adduct (B). Intermediate (B) readily isomerizes 
to afford the more stable final product (C).
Several unsuccessful attempts were made to introduce a 
different second dienophile to the mono-adduct (A), (See
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Schemes 43 and 44). These may have failed due to one of two 
factors:-
1) Unfavourable reaction as dictated by the Woodward- 
Hoffmann rules for pericyclic reactions (see 
Section 5.3.3).
2) Mono-addiict (A) , (Schemes 43 and 44) , is not 
sufficiently soluble in solvent employed, for 
reaction to occur.
Reactions shown in Schemes 43 and 44 were carried out as 
suspensions in acetonitrile. When attempted in tetrahydrofuran 
(THF), N,N-dimethylformamide(DMF), or dimethyl sulphoxide 
(DMSO), decomposition of the mono-adduct (A) resulted. Owing 
to solubility problems encountered, the results are not 
conclusive.
Scheme 43
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X  = ^ 0
Since no mono-adduct (A) could be isolated from the 
reactions shown in Scheme 42, it may be interesting to 
examine the possibility of mono-adduct formation by employing 
a diene with a sterically hindered position 5 so as to render 
stage (ii) (Scheme 42) unfeasible. Steric hindrance may be 
caused by the introduction of a methoxy, phenyl, or phenoxy 
function at position 5 of the diene (see Scheme 45).
C O 2 R
Scheme 45
N - R 'N - r '
0
R







5.4 Reduction of Adducts (399) and (401)
Several reducing agents^^^ were employed in attempts 
to selectively reduce adducts (399) and (401), in order to 
investigate the chemistry of these adducts and also to 
obtain potentially useful samples for biological testing.
(399) X =;îO
(401) X = o 5
0
5.4.1 Lithium Aluminium Hydride (LiAlH^) 559 is a powerful reducing 
agent for a wide range of organic compounds. It is known 
for its ability to reduce the carbonyl functionality in compounds 
such as esters, ketones, amides etc.
In ether solutions, LiAlH^ is postulated to exist largely
as ionic aggregates of strongly solvated lithium ions and
©aluminohydride anions (AlH^ ). Most normal reduction reactions 
involve the displacement of a strongly electronegative atcxn 
(oxygen, nitrogen, or halogen)and the addition of a hydrogen 
atom to the electron-deficient centre (usually a carbon atom). 
Hydrogen is transferred from the reactive species (alumino­
hydride anion) as the hydride ion, in a bimolecular nucleophilic 
displacement type mechanism. A possible mechanism for the 




A I H 4 ♦ A I H 3
hydrolysis
Theoretically, the reduction of adduct (399) or (401) 
with LiAlH^ was expected to yield one product which may be 
present as one or more stereoisomers i.e.
> C H
O H
However, experimentally it was found that several reduced 
products resulted, which could not be isolated satisfactorily 
owing to their extremely insoluble nature. Attempted 
separation by column chromatography and preparative thin- 
layer chromatography resulted in decomposition of products.
150.
5.4.2 Sodium borohydride (NaBH^) which is not as powerful 
a reducing agent as LiAlH^, was then employed in 
attempts to reduce the adducts (399) and (401) more 
selectively. Although three modified conditions 






Owing to the complexity of the adducts (399) and (401) , 
attempts to reduce them can lead to several different 
products (some of which cire shown in Figure 22.).
One final, fully reduced product could not be obtained 
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O Hvia NaBH^/C^H^OH/CH^OH reduction:-
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0
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5.4.3 Attempts to reduce selectively the adducts (399) and (401)
were also made with d i b o r a n e , a n d  again a complex 
mixture of reduced products was obtained each time (see 
Figure 22).
These adducts could not be reduced successfully to 
one product owing to several factors
i) Complex nature of adducts. Adducts contain several 
reducible functionalities, 
ii) Adducts are extremely insoluble in most solvents, 
but in other solvents (e.g. THF, DMSO etc.) they 
undergo decomposition readily, 
iii) If reducing conditions employed are too harsh,
then complete decomposition of starting material 
and/or reduced products occurs, 
iv) The 'work-up' procedures necessary at the termination 
of some reduction reactions (especially those 
involving hydroboration) to cleave the carbon-boron 
bond in order to release the free reduced product, 
are sometimes so harsh (e.g. alkaline hydrogen 
peroxide) that decomposition of the reduced products 
occurs rapidly.
Some success was achieved when diborane was employed as a 
reducing agent i.e. only seven products resulted.
154.
PART II RESULTS AND DISCUSSION (CONTINUED)
C H A P T E R  S I X  
SYNTHESIS OF DI- AND TRI-AZASTEROID INTERMEDIATES FROM 
4-SUBSTITUTED QUINAZOLINES 
4-Chloroquinazoline (417) (see Scheme 47) and 4-aminoquina-




3,200 cm and 1,700 cm in the
6.1.1 4-Hydroxyquinazoline (415) is obtained readily in yields
of >95% by the condensation of anthranilic acid with formamide, 
Absorption peaks at vr
infra-red spectrum of (415) confirmed the presence of a hydroxy 










Treatment of 4-hydroxyquinazoline (415) with thionyl chloride 
(freshly distilled from linseed oil) afforded 4-choroquinazoline 
(417), in 80% yield, which was found to be extremely unstable.
In presence of acid, 4-chloroquinazoline readily undergoes 
hydrolysis to give 4-hydroxyquinazoline (415), and in the 
presence of trace amounts of 4-hydroxyquinazoline, 4-chloroquin­
azoline undergoes "dimerization" to give the "dimer" (419). 
Purification of 4-chloroquinazoline was achieved by passing the 
crude material through an alumina column.
The molecular ion observed at m/e 164 by mass spectrometry 
supports structure (417). The PMR spectrum shows four aromatic 
protons resonating at 67.7 - 8.4 ppm and the ~ aromatic 
proton downfield at 69.2 ppm.
6.1.2 4-Aminoquinazoline (443) was prepared in yields of >68%,
by the reaction of 4-hydroxyquinazoline (415) with phenyl 
phosphorodiamidate (PPDA). The PMR spectrum obtained 
for product (443) showed the five aromatic protons appearing 
together as a multiplet at 67.2 - 8.5 ppm, and the two 
protons of the amino functionality as a broad b^ak at
64.6 - 6.0 ppm. Mass spectral evidence (molecular ion at 
m/e 145) also supported this structure for product (443).
A possible mechanism for this amination is outlined in 
Scheme 48. The reaction has been proposed by Rosowsky et al.^^^ 
to involve the transition states [a ] and [b ] (Scheme 48).
The free energy gain associated with formation of a new 
P-0 bond and rupture of a P-N bond is high enough to drive 
















An alternative mechanism, involving ring-opening and 
ring-closure, has been proposed by Kroon and Plas,^^^ (see 
Scheme 49).
1976.2 Many workers, including Jones have reported diazasteroid
synthesis from quinazoline derivatives. An outline of the route 
employed in this project leading to diazasteroids, based on 
the Torgov synthesis (see Section 2.3.3), is shown in Scheme 
So. The main disadvantage to this routé is the relative 
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4-Methylquinazoline was prepared via several methods 
(see Sections 6.3 and 6.4).
Cl Scheme 50
(417)




R = CHg, n = 1 







(ii) Michael reaction with cyclic, 
1,3-diones 
(iii) Catalytic reduction
The Mannich^^^ condensation of 4-methylquinazoline (423) 
with dimethylamine hydrochloride and formalin in ethanol 
afforded the Mannich base hydrochloride (424) in 91% yield, 
which underwent potassium t-butoxide- catalysed Michael 










The yields at this stage were so poor (less than 10%) that 
catalytic reductions to,furnish the required cyclized products .
(426), had to be abandoned.
6.3 An investigation of 4-substituted quinazolines as potential 
intermediates for diazasteroid synthesis
Ethyl 4-quinazolylacetate (420) was obtained by the reaction 
of 4-chloroquinazoline with sodio-ethylacetoacetate in yields 
of >55%. Similarly, diethyl 4-quinazolylmalonate (421) was 
obtained in 54% yield by the reaction of 4-chloroquinazoline
with sodio-diethylmalonate. (see Figure 23).
-1 -1 Absorption peaks at 3,500 cm (^H) and 1,710 ( ~C=0) cm
in the infra-red spectrum, together with the PMR - and mass -
spectra (molecular ion at m/e 216) for product (420), support








A possible mechanism for each of the above two condensation 















(420) C - C HCH OOCH
(i) Nucleophilic attack by the ethylacetoacetate anion.
(ii) Attack by a further ethylacetoacetate anion,
(iii) Acid-assisted cleavage of condensation product.
Alkaline hydrolysis of the monoester (420) or diester (421) 











The diester (421) underwent a sodium ethoxide-assisted 
Michael reaction with methyl vinyl ketone to give the 
addition product (427):-
H-C— CO^C^H
C H _ = C H  'OOCH 2(421)
CO^C^H
C^H^O^C — C- CH —  CH—  OOCH
(427)
The product (427) could not be purified satisfactorily. 
N-Benzoylation, N-acétylation, and N-methylation reactions 
were carried out on the monoester (420) and diester (421). 
However, proton nuclear magnetic resonance (100 MHz) and 
mass (low resolution) spectral evidence were not adequate 
to confirm the absolute structures of the products, (see 
Figure 24). Since there are two nitrogen atoms in the ester.
162
theoretically ^-substitution may occur at either atom. Di-
569substitution did not occur. Leonard et al. report several 






RX = CLH.COCl; R = C^H_CO- 6 5 6 5














(441) R = H
(442) R = CO C H
r \
(A)








No. of Compound — 1V cm max.
Spectra
Melting Yield PMR MassIbee Appendix xv 
for Structures) Point (:C=0) ôppm from TMS
(Cg-H) m/e
(415) 215-216° 98% 1,700 8.4 146 (M̂ )
(417) 97-98° 80% - 9.2 164(M̂ )
(419) 233° Variable 1,685 9.0 274(M*)
(420) 106° 54% 1,710 7.3-7.8 216(M̂ )
(421) 86° 55% 1,720 9,3 288(M*)
(422) 45-47° 93% - 8.9 174(M̂ )
(423) 34-37° 67% - 9.1 144 (M̂ )
(424) - 91% - 9.0-9.3 200
(425) - - 1,7101.685 - 268(M̂ )
(427) - ca.20% - 6 .8-8.1 358 (m'*’)
(428) 168-170° 87% 1,660 9.0 230(M^)







When 4-methylquinazoline was treated with a large excess of 
methyl iodide, the quaternary salt (436) resulted. Several 
attempts were made to reduce the monoester (420) and diester 
(421) to provide intermediates (441) and (442) respectively, 
which may undergo cycloaddition reactions to give the required 
diazasteroids, (see Figure 25). The reduced products (441) 
and (442), if reacted with cyclopentanone derivatives may give 
enamine intermediates which on cyclization, it was anticipated, 
might furnish diazasteroids.
Reductions of the esters (420) and (421) attempted with 
sodium borohydride, lithium aluminium hydride, and catalytically 
with platinum dioxide and palladium/charcoal up to 6 atmospheres 
pressure, all failed to give the required products (441) and 
(442). (Very high pressure hydrogenation apparatus was not 
available when these experiments were conducted). Later,
Yamazaki et al^^^ reported the successful reduction of these 
esters at 120 atmospheres pressure employing Adam's catalyst. 
However, their attempts to react the dihydro ester (441) with 
cyclopentanone in presence of trifluoroacetic acid, to give 
the required diazasteroid (A) (see Figure 25) failed. This 
line of approach to the synthesis of diazasteroids was thus 
abandoned.
6.4 The Wittig reaction of 4-chloroquinazoline
Attempts to introduce vinylic substituents at the 4-position 
of the highly reactive 4-chloroquinazoline were made by 
employing Wittig reagents.
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577The normal Wittig reaction is defined as one which 
occurs between the phosphonium ylid or a phosphorane, and an
aldehyde or ketone, to form a phosphine oxide and an olefin:-
0  k V
R ' -  -1 R 1 " R.
+ A  ------* R - P = 0
/  \ 2  \ 2 R '







The ylid (I) generated in situ by the reaction of 4-chloro­
quinazoline with triphenylphosphonium-methylbromide in the 
presence of a base (n-butyllithium),may be reacted with 
carbonyl compounds (II and III) or can be hydrolysed as such, 
















(440) R = 
12% yield
f439) r W *  CHj 
<10% yield
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The PMR spectrum obtained for product (440) shows the C^- 
aromatic proton of 4-styrylquinazoline (440) resonating at 
68.8 ppm. The remainder of the aromatic protons together 
with the two olefinic protons appear as a complex multiplet 
at 67.3-8.4 ppm. Mass spectral evidence (molecular ion at 
m/e 232) also supports structure (440) for the 'diene'.
The Wittig reaction was found to be a good method for the 
preparation of the versatile intermediate, 4-metnylquinazoline 
(423). Products (439) and (440) were isolated in very low 
yields (< 12%), which could not be improved by modifying the 
reaction conditions. It may be possible to improve the yields 
by employing a more effective base such as potassium t-butoxide. 
Lithium is known for its ability to stabilize Wittig adducts, 
and this may be the factor hindering the progress of the 
reaction.
Mechanism of the reaction
Phosphoranes are resonance-stabilized structures in which 
there is some overlap between the carbon P-orbital and one 
of the phosphorus d-orbitals. Reaction with a carbonyl 
compound involves nucleophilic attack by the carbanionic carbon 
of the ylid form on the electrophilic carbon of the carbonyl 
group, resulting in the formation of a betaine. The betaine 
breaks down to the products via a four-membered cyclic 
'transition state'. The driving force of the reaction is 
provided by the formation of the very strong phosphorus- 




o — o y
betaine *'
(ii)
r"->=o . ^ = c c f —
R*
The rate-determining step is either step (i) or step (ii),
depending on the nature of the reactants, and never step (iii)
Although it is uncertain whether the 4-membered ring is a
true intermediate or a transition state, one example of an
oxyphosphorane intermediate (see below) with an axial oxygen
.571atom as required by theory, has been isolated
/^e‘% \  ^ / C 6 H 5
0 —  C — CF-J I ^CF3
Experiments with optically active phosphonium salts have 
established that the Wittig reaction proceeds with complete 
retention of c o n f i g u r a t i o n , a s  required by a cyclic 
mechanism (see Scheme 55).
The Wittig reaction was originally thought to be stereo- 
574specific. However, it is now known that the reactions of
Scheme 55
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(D)- f^-p=cH-c^Ft ---— * 5;;P=o *
(D)-
r 3 /  
e ®
|-> H 2 O 2
'6 5
" (°)-
unstable ylids give rise to varying ratios of cis/trans 
alkenes depending on the reaction conditions employed (salts 
present,polarity of solvents, activity of nucleophiles, etc.)575,576
6.5 Condensation reactions of 4-substituted quinazolines .
When 4-methylquinazoline was reacted with benzaldehyde 
in the presence of an anhydrous solvent (toluene or benzene), 
condensation occurred to give the "diene" (440) in 29% yield, 
which had also been prepared via the Wittig reaction on 
4-chloroquinazoline. The reaction was carried out under 
Dean-Stark conditions, the removal of water during the reaction 
providing the driving force for the reaction. The use of 





4-Methylquinazoline has one acidic proton and thus readily 
generates a methylene functionality which is activated by 
the heterocyclic ring.
S'a.oSimilarly, condensation of 4-aminoquinazoline with 
benzaldehyde under anhydrous conditions, furnished the 




The PMR spectrum of 4-azastyrylquinazoline (444)shows the 
Cg-aromatic proton as a singlet at 68.5 ppm. The remaining 
nine aromatic protons, together with the olefinic proton, 
appear as a complex multiplet at 67.2 - 8.2 ppm. The 
molecular ion observed at m/e 233 by mass spectrometry, also 
supports structure (444).
6.6 Diels-Alder reaction of dienes (440) and (444)
The dienes (440) and (444) underwent Diels-Alder reactions 
with the two dienophiles (see Schemes 57 and 58) employed.
For details of the mechanism of the Diels-Alder reaction 
see Section 5.3.3.
In this series of experiments, only two readily available 
dienophiles were employed. It was not possible to purify 
the adducts satisfactorily owing to tlieir extremely insoluble 
nature. Examination of the mass spectra obtained for the 








The molecular ions seen on the mass spectra were in agreement 
with the molecular weights of the required products. However, 
these results are inconclusive. Further work is necessary 
in order to establish the nature of the products formed via 
these reactions.
An extension of this reaction scheme by using a wide 
range of dienophiles may lead to a whole series of novel 
di- and tri-azasteroids, some of which may have interesting 
pharmacological properties. Solubility was the main problem 
encountered with these adducts. They were found to be extremely 




(447) X = %:0
(448) X =
173.
PART II RESULTS AND DISCUSSION (CONTINUED)
C H A P T E R  S E V E N  
SYNTHESIS OF TRI-AZASTEROIDS AND INTERMEDIATES 
FROM SUBSTITUTED NAPHTHALENES 
Tri- and tetra-cyclic compounds containing the guanidinium 
moeity were prepared by the condensation reaction of hydroxy- 
naphthaldehydes with guanidine carbonate.
7.1 The benzo(h]quinazoline (461) was prepared via the route





7.1.1 Reduction of 1,4-naphthaquinone (454) to 1,4-dihydroxy-
naphthalene (455) with sodium hydrosulphite was a straight­
forward reaction, but yields (ca. 50%) obtained were lower 
than expected for this type of reaction. The reduced product 
(455) was extremely sensitive to light and moisture, therefore 
suitable precautions had to be taken i.e. storage in a vacuum 
desiccator in the absence of light.
* •»
In the PMR spectrum, the two protons of the hydroxyl groups 
appear as a singlet at 68.25 ppm. The six aromatic protons 
appear as three quartets in the aromatic region (66.79-8.25 ppm).
7.1.2 The methylated product (456) was obtained by the action
of dimethyl sulphate in methanol on 1,4-dihydroxynaphthaline, 
in the presence of potassium hydroxide. Due to the instability 
of intermediate (455), the reaction was carried out under an 
atmosphere of nitrogen. The yield of product (456) was dependent 
on the rate of addition of potassium hydroxide solution to 
the reactants (the slower the addition, the greater the yield). 







The PMR spectrum of product (456) shows the six protons of 
the two methoxy groups as a singlet at 63.95 ppm. (See 
Table 12).
7.1.3 Introduction of an alkyl halide function at position 2
of 1,4-dimethoxynaphthalene (456) was brought about by the 
action of monochloromethyl-methylether, in glacial acetic 
acid solvent, on 1,4-dimethoxynaphthalene (456). Yields of 
up to 56% were obtained. Distillation of the crude product 





The PMR spectrum obtained for product (457) shows five 
aromatic protons (66.91-8.15 ppm). The methylene chloride 
protons appear as a singlet at 64.89 ppm., and the six protons 
of the two methoxy groups resonate as a singlet at 63.95 ppm. 
(See Table 12).
7.1.4 A Sommelet reaction on the chloromethyl compound (457) 
furnished the aldehyde (458), in yields of up to 61%. The 
Sommelet reaction involves the reaction of any aryl-, aryl 
methyl-, or alkyl-halide with hexamine to form a hexaminium 
salt, which is then hydrolysed in an aqueous medium such as
176.
aqueous ethanol or aqueous acetic acid to give the amine.
The amine undergoes further hydrolysis readily to generate the 
aldehyde (458). A feasible mechanism for the Sommelet reaction 


















(i) Quaternary salt formation
(ii) Hydrolysis of quaternary salt to an equilibrium 
mixture of amine and methyleneamine.
(iii) Dehydrogenation of amine to an aldimine.
(iv) Hydrolysis of aldimine to the aldehyde (458).
Absorption peak indicating a carbonyl group, in the infra-red
-1spectrum of product (458), occurs at u 1,680 cm . The
structure for the product was further supported by PMR spectral
177
data. The aldehydic proton appears downfield at 610.8 ppm. 
as expected, and the six protons of the two methoxy groups 
appear as two singlets at 64.15 and 64.05 ppm.
7.1.5 1,4-Dihydroxy-2-naphthaldehyde (460) was prepared by
déméthylation of 1,4-dimethoxy-2-naphthaldehyde with boron 
trichloride, in yields of greater than 90%. The reaction 
proceeds via the formation of a tricyclic complex (A) (see 
Scheme 61). 1-Hydroxy, 4-methoxy-2-naphthaldehyde (459) 
was prepared by selective déméthylation of l,4-dimethoxy-2- 
naphthaldehyde with boron trichloride (5 equivalents). The 
red, tricyclic intermediate (A) (see Scheme 61) was hydrolysed 
with water after a controlled reaction time (2 - 3h) to give 
the product (459). Yields of pure 1-hydroxy, 4-methoxy-2- 
naphthaldehyde were as high.as 96%.
The infra-red spectrum of product (459) shows absorption
-1 -1peaks at v 3,400 cm and 1,650 cm due to the hydroxy
and aldehyde functionalities, respectively. In the PMR 
spectrum, the aldehydic proton appears downfield at 610.98 ppm. 
The hydroxyl proton resonates at 69.88 ppm. The three 
protons of the methoxy group appear as a singlet at 63.98 ppm.
178,
Scheme 61578,579





<  . CH.C1Î
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7.1.6 The reaction of 1-hydroxy, 4-methoxy-2-naphthaIdehyde
with guanidine carbonate in n-octanol furnished 2-amindbenzo- 
[hjquinazoline (461) in low yields (ca. 19%). The 
condensation reaction is thought to proceed via a 






- H_0 H N
OCH
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7.1.7 Other syntheses leading to benzoff]- and benzo[h]-quinazolines 
Taylor et a l . report the synthesis of some benzoff]- 
and benzo [h]- quinazolines from o^aminonitriles, some of 





1 - t e t r a l o n e
d e r i v a t i v e
CH^O
H





Rosowsky et have prepared seme benzo [f ] quinazolines






Several isomeric benzoquinazolines,(see Figure 21), 
have been prepared via the condensation of an appropriately 
substituted naphthyl derivative with some small nitrogen 
containing substrate such as guanidine, formamide, urea, etc.
Figure 27
n ' ^ n
Benzo[fjquinazoline Benzo[h]quinazoline Benzo[g]quinazoline 
A novel approach to the synthesis of benzo [ f ) quinazolines
employing a preformed pyrimidine nucleus is described by 
584Muhslow and Delia.
7.2 Synthesis of 3-aminobenzo [ f 1 quinazoline
When 2-hydroxy-l-naphthaldehyde was reacted with guanidine 
carbonate in ri-octanol, condensation occurred to furnish
3-aminobenzo ( f] quinazoline in yields of ca. 25%, (see 
Scheme 63 overleaf).
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The 3-amino derivative (463) is a useful intermediate for the 
synthesis of triazasteroids, (see Section 7.4).
.me7.3 Some reactions of 3-aminobenzo [f] quinazol:
The chemistry of the amino function of this compound was 
investigated.
7.3.1 Reaction of the benzo [f ) quinazoline (463) with acetyl
chloride in the presence of triethylamine, gave the N-acetylated 
product (467), as expected:-
N  N
R = CH(467)toluene
A yield of 45% was obtained for the product (467). When 
N-acetylation of compound (463) was attempted with acetic
183.
anhydride as acetylating reagent, starting material (463) 
was recovered and no reaction occurred, suggesting that the 
amino function of the benzo [f] quinazoline (463) is extremely 
stable. This was further supported when attempts were made to 
replace the amino function by a hydroxy group.
7.3.2 Several attempts were made to replace the amino group
of the benzo [f ] quinazoline (463) with a hydroxy group, by 
the following reactions
i) Reaction with hydrochloric acid 
ii) Treatment with nitrous acid, 
iii) Diazonium salt formation.
In most cases, starting material (463) was recovered on 
completion of the reaction.
Treatment of the benzo [f] quinazoline (463) with hydro­
chloric acid followed by ammonia, yielded the hydrochloride 
salt (465): -
(463) (465)
N>yOHN H ?  H C I




However, the replacement was effected in high yields (ca. 75%) 







It may be possible to employ 3-hydroxybenzo [f] quinazoline 
as starting material for an alternative route (see Scheme 64) 





DMF catalyst Nal, acetone(466) (iii)
o ,
and/or
(i) Preparation of the 3-chloro derivative from 
the 3-hydroxy compound (466) by treatment 
with thionyl chloride.
(ii) Reaction of the 3-chloro intermediate with 
aziridine.
(iii) Sodium iodide/acetone-assisted rearrangement 
of the aziridino intermediate to give the 
triazasteroid shown in Scheme 64.
Stages (ii) and (iii) (Scheme 64) have been successfully
attempted with 4-chloroquinazoline by Hardtmann et al.^^^ 







3-Hydroxybenzo[fjquinazoline was also prepared via 






Unfortunately, the yields obtained by this direct route 
were extremely poor (<10%).
7.4 Preparation of triazasteroids via the N-chloroacetylation 
reaction of 3-aminobenzo[fjquinazoline
Having attempted successfully preliminary experiments to N- 
acetylate the 3-aminobenzo[f]quinazoline in order to establish 
the most favourable conditions required for the reaction, 
work was extended to involve N-chloroacetylation reactions 
of 3-aminobenzo[fjquinazoline.
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Reaction conditions had to be modified several times 
before it was possible to isolate the required product (469). 
Chloroacetyl chloride was freshly distilled prior to use. 
Reactions were attempted in a variety of solvents, such as 
ethylacetate, acetone, etc. Finally, success was achieved 
when anhydrous toluene was employed as solvent. The reaction 
was carried out in the form of a suspension in toluene, under 
an atmosphere of nitrogen, and in the presence of a base 
(pyridine or triethylamine). Triethylamine was found to be 
too basic, reacting readily with the reagent, chloroacetyl 
chloride. However, pyridine proved to be an excellent base 
for the removal of hydrogen chloride generated during the 
reaction, by salt formation.
When reaction conditions employed were too vigorous
i.e. too high a temperature or large excess of reagent 
(chloroacetyl chloride), the dimer (464) was the major 
isolable product, contaminated with some starting material 
(463).
The reagent (chloroacetyl chloride) had to be added 
very slowly, at 0°, with a microlitre syringe to prevent 
self-polymerisation;-
o o o
Cl'CH^'C "^Cl------- >Cl'CHg"C---C*CH.,C1-- > -- * polymer
Hi mgr
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The initial stage of the reaction was carried out at O , 
then the temperature raised gradually to ca. 60° in order 
to effect cyclization of intermediate (468). See Scheme 66. 
Although the product (469) was isolated as 43% yield of 












Data obtained by elemental analysis and mass spectrometry 
confirm the structure to be either one or both of the two 
forms (469) (Scheme 66). Satisfactory proton and carbon-13 
nuclear magnetic resonance data was not obtainable owing to
189
the extremely insoluble nature of product (459). Further 
experimental and spectroscopic data is required in order to 
establish an ^solute structure for product (469) .
Table 12
No. of Compound Mass Spectral Data
(see Appendix IV Melting Yieldfor structures Point (m/e)of compounds)
(455) 175-176° 50% 160 (M*)
(456) 86-87° 95% 188 (M*)
(457) 63-64° 56% 237 (M̂ )
(458) 117° 61% 216 (M*)
(459) 85-86° 96% 202 (M̂ )
(460) 190-192° 97% 188 (M̂ )
(461) 293-296° 19% 225 (M̂ )
(463) 257-259° 25% 195 (M̂ )
(466) 328-331° 75% 196 (m "̂)
(467) 210-214° 45% , 237 (M"*")
(468) - - 271 (m "̂)
(469) 283-285° 43% 236 (M̂ )
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PART II RESULTS AND DISCUSSION (CONTINUED)
C H A P T E R  E I G H T  
BIOLOGICAL RESULTS AND FUTURE STUDIES ‘
8.1 Pharmacological Activity
A few compounds (see Figure 29) were tested for anti­
convulsant activity by Organon Laboratories. An outline 
of the experimental procedures is given in Appendix III.
The samples which were tested, showed no significant 









Further CNS screening of these compounds and the compounds 
derived via the quinazoline route, especially (447) and (469), 
is necessary before a conclusion can be drawn as to the pharma­





Biological evaluations of the quinazoline-based structures 
were not made during the course of this work, as sufficient 
quantities (ca. 1.0 g) of analytically pure products were 
not available.
8 .2 Suggestions for further work, including some extensions of
the routes already employed (Chapters 5, 6 and 7), leading 
to the synthesis of azasteroids
Several modifications and extensions to the routes 
employed, together with many alternative routes, were 
considered. Some of which, described below, may be of 
interest at a later date.
8.2.1 Diazasteroid synthesis from substituted quinazolines
8.2.1.1 4-Methylquinazoline, if reacted with suitable cyclopentanone 
and cyclohexanone derivatives, may give the required 
diazasteroids. Condensation of 4-methylquinazoline with 
cyclopentanone-2-aldehyde or cyclopenta-1,3-diol-2-aldehyde, 
may yield the diazasteroids shown in Scheme 67. Ultra­
violet light - assisted condensations may occur selectively 
to give the cis isomer only (with no formation of the trans). 
The starting material (438) prepared in low yields (ca. 16%) 







The yields for this reaction are poor since the anion (A) can 
undergo self-condensation.
Scheme 67






8.2.1.2 Reaction of lithium or sodium acetylide with 4-chloro-
quinazoline may yield intermediates suitable for the synthesis 
of diazasteroids.
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Lithium acetylide-ethylenediamine complex 
(HC 5 CLi.H2N.CH2.CH2.NH2) was reacted with 4-chloroquinazoline 
in anhydrous, freshly distilled dimethylsulphoxide, (see 
Scheme 68). To the resulting 4-acetylenoquinazoline a 
dienophile was added and the mixture stirred for a further 
24h., under an atmosphere of nitrogen at 25°. Although 





N-phenylmaleimide or maleic anhydride as dienophile, a 
crude mixture of decomposition products was obtained each 
time. The failure of the reaction may be due to the highly 
reactive, acid-labile nature of the starting material,
4-chloroquinazoline.
Methods involving the preparation of an acetylide in 
liquid ammonia, and the reaction of which situ with
4-chloroquinazoline, may yield the intermediate required
194,




HC E CH + NaNH, ->Na.C E CH
X =
Further work is necessary to establish the synthetic 
value of this reaction.
8.2.2 Synthesis of nitrogen-containing steroidal compounds from 
isoquinoline derivatives
It may be possible to synthesize di- and tri-azasteroids 































8.2.3 Synthesis of N-containing steroids from substituted 
naphthalenes
The reaction of 3-aminobenzo [f ] quinazoline with a 
series of chloroalkyl-chlorides may lead to a range of 
triazasteroids, (see Scheme 72). Introduction of methoxy, 
phenoxy, halo, or alkyl substituents in rings A and/or 
B of the steroid skeleton, may yield compounds with a
variety of potentially interesting pharmacological properties.
. Scheme 72 H








Infra-red spectra were recorded as stated, on a Perkin-Elmer 237 
grating spectrophotometer, or a Pye Unicam SP.200 spectrophotometer. 
Ultra-violet absorption spectra were measured in the solutions stated, 
with a Perkin-Elmer 402 spectrophotometer or a Perkin-Elmer 124 double 
beam ultra-violet spectrophotometer, in matched 1cm. silica cells.
Proton magnetic resonance spectra were recorded on a J.E.G.L. P.S.100 
nuclear magnetic resonance spectrometer operating at 100 MHz and 
2.349 Tesla, or a Varlan A60, 60 MHz spectrometer, using tetramethyl 
silane as internal reference, in the solvents stated.
Carbon-13 magnetic resonance spectra were recorded on a J.E.O.L. FX 90Q 
Fourier Transform nuclear magnetic resonance spectrometer, operating at 
a frequency of 22.5 MHz, using tetramethyl silane and a deuterated solvent 
as internal locks.
Mass spectra were recorded at 70 eV with an A.E.I. single focussing 
mass spectrometer or an A.E.I. high resolution MS50 mass spectrometer.
Elemental analyses were carried out at the mlcroanalytical laboratories 
in Oxford (Dr. F.B. Strauss) and London (G.S. Crouch, Esq.), and in 
Organon Laboratories (Newhouse).
Analytical and preparative thin layer chromatography (T.l.c.) was 
carried out on silica gel (GOFg^.^ or 60) plates [Merck], or aluminium 
oxide (GOFg^^ or 60) neutral type E plates [Merck].
Column chromatography was performed on silica gel m.f.c., alumina H 
m.f.c., or aluminium oxide m.f.c. (neutral or acidic) [Hopkin and Williams]
198,
T.l.c. plates were examined under visible and ultra-violet light 
(Xsesnm &nd Agg^nm)' Staining reeigents used to develop plates:- 
iodine, sulphuric acid(4%) in methanol, or ethanolic solution of
2,4-dinitrophenylhydrazine.
Thin Laver Chromatography (T.l.c.)













Melting points were recorded on a Gallenkamp melting-point apparatus, 
Kofler Hotstage, or a microscope fitted with a ÈLOlsLage,














PART III EXPERIMENTAL (CONTINUED)
C H A P T E R  N I N E
SYNTHESIS OF AZASTEROIDS FROM SUBSTITUTED 
ISOQUINOLINES VIA THE DIELS-ALDER REACTION
9,1 Isoquinoline methlodide(381)
Isoquinoline(258g, 2M) and iodomethane(284g, 2M)
dissolved in methanol (500 ml) with cooling in an ice-bath.
On allowing to stand overnight, a bright yellow, crystalline
product precipitated. This was collected by filtration.
The mother liquor was evaporated, under reduced pressure to
low volume, resulting in further precipitation of product.
The product was washed with cold methanol, dried and weighed
(530g, 97.8%), m.p. 159° (lit.^°^ 159°).
1,H nmr^^^ COOH) 9.64( IH, s,C^-H) ; 8.7-8.0(6H,m,aromatic
 ̂ ©protons); 4.26(3H,s,=N-CH3)ppm.
Mass Spec. 142,129 m/e.
9.2 2-Methylisoquinol-l-one(382) via the oxidation of (381)
Isoquinoline methiodide (30g, O.llM) was dissolved in water 
(500 ml). After the addition of a cooled solution of potassium 
hydroxide (24.8g, 0.44M) in water (150 ml), an aqueous solution 
(300 ml) of potassium ferricyanide (73.Ig, 0.22M) was added.
The resulting thick yellow emulsion was stirred for 2 h. at 25°. 
The product was extracted with benzene (4 x 100 ml), washed with 
water (2 x 60 ml), dried over anhydrous magnesium sulphate, and 
finally the solvent removed under reduced pressure to yield a
200.
red oil (16,8g, 95.4%). Distillation of the red oil under 
reduced pressure afforded a yellow oil, which on standing, 
formed platelets of low m.p. (26°). The red oil was 
sufficiently pure to react further, thus making the final 
distillation step unnecessary in most cases.
V 3,500; 3,050; 2,925; 1,640 (>C=0);
(neat film)
1,490; 790 cm'l.
nmr 5 8.3-8.45(lH,m,C_-H); 7.25-7.5(3H,m,(CDCI3) 8 - '
C -H*s); 6.82-6.92 [lH,d(J=8Hz),5,6,7
C3-H]; 6.2-6.3 [lH,d(J=8Hz), C^-H]; 
3.4(3H,s,)N-CH2) ppm.
Mass Spec. 159(M'*') m/e units.
Elemental Analysis;- C^qH^NO requires C,75.47%; H,5.66%; N,8.81%,
found 0,75.52%; H,5.67%; N,8.84%.
(See Appendix II for Carbon-13 spectral data).
9.3 2-Methylisoquinol-l-one-4-mercuric acetate(383)
Tb a solution of mercuric acetate (6.5g) in glacial acetic 
acid^^^»^^ (200 ml), 2-methylisoquinol-l-one (3.3g) was added. 
The resulting yellow solution was stirred for 18 h. at 25°. 
Removal of the acid under reduced pressure gave an almost 
colourless solid. Recrystallization of the crude product from 
absolute ethanol yielded colourless needles (8.2g, 94.6%); m.p, 
218-220°.
201.
3,400; 1,620; 1,570; 1,300 cm“^(liquid paraffin)
\ cD3)JS0 8.4(lH,d.Cg-H); 7.4-7.75(3H.™,C^^^^^-H*s) ;
7.18(1H,s,C3-H); 3.6(3H,s,>N-CH3); 
2.06(3H,s,CH‘C=0) ppm.
Mass Spec. 417(M^); 158 m/e.
Elemental Analysis;- requires C,34.5%; H,2• 5.4^
found C,34.5%; H,2.6%; N,3.3%
- Ij- _  o  X.O -
9.4.1 Methyl trans 3 * [4(2-methy!^, 1-lsoquinolyl] propenoate(384)
Methyl cyanide (30 ml) was added to a mixture of dried 
2-methylisoqulnol-l-one-4-mercurie acetate(383) (4.18g, 10 mM) and 
palladium II acetate (2.25g, 10 mM). The resulting brown-green 
emulsion was stirred for 0.5 h. at 25°, after which an excess of 
methyl acrylate (1.72g, 20 mM) was added dropwise. The black 
suspension thus formed was stirred for 48 h. at 25°. The black 
suspension was then filtered by suction through a Ce 11 te bed 
(3 cm depth) on a sinter. The Cellte was carefully rinsed with
chloroform (300 ml). The yellow filtrates were combined, and 
after removal of the solvents under reduced pressure, the off- 
white solid was crystallised from methanol to give colourless 
crystals (2.1g, 87.5%), m.p. 172° of the required diene(384).
'’"“ (liquid paraffin) c"'"'
^  nmr 8.35-8.55(lH,d,Cg-H); 7.96[lH,d(J=15Hz),




Mass Spec. 243(M'*‘); 212; 184 m/e.
Elemental Analysis;- ^14^13^3 requires C,69.1%; H,5.4%, N,5.8%
found C ,69.2%; H ,5.4%; N, 5.8%
_ It-0X0-
9.4.2 Ethyl-trans 3*[4(2-methyl,1-isoqulnolyl)] prppenoate(385)
A
Tb a mixture of 2-methylisoquinol-l-one-4-raercuric acetate(383) 
(2.09g, 5nAI) and palladium II acetate (1.13g, 5 mM), methyl cyanide 
(20 ml) was added. The dark grëen emulsion was stirred for 0.25 h. 
at 25°, after which an excess of ethyl acrylate (l.Og, 10 mM) was added, 
The resulting black suspension was stirred for 16 h.. at 25°, and then 
filtered through a 'Cellte * bed (4 cm depth) on a sinter. After 
careful washing of the celite with chloroform, the yellow filtrates 
were combined and the solvents removed under reduced pressure to 
afford a yellow oily solid. The yellow solid was crystallised 
from ethanol to give almost colourless crystals (0.9g, 70.3%), m.p.
187° of the diene(385).
'’raax.„, . 1.7CX); 1,685; 1,625; 1,560 cm'^.QNUJOl)
hi nmr 8.45-8.62( lH,d,Cg-H) ; 7.91-8.12( IH, d [J=16Hz] ,
Cg-H) ; 7.40-7.90(4H,m,C3 g ,̂7-aromatic 
protons) ; 6.28-6.4K lH,d[J=16%],C^Q-H) ;
4.16-4.52(2H,q ,-CHg); 3.62(3H,s ,^N-CH3);
1.29-1.52(3H,1,-093) ppm*
Mass Spec. 257(M^) m/e.
Elemental Analysis;- ^15^15^3 requires 0,70.0%; H,5.8%; N,5.5%
found 0,70.2%; H;5.8%; N,5.5%.
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9.5 Preparation of dienophiles
9.5.1 Preparation of N-phenylmaleimlde(387)
To a stirred, refluxing solution of maleic anhydride 
(49.Og, 0.5M) in diethyl ether (600 ml), a solution of 
aniline (46.5g, 0.5M) in diethyl ether (50 ml) was added 
dropwise through a dropping funnel. The resulting suspension 
was stirred at 25° for 0,5 h. After cooling in an ice-bath, 
the off-white precipitate was isolated by suction filtration.
The cream-coloured amide-acid intermediate(387A)(83.0g, 86.9%), 
m.p. 202°, was cyclized without further purification.
Tb a mixture of acetic anhydride (170 ml) and anhydrous 
sodium acetate (20.5g), the roaleanilic acid(387A) (48.Og) was 
added. The resulting pale yellow suspension was stirred whilst 
heating on a steam bath for ca. 0.5 h. until a solution formed.
The reaction mixture was cooled in a water bath (20°) and then 
poured into ice water (300 ml). The yellow precipitate which 
formed, was isolated by suction filtration, washed with ice-cold 
water (3 x 100 ml) and then with petroleum ether (b.p. 30-40°)
(2 X 50 ml), and finally dried in an oven at 60° overnight to give 
a pale yellow powder (37.5g, 86.7%), m.p. 88-90°. Recrystallization
from cyclohexane afforded bright yellow needles(387), m.p. 90°.^ /̂
1H nmr 7.20-7.60[5H,m,aromatic protons];
6.80 [ 2H, s,-CH=CH - ] ppm.
Mass Spec. 173(M^) m/e.
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9.5.2 Preparation of N-benzylmaleimide(388)
Tb a stirred, gently refluxing solution of maleic anhydride
(49.Og, 0.5M) in diethyl ether (850 ml), benzylamine (53.5g, 0.5M)
in diethyl ether (70 ml) was added dropwise through a dropping
funnel^ The resulting white emulsion was stirred for a further 
o2.0 h. at 25 . After cooling the reaction mixture in an ice 
bath, followed by filtration, the white'powder(388A) thus obtained 
was dried, then cyclised without further purification.
Tb a stirred mixture of acetic anhydride (150 ml) and sodium 
acetate (20.5g, 0.25M), the intermediate(388A) (51.25g, 0.25M) Was 
added. The resulting white emulsion was stirred on a steam bath 
for 0.5 h. The brown solution thus formed was cooled to 25° then 
poured into ice water (200 ml). The pale brown precipitate thus 
formed was filtered under suction, washed with ice-cold water 
(2 X 100 ml), then with petroleum ether (b.p. 30-40°) (2 x 50 ml.) 
to afford off-white crystals (39.5g, 84.49%) which on recrystal­
lization from cyclohexane gave colourless needles(388), m.p. 64-65°
nmr <5^^^ 7.2-7.4(5H,m,aromatic protons); 6.6(2H,s,
-CH=CH-); 4 .6(2H,s,-CH2-) ppm.
CDCI3
Mass Spec. 187(M^) m/e.
Elemental Analysis;- C^^HgOgN requires C,70.6%; H,4.8%; N,7.5%
found C,70.5%; H,5.0%; N,7.4%
[See Appendix 11 for Carbon-13 spectral data).
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9.5.3 Attempted preparation of maleimide(389) from N-benzylmaleimide(388)
A solution of N-benzylmaleimide (18.Og) in methcinol (200 ml)
was added to the catalyst (5% palladium/charcoal) (l.Og). The
2mixture was placed in a hydrogenator (pressure = 100 ll/in. ) and 
shaken at 25° for 12 h. The resulting black solution was filtered 
through a Celite bed (3 cm depth) on a sinter to remove the palladium 
and charcoal. On removal of the solvent from the green solution 
under reduced pressure, a white solid was obtained. , Recrystalliz­
ation of this solid from benzene afforded colourless platelets of a 
pure produdt(390) (15.9g, 87.4%), m.p. 84°, which was not the 
required product(389).
nmr 7.2-7.4(5H,m,aromatic protons); 4.6(2H,s,
N-CHg-); 2.66(4H,s,-CH2-CHg-) ppm.
CDCI3
Mass Spec. 189(M^) m/e.
Elemental Analysis:- C,69.8%; H,5.8%; N,7.4%
found C,69.5%; H,5.8%; N,7.2%.
(See Appendix 11 for Carbon-13 spectral data).
9.5.4 Preparation of N-ethylmaleimide(391)
To a stirred solution of maleic anhydride (24.5g, 0.25M) in 
diethyl ether (400 ml), ethylamine (11.3g, 0.25M) in diethyl ether
(30 ml) was added dropwise. The resulting off-white emulsion was
ostirred for 1.5 h. at 25 . After cooling the reaction mixture in 
an ice bath, followed by suction filtration, the white intermediate 
(391A) (29,5g, 82.5%) thus obtained, was dried, then used in the 
final step without further purification.
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Tb a stirred mixture of acetic anhydride (100 ml) auid 
sodium acetate (16,4g, 0.2M), the intermediate(391A) (28.6g, 0.2M) 
was added. The white emulsion was stirred under reflux, on a 
steam bath for 0.5 h. After cooling in an ice bath, the yellow 
solution was poured into ice-water (80 ml). On allowing to stand 
for 2.0 h., the white precipitate which formed, was isolated by 
suction filtration to yield the required product(391) (22.6g, 90.4%), 
m.p. 44-46°. After washing with ice-water (2 x 30 ml) and 
petroleum ether (b.p. 30-40°) (2 x 40 ml), the white powder was 
recrystallised from cyclohexane to afford colourless crystals, 
m.p. 46°.
^  nmr 6.70(2H, s,-HC=CH-) ; 3.40-3.70(2H,q,-CH2-) ;
1.05-1.25(3H,t,-CH3) ppm,
Mass Spec. 125(M^) m/e
5059.5.5.1 Preparation of 5.5-diphenvlhydantoin(392)
This compound(392) was prepared by condensing benzil with
urea, as described in the text by Vogel.
Yield 58%, m.p. 297-298°.
V 3,300(-0H); 1,730(>C=0) cm'^.max
*CDCl3/(CD3)^SO ll.OOClH.s.-OH); 8.98(lH,s.-OH);
7.20-7.60(10H,m,aromatic protons) ppm.
Mass Spec. 252(M^) m/e.
(See Appendix 11 for Carbon-13 spectral data)•
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9.5.5.2 Attempted 0-methylation of the hydantoin(392)
lb a white suspension of hydantoin(-392) (3,0g) in ethanol 
(50 ml), an ethanolic solution of potassium hydroxide (0.6g in 50 ml) 
was added. Methyl iodide (6.0g) was added dropwise to the 
resulting colourless solution, under an atmosphere of nitrogen.
The mixture was stirred under reflux for 6 h. The yellow suspension 
thus formed, was poured into ice-water (100 ml) giving a solution of 
pH = 6. Hie product precipitated on basifying the solution to 
pH = 11, by dropwise addition of sodium hydroxide (5M, ca. 2 ml). 
Suction filtration, followed by washing with water (10 ml), afforded 
a white powder (2.9g, 93.5%), m.p, 185°, which was not the required 
product(393). The product was found to be the N-methylated 
hydantoin(394).
^max 3,450(-0H); 1,790; 1,720(>C=0); 1,160(C-0-C) ;
1,100(0-0-0 cm-1.
H nmr /(CD )*S0 ®*X5(lH,s,-0H) ; 7.20-7.55(lOH,m,aromatic“ 0̂ 0013/(003)^80
protons); 3.00(3H,s,/N-0H3) ppm.
Mass Spec. 266(M'*‘); 251 m/e.
9.5.6 Preparation of 2-ethoxypyrroline(395)^^^
lb the pale-green solution formed by dissolving triethyl- 
oxonium fluoroborate(25g) in dichloromethane (100 ml) under an 
atmosphere of nitrogen at 0°, 2-pyrrolidinone (11.2g) was added 
dropwise via an addition funnel. The mixture was stirred at 25° 
for 12 h. under an atmosphere of nitrogen. The resulting dark-
2C8 .
yellow solution was slowly poured into cooled, saturated aqueous 
sodium carbonate solution (20 ml). After stirring the mixture 
vigorously for 1 h., the organic layer was separated, washed with 
saturated sodium carbonate solution (2 x 10 ml), dried over 
anhydrous magnesium sulphate, and finally, the solvent removed 
under reduced pressure. The product was distilled under reduced 
pressure (10 mm Hg), using a \Agpreux column (15 cm) to yield a 
colourless liquid (8.4g, % based on 2-pyrrolidinone).
V 
max 1,655; 1,375; 1,335; 1,309; 1,030 cm”^(Nujol)
nmr 4.2(2H,q,-CH2-); 3.3(2H,t,>CHg);
2.2(4H,ra,[>CH2]2); 1.2(3H,1,-093)
Mass Spec. 113(M^) m/e.
9.5.7 Preparation of Imidoyl Ohlorides(397)
The imidoyl chlorides were prepared by reacting the amide 
(1 equivalent) with phosphorus oxychloride (2 equivalents) in 
benzene. The mixture was allowed to stir at 0° for 3 h. under 
an atmosphere of nitrogen, before addition of the diene dissolved 
in a suitable solvent.
9.6.1 Reaction of diene(384) with acrylic acid to obtain adduct(398)
The diene(384) (100 mg) was dissolved in acetonitrile (10 ml). 
After the addition of acrylic acid (1.5 ml) in excess, the colourless 
solution was stirred under reflux for 8 h. The solvent and excess 
reagent (acrylic acid) was removed under reduced pressure to afford
209,
a white solid. The solid was washed with ether and then 
recrystallised from acetic acid to yield colourless crystals 
(106 mg, 82%), m.p. 223-225^
V 2,800(-0H); 1,740(>C=0); 1,640(>C=0) cm” ,̂
”^ (  Nujol)
nmr & 7.10-8.0(X4H,m,aromatic protons);
3 2 *^^ 6.20-6,70(lH,m,olefinic proton);
2.00-4.60(5H,ra,aliphatic protons);
3.65(3H,s,-O-CH3);3.00(3H,s,)N-CHg) ppm.
Mass Spec. 315(M^) m/e
Elemental Analysis:- ^17^17^5 requires C,64.8% H,5.4%, N,4.4%
found C ,64.9%; H,5.3%; N,4.5%.
9.6.2 Reaction of diene(384) with maleic anhydride to obtain methyl
1.3.3a.3b.4.5.11.lla-octahydro-4-methyl 1.3.5-trioxofuro[3.4-cl 
phenanthridine-ll-carboxylate(399)
lb a solution of the diene(384) (l.Og) in acetonitrile (50 ml), 
maleic anhydride (0.8g) in excess was added. The resulting mixture 
was stirred under reflux for 12 h. The lemon-yellow solution was 
cooled in an ice-bath to afford colourless crystals, which were 
purified by washing with acetonitrile to yield product (399)
(1.28g, 91.4%), m.p. 244-246°.
^max 250,335 nm
l,800(x:=0); 1,770(>C=0); 1,755(>C=0 );
Nujol)
1,670(>C=0); 1,230 cm‘ .̂
nmr 6 7.85-8.09(2H,m,C -H's); 7.34-7.65(2H,m,(003)2-30 6,7
Cg g-H’s); 7.00-7.15(lH,m,C^Q-H); 4.60(lH,m, 




Mass Spec. 341(M ) m/e.
Elemental Analysis:- ^18^15^6 requires C,63.3%; H ,4.4%; N,4.1%
found C,63.0%; H,4.4%; N,4.1%,
9.6.3 Methvl-2.3.3a.3b.4.5.11.lla-octahydro-4-methvl-l.3.5-trioxo-lH-
cyclopenta[c]phenanthridine-ll-carboxylate(400).
4-Cyclopentene-l,3-dione(0.4g) was added to a solution of the 
diene(384) (0.5g) in acetonitrile (20 ml). The mixture was stirred 
under reflux for 12 h. On cooling the intense yellow solution, a 
pale orange product precipitated. The precipitate was washed 
with acetonitrile and dried, to yield a yellow/orange microcrystalline 




1,755(>C=0); 1,705(>C=0); 1,650; 1,610;
1,220 cm"^.
7.2-8.0(4H,ra,C_ _ _ .-aromatic protons);
6.8-7.0(lH,m,C^Q-H); 4.38-4.55(lH,m,ejy-H);
3.5-4.0(2H,m,C3ĝ ]̂ ]̂̂ -̂H's); 3.70(3H,s,-0C%;; 
3.50-3.65(lH,m,C]^]^-H); 3.25-3.40(2H,m,C2-H’s) ;
3.10(3H,s,>N-CH3) ppm.
339(m '̂ ) m/e.
Elemental Analysis : - ^^gH^yO^N requires C,67.3%; H,5.0%; N,4.1%
found C,67.2%. h ,5.0%; N,4.2%.
211.




The dlene(384) (0.5g) was dissolved in acetonitrile (30 ml). 
N-Phenylmaleiraide (0.71g) was added and the resulting yellow 
solution stirred under reflux for 24 h. The product which 
crystallised in the mother liquor was filtered off, washed with 
acetonitrile, and finally dried to afford colourless microcrystals 
of the required adduct(401), (0.74g, 86.4%), m.p. 259-260°.
X
max 266; 338 nm
\^max 1,750(>C=0); 1,700(>C=0); 1,640(>C=0);CKCI disc)
1,600; 1,495; 1,400 cm*' . 
nmr 6^^^  ̂ 7.88-8.10(2H,m,Cg ,^-H's); 7.20-7.65
3"2
(5H,m,/N-CgHg aromatic protons); 7 .00-7.20 




Mass Spec. 416(M^) m/e.
Elemental Analysis;- ^24^20^5^2 C,69.2%; H,4.8%; N,6.7%
found C,69.1%; H,4.7%;_N,6.8%.
Tb a suspension of the adduct(399) (0.34g) in sodium-dried 
benzene (50 ml), freshly distilled aniline (0.4 ml) was added. 
The resulting cloudy solution was refluxed, employing a 'Dean-
212
Stark separator', for 15 h. After removal of the solvent 
(benzene) under reduced pressure, the yellow oil was titurated 
with diethyl ether to afford a white solid. Suction filtration, 
followed by washing with diethyl ether gave a white powder 
(0.21g, 50.7%), m.p. 259-260°, which was found to be identical 
to product (401) by spectroscopy and thin layer chromatography.
9.6.5 Reaction of diene(384) with *p'-benzoquinone
The yellow solution formed by dissolving the diené ester ,(384) 
(O.lOg) and -benzoquinone (0.16g) in glacial acetic acid (15 ml) , 
was heated for 3 h,under reflux. After removal of the solvent 
by distillation under reduced pressure, the dark yellow solid was 
carefully washed with methanol (2 ml) and acetonitrile (2 ml) to 
afford a pale yellow powder (0.06g, 42.8%),m.p. 259°, of the 
adduct (402) .
^ max, 1,71000=0); 1,66000=0) cm"^.V. Nujol)
ODOl 9.10-7.60(5H,m,0,^ g g ^^-aromatic protons);
7.29(2H,s ,02 g-olefinic protons); 3.72(3H,s,
-O-OH^); 3.12(3H,s,)N-0H3) ppm.
Mass Spec. 347(M^) m/e.
Elemental Analysis:- CggH^gO^N requires 0,69.2%; H,3.8%; N,4.0'o
found 0,69.5%; H,3.8%; N,4.2%
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9,6.6 Preparation of adduct(403) via the reaction of diene(384) with
1.4-naphthoquinone
Tb a solution of the diene(384) (0.24g) in acetonitrile
(30 ml), 1,4-naphthoquinone (0.31g) freshly recrystallised from
petroleum ether (b.p. 60-80°)̂ was added. The resulting green
solution was refluxed for 24 h. The green crystals which formed
on cooling the mother liquor in an ice-bath, were filtered off,
washed with petroleum ether (b.p. 60-80°) and acetonitrile, and
finally dried at 100° overnight to afford pale green crystals of
the product(403) (0.35g, 89.7%), m.p. 302-305°.
V 1,720(>C=0), 1,665(>C=0); 1,348; 1,304 cm"^.
“̂ (Nujol)
Proton nmr could not be recorded as the product was extremely 
insoluble in the usual solvents (dimethylsulphoxide, trifluoroacetic 
acid, etc.)
Mass Spec. 397(M^); 380 m/e
Elemental Analysis:- ^24^15^5 requires 0,72.5%; H,3.8%; N,3.5%
found 0,72.55^ *H,3.7%; N,3.6%.
9.6.7 Reaction of diene(384) with diethyl azodicarboxylate
The diene(384) (0 .20g) and diethyl azodicarboxylate (0 .57g) 
were dissolved in acetonitrile (15 ml). The yellow solution was 
refluxed for 24 h. The solvent (acetonitrile) was removed under 
reduced pressure to give a pale yellow oil. Attempts to com­
pletely remove the excess reagent (diethyl azodicarboxylate) by 
distillation at 100 and low pressure (0.1 mm Hg) were not
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successful. At temperatures greater than 100 , decomposition 
of product (404) occurs (as observed by thin layer chromatography). 
Attempts to purify the product by column chromatography were 
unsuccessful (decomposition of product (404) occurred when either 
a silica or alumina column was employed).
Complete loss of starting material was not achieved even 
after heating the reaction mixture under reflux for 68h. The 
product could not be crystallized satisfactorily from methanol, 
acetonitrile, ether,etc. However, pale yellow platelets, 
m.p. 164-168° (0.08g), were obtained frcrn diethyl ether.





= 0.06 (product (404))
= 0.22 (diene (384))
R^ = 0.66 (diethyl azodicarboxylate)
1,750(>C=0); 1,650(>C=0) cm“ .̂





9,6.8.1 Reaction of diene(384) with N-benzylmaleimide
lb a solution of the diene(384) (0.50g) in acetonitrile (30 ml), 
N-benzylmaleimide (1.50g) was added. Ihe resulting yellow solution 
WcLS re fluxed for 96 h. On cooling, the grey-white solid which 
formed, was isolated by filtration, washed with acetonitrile (10 ml) 
and methanol (10 ml) to afford a colourless microcrystalline product 






1,660(>C=0); 1,615; 1,170 cm’^
6.70-8.0K13H,4multiplets and 1 singlet, 
aromatic protons); 4.20-4.53(5H,m,2bN-CH2 ]
and Cjb-H); 1.40-4.60(7H.broad,C3a,8b,lla,llb, 
12,12a,15"&liphatic protons); 3.70(3H,5,0-0113);
3.09(3H,s ,>N-CH3) ppm.
632, 615, 555 m/e.
requires 0,68.0%; H,5.2%; N,6.6%
found 0,67.9%; H,5.2%; N,6.7%
9.6.8.2 Attempted preparation of adduct(406)
9.6.8.2.1
The diene(384)(l equivalent) was heated under reflux with 
N-benzyl maleimide (1 equivalent) in acetonitrile for 96 h. On 
cooling, no product was isolated. Starting material(384) was 
recovered. Examination by T.l.c. on a silica plate showed absence 
of any new product.
9.6.8.2.2
The adduct (399) (O.Sg, 1 equivalent) was heated under 
reflux with benzylamine (4 equivalents) in sodium-dried benzene 
(40 ml) under a 'Dean-Stark separator' for 48h. The reaction 
was followed by T.l.c. on a silica plate. Although complete 
loss of starting material (399) was observed, proton nmr of 
the crude reaction mixture indicated that decomposition of 
starting material (399) had occurred.
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9,6,9 Reaction of the adductC399) with sodium acetate in acetic anhydride
The adduct(399) (0.5g) was dissolved in acetic anhydride (16 ml), 
After the addition of anhydrous sodium acetate (0.6g), the mixture 
was heated on a steam bath for 0,5 h. The resulting yellow 
solution was poured into ice-water (10 ml), extracted with chloroform 
(2 X 30 ml), and the chloroform extract washed with aqueous, 
saturated sodium bicarbonate solution (10 ml) followed by water 
(2 X 10 ml). Removal of the solvent (chloroform) under reduced 
pressure, afforded a white solid (0,26g, 55/v ), m.p. 84-86° of the 
amide(407). Ihe product (407) was recrystallised from water.
3,500; 2,700-3,200(— COOH); 1,715(>C=0);
9.6.10.1
(KBr disc)
1,680; 1,620; 1,260 cm"l.
nmr  ̂ gQ 9.90(1H, broad singlet,-CO2H); 6.95-7.65
(6H,m,aromatic protons); 3.32(lH,s,)NH);
2.03(3H,s ,)N-CH3) ppm.
Mass Spec. 325(M"*") m/e.
Elemental Analysis;- requires 0,62.8%; H ,3.4%; N,4.3%
found 0,62.6%; H,3.4%; N,4.3%.
9.6.10 Reaction of diene(384) with N-ethylmaleimide
Tb a solution of the diene(384) (0.5g) in acetonitrile (40 ml), 
N-ethylmaleimide (1.03g) was added. The clear yellow solution was 
stirred under reflux for 72 h. The pink precipitate which resulted 
on cooling the mixture in an ice-bath, was isolated by filtration, 
washed with methanol (20 ml) and acetonitrile (20 ml), to afford an
217,
9.6.10.2
almost colourless microcrystalline productC408) (0.62g, 61.2%), 




3,220; l,780e>0=0); 1,750C>0=0); 1,710; 
1,700; 1,640; 1,595 cm"^.
7.70-7.90(lH,m,aromatic proton); 7.39-7.58 
(2H,m,aromatic protons); 4.10-4.38(2H,m, 
-OH^-); 3.70-4.00(2H,m,-0H2-); 3.10-4.00 
(8H,complex,aliphatic protons); 3.69(3H,s, 
-OOH3) ; 3.02(3H,s, >N-0H3); 0.65-1.05(6H, 
m,2x-0H3) ppm.
509,493(M+),492,444,431 m/e.
Elemental Analysis:^ ^26^27^3^7*^2^ requires 0,61.1%; H,5.7%; N,8.2%
found 0,60.8%; H,5.5%; N,8.3%.
The above reaction was repeated, employing a 1:1 equivalent of 
the diene(384) and N-ethylmaleimide, and refluxing the mixture for 
96 h. in an attempt to obtain the adduct(409). However, no product 
could be isolated. Starting material(384) was recovered, together 
with some degradation products.
9.7.1 Preparation of ethyl 1.3.3a.3b.4.5.11.11a-octahvdro-4-methvl-1.3.5-
trioxofuro [3,4-c]phenanthridine-ll-carboxylate(410) via the 
reaction of diene(385) with maleic anhydride
To a solution of the diene(385) (l.Og) in acetonitrile (50 ml), 
maleic anhydride (1.5g) was added. The resulting pale yellow 
solution was stirred whilst heating under reflux for 24 h. On
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cooling the white precipitate which formed was isolated by 
filtration, washed with ethanol (10 ml) and acetonitrile (10 ml) 
to afford a colourless microcrystalline product(410), (1.15g, 
83.3%), m.p. 239-240°.
1,885; 1,800; 1,770(>C=0); 1,750(>C=0);
XNujol)
1,670; 1,320; 1,220 cm"^.
nmr 6 7.89-8.10(2H,m,C^ ̂-H*s); 7.38-7.63(2H,m,(CD ) .SO 6,7 -
Cg g-H's); 7.02-7.18(lH,m,C^Q-H); 4.50-4.70 
(lH,m,C3^-H); 3.50-4.40( 3H, m,C3 ^  ̂  ̂ * s ) ;
4.09-4.35(2H,q,0 ^3 -0 9 :2 ); 3.15(3H,s,)N-CH3); 
1.3(3H,t,0 ^̂4 -0113) ppm.
Mass Spec. 355(M'*'), 310, 283 m/e.
Elemental Analysis;- C H O N  requires C,64.2%; H,4.8%; N,3.9%
found C,64.8%; H,4.8%; N,3.8%. -
9.7.2 Reaction of diene(385) with 4-cvclopentene-l.3-dione
The diene(385) (l.Og) was added to a solution of 4-cyclo- 
pentene-1,3-dione (1.5g) in acetonitrile (50 ml). The resulting 
yellow mixture was stirred whilst heating under reflux for 72 h. 
After cooling the solution in an ice-bath, the resultant dark 
yellow precipitate was isolated by filtration, washed with 
acetonitrile (20 ml) and ethanol (20 ml), to afford a yellow 
microcrystalline product(411) (l.Olg, J4^ ), m.p. 348°-350°.




nmr 5 . 7.75-8.10(2H,m,aromatic protons); 7.29-7.60\CD3)2'SO
(2H,m,aromatic protons); 6.85-7.02(lH,m, 
aromatic proton); 4.35-4.G0(lH,m,C3^-H);
4.05-4.31(2H,q,C^3-CH2-); 3.25-3.75(5H,m, 
C3 a , l l , l l a , 2 , 2 - a l lP h a t lc  protons); 3 .1 0
(3H.S./N-CH ); 1.12-1.33(3H,s.C -CH ) ppm.» f — 3 14 —3
Mass Spec. 353(M+), 281, 257, 229, 212, 184 m/e.
Elemental Analysis:- ^20^19^5’^^^2^ requires C, 6^*2%; H,5.8%; N,3.7%
found C,63.0%; H,5.6%; N,3.9%
9.7.3 Reaction of diene(385) with N-phenylmaleimide
N-Phenylmaleimide (2.7g) and the diene(385) (l.Og) were dissolved 
in acetonitrile (40 ml). The yellow-green solution was stirred 
whilst heating under reflux for 120 h. After cooling in an ice-bath, 
filtration of the dark-brown suspension afforded a pale-grey product. 
The solid was washed with acetonitrile (30 ml) and ethanol (20 ml) to 
give an almost colourless microcrystalline product(412) (0.82g, 35.0%),
m.p. 352-354°.
1,770(>C=0); 1,735(>C=0); 1,700(>C=0); 1,630 
(>C=0); 1,500; 1,460; 1,180; 1,140 cm'l.
nmr 6^^^  ̂ 6.95-8.02(13H,3 multiplets, aromatic protons);
3'2 4.10-4.32(2H,q,C^^-CH2-); 3.25-4.70(8H,m, 




Mass Spec. 619, 603CM'''), 602, 527, 445 m/e.
Elemental Analysis:- C H N O  «H 0 requires 0,67.6%; H,5.0%; N,6.8%V 6 y O / ^
found 0,67.7%; H,4.8%; N,6.8%
A solution of the diene(385) (0,5g) and N-phenylmaleimide 
(0.34g) in acetonitrile (30 ml) was stirred whilst heating under 
reflux for 120 h. Ihe starting materials were recovered, 
together with some products of decomposition. Formation of 
adduct(413) was not observed.






A mixture of the diene(385) (1 equivalent) and dienophile 
((i)—&Xv)) (4 equivalents) was heated under reflux in acetonitrile 
for 72 h. In all cases, the expected adduct formation was not
observed. Starting material and/or decomposition products were
recovered in each case.
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(vi) Imidoyl chloride(397).(R^CItg). obtained from acetamide
(vii) Imidoyl chloride(397).(R=C^Hr). obtained from benzamide
Tb a solution of the diene(384) (1 equivalent) in acetonitrile, 
the dienophile ((i),(ii),(iii),(iv) or (v)) (4 equivalents) was 
added. After stirring and heating the mixture under reflux for 
72 h., the reaction mixture was examined by T.l.c. on a silica 
plate.
A solution of the diene(384) (1 equivalent) in acetonitrile, 
was added to a stirred mixture of the imidoyl chloride ((vi) or (vii)) 
(4 equivalents) in benzene. The resulting mixture was stirred 
whilst heating under reflux for 48 h. The crude reaction mixture 
was examined by T.l.c. on a silica plate.
In each of the above seven cases, no adduct formation was 
observed. Starting materials were recovered from reactions 
(i),(ii),(iii),(iv) and (v). However, in reactions (vi) and (vii), 
decomposition of starting material had occurred.
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9,10 Attempted formation of diadducts via the reaction of 
diene(384) with two dissimilar dienophiles
9.10.1 Reaction of adduct (399) with N-phenylmaleimide.
9.10.2 Reaction of adduct (399) with N-benzylmaleimide.
9.10.3 Reaction of adduct (400) with N-phenylmaleimide.
9.10.4 Reaction of adduct (401) with maleic anhydride.
9.10.5 Reaction of adduct (401) with 4-cyclopentene-l,3-dione.
General Procedure
lb a stirred suspension of the adduct (1 equivalent) in 
acetonitrile, the dienophile (2 equivalents) was added. The 
resulting mixture was heated under reflux for 72 h.
In each case, no diadduct formation was observed, but 
starting material (ca. 80%) was recovered. When the above 
reactions were repeated, employing N,N,-dimethylformamide or 
dimethylsulphoxide as solvent, decomposition of starting material 
(adduct) occurred in each case, with no formation of diadduct.
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9.11 Attempted selective reductions of adducts(399) and (401)
9.11.1 Attempts to selectively reduce the ester functionality of adducts(399) 
and (401) with lithium aluminium hydride
9.11.1.1 In tetrahydrofuran
Tb the grey suspension of lithium aluminium hydride (0.4g, large 
excess) in anhydrous, freshly distilled tetrahydrofuran (40 ml), the 
adduct (401) (0.2g) was added. The resulting brown suspension was
heated under reflux for 6 h. After the addition of ethyl acetate
(3 ml) and water (20 ml), the solvent (tetrahydrofuran) was removed 
under reduced pressure. The product was extracted from the aqueous 
suspension with ethylacetate. Removal of solvents under reduced 
pressure (0.1 mm.Hg.) afforded a dark yellow "oily* solid (0.18g), 
which was found to be a crude mixture containing decomposition products 
(thin layer chromatography, and infrared and mass spectroscopy).
9.11.1.2 In diethyl ether
Tb the grey suspension of lithium aluminium hydride (0.3g, large
excess) in anhydrous freshly distilled diethyl ether (30 ml), the adduct
(401) (0.2g) was added. The resulting grey emulsion was stirred at 25°
for 12 h, then water (10 ml) was added dropwise. After the removal of
diethyl ether under reduced pressure, the solids were isolated by
filtration then washed several times with water. The product was
extracted from the solids with dimethyl sulphoxide. Drying of the
dimethyl sulphoxide extract with anhydrous magnesium sulphate, followed
by removal of solvent (dimethyl sulphoxide) under reduced pressure




3,300; 2,920; 2,860; 1,715; 1,670; 1,630; 1,600; 
1,500 cm'l.
Mass Spec,:- 376; 362; 344 m/e.
9.11.2 Attempts to selectively reduce the carbonyl functionalities of adducts 
(399) and (401) with sodium borohydride
9.11.2.1 With sodium borohydride/ethanol
To an emulsion of the adduct(399) (O.lOg) in ethanol (20 ml, 95%), 
sodium borohydride (0.5g, large excess) was added. Hie resulting mixture 
was stirred for 4 h at 25°. After the addition of water (10 ml) stirring 
was continued for a further 12 h at 25°. Removal of solvents (ethanol 
and water) under reduced pressure gave a white solid, which was washed 
several times with cold water. Hie white solid was found to be a 
mixture of starting material (399) and several decomposition products 
(thin layer chromatography and mass spectroscopy).
9.11.2.2 With sodium borohydridc/mcthanol/cthanol
Tb a stirred suspension of the adduct(401) (O.lOg) in a mixture of 
methanol (1 ml) and ethanol (3 ml), sodium borohydride (0.5g, large 
excess) was added portionwise over 10 minutes. Hie mixture was heated 
under reflux for 2 h (reaction followed by thin layer chromatography on 
silica,solvent J elution,until complete loss of starting material(401) 
observed).
Water (10 ml) was added to the grey emulsion giving an almost clear 
solution (pH = 10-11). Glacial acetic acid was added dropwise until 
effervescence ceased. The solution was then basified by the dropwise 
addition of aqueous sodium hydroxide solution (4M). The product was
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extracted with dichloromethane, washed with water, dried 
(anhydrous magnesium sulphate) and finally, removal of solvent 
(dichloromethane) under reduced pressure gave a brown 'oily' 
solid containing three different products.
The three components of the mixture were separated by 
preparative thin layer chromatography on silica, solvent J 
elution:r Fraction A, = 0.15
Fraction B, = 0.35
Fraction C, R^ = 0.80
(Fraction A undergoes decomposition whilst standing for 24h. 
at 25°).
Data for Fraction C:-
-1V (neat film) 3,400 (broad) ; 3,060; 3,960; 1,630; 1, 420cm
'H 6 1 qn 7.9-8.1 (IH, m. aromatic proton);nmr
6.9-7.7 (7H, m, aromatic protons);
6.5-6.8 (IH, m, aromatic proton);
6.1-6.4 (IH, m, olefinic proton);
3.8-4.6 (4H, m, aliphatic protons);
3.3-3.7 (5H, m, -OCH.and aliphatic protons);—3
3.1 (3H, s,^N-CH^); 2.3-2.5 (2H,m, -CH^-) ;
1.4-1.6 (2H, m, ppm.
Mass spec.:- 374 (M^); 359 m/e
9.11.2.3 With sodium borohydride/acetic acid
To a cooled (0°) suspension of the adduct (401) (0.2 g)
in tetrahydrofuran (10 ml), sodium borohydride (1.0 g, large
excess) was added. Acetic acid (6 ml) in tetrahydrofuran (10
oml) was then added dropwise to the stirred suspension at O 
over 0.5 h. The resulting mixture was heated (55°) under reflux
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until complete loss of starting material (401) occurred 
(reaction followed by T.J.o. on silica) (ca. 6b), After the 
addition of acetic acid (10 ml) and water (20 ml), the product(s) 
was extracted with chloroform, washed with water, dried over 
anhydrous magnesium sulphate and finally, removal of solvent 
(chloroform) under reduced pressure afforded a pale-yellow 
solid (0.18 g). The solid was found to be a; mixture of four 
products, which could not be separated satisfactorily by 
preparative T.l.c. or crystallization procedures.
Vjjjax. (KCl disc.) 3,350; 2,960; 1.710; 1,635; 1,600,1,500 cm~^
9.11.3 Attempted selective reduction of one or more carbonyl
functionalities of adducts (399) and (401) with diborane 
General Procedure
To a suspension of the adduct (399) or (401) (0.2 g) in
anhydrous diethylene glycol dimethyl ether (20 ml) under an 
atmosphere of nitrogen, diborane (B^H^: THF) (5 equivalents) 
was added at 0° over 0.25 h* The resulting grey emulsion was 
stirred at 25° for 12h. under nitrogen. After the dropwise 
addition of aqueous sodium hydroxide solution (5 ml., 5M) 
and hydrogen peroxide (5 ml., 50%) at 0°, the mixture was 
stirred at 25° for 18 h.
The product(s) was extracted with diethyl ether, washed 
with water (3x), dried with anhydrous magnesium sulphate and 
finally, removal of solvent (ether) under reduced pressure 
afforded a white pr pale-yellow solid. The solid was found 
to consist of a mixture of 4-7 components by T.l.c.-Although 
some reduced products were present, some degradation products 
of starting materials (399) or (401) were also present.
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PART III EXPERIMENTAL (CONTINUED)
C H A P T E R  T E N  
DIAZASTEROID INTERMEDIATES FROM 4-SUBSTITHTED QUINAZOLINES
10.1.1 4-Hvdroxvquinazollne(415)
Anthrajiilic acid (68.5g, 0.5M) was heated with an excess of
formamide (45g) for 3 h. at 120-1)0 . Filtration of the pale-
yellow solid on a buchner funnel, followed by recrystallization
from aqueous ethanol (95%) yielded colourless needles (72.Ig, 98%),
m.p. 215-216° (lit.507 215-217°).
V ^ 3,200(OH); 1,700()C=0) cra'̂ .
“^ (  Nujol)
hi nmr 8.35(IH,s,C2-H); 8.12(IH,s,-OH); 7.5-8.25
(4H,m,aromatic protons; ppm.
Mass Spec. 146(M^) m/e
10.1.2 2-Methvl-4-hvdroxyquinazoline(416)^^^
Anthrajiilic acid (50g) and acetic anhydride (150 ml) were
heated together under reflux for 1.5 h. Hie off-white solid,
obtained by removal of the acetic acid and excess acetic anhydride,
by distillation under reduced pressure, was washed with
di-isopropyl ether. The intermediate(416A) (2-methyl,3,1,4-
benzoxazone) (m.p. 114-116°), was allowed to dry in air.
1^740; 1,670; 1,630; 1,590; 1,570; 1,500;( liquid paraffin)
1,280; 1,220 cm'l.
^H nmr <S 7.70-8.50(4H,m,aromatic protons); 2.39( 3H, s,-CHo)(003)2-80 » » -J
ppm.
Mass Spec. 161(M^); 146 m/e.
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3,l,4-Benzoxazone(416A) was crushed to a fine powder and 
then suspended in concentrated ammonia solution (0.880 S.G.).
The yellow suspension was shaken for 24 h., after which, sodium 
hydroxide (10% aq. solution, 20 ml) was added. The mixture was 
heated on a water bath until bubbling ceased. The yellow sus­
pension was dissolved completely by the addition of sodium 
hydroxide (10% solution, ca. 200 ml). The resulting brown 
solution was treated with decolourising charcoal and filtered 
whilst hot. Acidification of the yellow filtrate with glacial 
acetic acid, followed by cooling in an ice-bath furnished colour­
less crystals. The produce was isolated by filtration, washed 
with ice-water and dried in a vacuum oven (100°); m.p. 233-234°^^ 
(53g, 91%).
V , 3,300; 1,640; 1,620; 1,590;1,310; 1,130 cmmax(liquid paraffin) ^
nmr  ̂ 7.60-8.15(4H,m,aromatic protons);
2.40(3H,s,-CH3) ppm.
Mass Spec. 160(M^); 145 m/e.
10.2.1 4-Chloroquinazoline(417)
10.2.1.1
4-Hydroxyquinazoline (15.Og) was stirred with freshly distilled 
thionyl chloride (60 ml). Phosphorus pentachloride (2.2g), N,N- 
dimethylformamîde (2 ml), and benzene 20 ml) were added to the 
stirred suspension. The mixture was heated under reflux for 4.5 h. 
The resulting clear yellow solution was evaporated to dryness under 
reduced pressure to give a pale-yellow solid. The yellow solid
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was extracted with chloroform (500 ml), washed with sodium 
bicarbonate (6.Og)-ice/water mixture, and finally washed with 
ice-cold water (3 x 100 ml portions). The solvent was removed 
under reduced pressure at 25° to yield a yellow solid, which 
recrystallised from petroleum ether (b.p. 40-60°) to give pale 
yellow crystals (13.5g, 80%), m.p. 97-98* (lit.^^^ 98°).
V l,640OC=N-); 1,590; 1,502; 1,012; 790,
""^liquid paraffin^™
nmr 5 ppm 9.18(lH,s,Cp-H); 7.7-8.4(4H,m,aromatic
CDClg^
protons).
Mass Spec. 164(M^); 129 m/e.
10.2.1.2
4-Hydroxyquinazoline(8.0g), phosphorus pentachloride (15.0g) 
and phosphorus oxychloride (70 ml) were mixed together and heated 
under reflux for 2.5 h. at 115-118°. Hie phosphorus oxychloride 
was removed by distillation under reduced pressure. The residue
was extracted with ether (3 x 200 ml portions). The combined
ether extracts were basified with sodium bicarbonate (ca. 4g), 
washed with water and finally dried (anhydrous magnesium sulphate). 
Removal of the solvent under reduced pressure gave a pale-yellow 
solid (5.6g, 63%), m.p. 98° (lit.^^? 96.5-97.5°).
Analytical data similar to that for experiment 10.2.1.1.
10.2.2 2-Methyl.4-chloroquinazoline(418)
2-Methyl,4-hydroxyquinazoline (lOg) in thionyl chloride (30 ml) 
and dimethylformamide (1 ml) was heated under reflux for 24 h.
After removal of the thionyl chloride under reduced pressure, the
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10.4.1
orange solid was extracted with dichloromethane (200 ml) and 
washed with an ice-cold aqueous solution of sodium bicarbonate 
(3g, 50 ml), followed by water (2 x 50 ml). The organic phase 
was dried with anhydrous magnesium sulphate, after which the 
solvent was removed under reduced pressure to yield a yellow 
solid (4.2g, 38%). Recrystallization from heptane afforded 
pale yellow crystals, m.p. 82-83° (lit.^^^ 81.5-83°).
Mass Spec. 178(M^), 143 m/e.
10.3 3.4-Dihydro-4-oxo-3-quinazolin-4 *-yl-quinazoline(419)
When 4-chloroquinazoline(417) is heated to above 50°, treated
with acid, or allowed to stand in the presence of 4-hydroxyquinazoline,
the *dimer*(419) results. Recrystallization from aqueous ethanol
(50%) furnished pale yellow crystals, m.p. 233° (lit.^^^ 232°).
^max 1,685; 1,617; 1,320 cm'l.
(liquid paraffin)
nmr 9.00(2H,s,C2 ^f-H’s); 7.60-8.30(8H,m,
aromatic protons) ppm.
Mass Spec. 274(M'*') m/e.
Elemental Analysis: ^16^10^4® requires C,70.0%; H,3.7%; N,20.4%
found C,70.0%; H,3.7%; N,20.3%.
10.4 4-(g -Ethdxycarbonyl)methvlquinazoline(420)
Redistilled and dried ethyl acetoacetate (8.2g) and sodium(l«44g) 
were stirred together at 25° in sodium-dried diethyl ether (200 ml) for 
24 h. lb the resulting milky suspension, freshly prepared and dried
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4-chloroquinazoline (10.5g) was added. A further quantity of 
sodium-dried diethyl ether (200 ml) was added. The yellow 
mixture was refluxed for 36 h. After removal of the ether 
under reduced pressure, water (100 ml) was added to obtain a 
clear yellow solution of pH = 8-9. The solution was brought 
to pH = 6 by dropwise addition of hydrochloric acid (2M). The 
resulting white precipitate was removed by filtration and dried. 
Recrystallization from aqueous ethanol (50%) afforded pale yellow 
needles of product (420) (7.5g, 54%), m.p. 106° with softening at 
82° (lit.^^^ 105°). Two further recrystallizations from hexane 
(with decolourising charcoal) gave very fine colourless needles 
with m.p. 108° (l i t 108-109°), in yields of < 30%.
l,640OC=N); 1,71000=0); 3,500()N-H) cm'^.
(Nujol)
^H nmr 7.30-7.81(5H,m,aromatic protons); 5.42( IH, s,Cg-H) ;
4.15(2H,q,-CH2-); 1.80(lH,s,>N-H); 1.3(3H,t,-CH3)
ppm.
Mass Spec. 216(M^) m/c.
(See Appendix II for Carbon-13 spectral data.)
To a stirred solution of sodium ethoxide (1.4g sodium in 
200 ml absolute ethanol), an ethanoiic solution of 4-(3,&-diethoxy- 
carbonyl)methylquinazoline(421) (4g in 20 ml) was added. After 
heating under reflux for 1.5 h., the mixture was poured into water 
(400 ml). The aqueous solution was acidified with hydrochloric 
acid (3M, ca. 20 ml) to pH = 5. The yellow precipitate thus 
produced was filtered, dried, and recrystallised from aqueous 
ethanol (50%) (using decolourizing charcoal) to yield pale yellow 
needles (2.6g, 86.6%), m,p. 106°.
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Analytical data was found to be identical to that for 
product (420), Ex. 10.4.1.
10.5 4-(q. (X-Diethoxvcarbonyl)methylquinazoline( 421)
Tb the white suspension of sodio-diethylmalonate, obtained 
by stirring sodium (1.75g) and redistilled diethylmalonate (12.5g) 
in sodium-dried diethyl ether (200 ml), freshly prepared and dried 
4-chloroquinazoline (15g) was added. The resulting yellow 
mixture was heated under reflux for 48 h. The yellow solid was 
filtered off and added to water (100 ml), giving a solution of 
pH = 8.5. Neutralization of the mixture to pH = 7, by dropwise 
addition of sulphuric acid (2M) afforded a yellow precipitate (14g), 
which was isolated by filtration. The ethereal filtrate was shaken 
with sodium hydroxide (2M, 20 ml). Removal of the aqueous layer, 
followed by neutralization with sulphuric acid (2M) resulted in 
further precipitation of the product (2g). The crude precipitates 
of the product (16g) were combined. Recrystallization from hexane 
afforded pale-yellow crystals (14.5g, 55,1%) m.p. 86° (lit.®^^ 85.5 - 
86.5°) of the diester (421).
1,72000=0); 3,5500N-H) cm"^.
(Nujol)
^H nmr 9.30( IH, s,C2-H) ; 7.30-8.15(4H,m, aromatic protons);
5.54(lH,s,-CH<); 4.30(4H,q,-CH2-); 1.31(3H,t,-CH^>;
1.29(3H,t,-CHg) ppm.
Mass Spec. 288(M^) m/e.
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10.6 4-Ethoxvquinazoline(422)
To a suspension of 4-chloroquinazoline (8.5g) in diethyl
ether (100 ml), an ethanoiic solution of sodium ethoxide (1.2g
sodium in 50 ml ethanol) was added. The yellow mixture was
heated under reflux for 48 h. After neutralization of the
mixture with hydrochloric acid (2M), the pale yellow precipitate
which resulted, was isolated by filtration. Recrystallization
from aqueous ethanol (95%) afforded colourless needles (8.4g, 93%),
m.p. 45-47° (lit.^^^47-49°) of 4-ethoxyquinazoline.
nmr 8.9( IH, s,C2-H) ; 7.5-8.3(4H,m, aromatic protons);
4 .6(2H,q,-CH2-); 1.5(3H,t,-CH3) ppm.
Mass Spec. 174(M‘*'), 159 m/e.
(See Appendix II for Carbon-13 spectral data)
10.7 4-Methylquinazoline(423)
10.7.1
The monoester(420) was boiled gently under reflux in an aqueous
solution of sodium hydroxide (20%) for 3 h. After cooling the
reaction mixture, the product was extracted from the yellow-green
solution with diethyl ether. The ethereal extract was washed
carefully with cold water, dried over anhydrous magnesium sulphate,
and finally, the solvent removed under reduced pressure to afford a
yellow oily solid, which on allowing to stand for 24 h., crystallized
to give 4-methyiquinazoline (46%), m.p. 35-37° (lit.^^^ 33.5-36.5°).
^H nmr 9,1( IH, s,C2-H) ; 7.3-7.9(4H,m, aromatic protons);
2 .75(3H,s,-CH3) ppm.




The picrate was prepared by adding a saturated solution of 
picric acid in ethanol (95%) to a solution of 4-methyiquinazoline 
in absolute ethanol. On allowing the solution to cool at 0°, 
pale green crystals resulted, which were recrystallized from 
aqueous ethanol (95%) to afford bright yellow platelets, m.p. 180-183 
Elemental Analysis: ^15^11^5^7 requires C,48.3%;H,3.0%;N,18.8%
o
found C,48.1%; H,3.0%;N,18.7%
The diester(421) was heated under reflux in a methanolic 
solution of potassium hydroxide ( 10%) for 4 h. TJie resulting 
yellow solution was neutralised with hydrochloric acid (2M).
After removal of the white precipitate by filtration, the solvent 
(methanol) was removed under reduced pressure to give a brown oil, 
which was extracted with diethyl ether. The ethereal extracts 
were combined, washed with ice-cold water (2x), dried over 
anhydrous magnesium sulphate, and finally, the solvent removed 
under reduced pressure to afford a yellow oily solid, which was 
crystallized from ether to give yellow platelets (67%), m.p. 34-37° 
of 4-methylquinazoline. (Analytical data similar to that for 
Ex. 10.7.Ij




Dimethylamine hydrochloride (0.6g) and formaldehyde (0.6 ml,
37% aqueous solution) were added to a solution of 4-methylquinazoline
(l.Og) in absolute ethanol (20 ml). - The resulting orange solution
was stirred at 25° for 20 h. The solvents were removed under
reduced pressure (0.1 mm Hg) at 35°, to afford a green oily solid
(1.5g, 91%). A small amount was crystallized from an acetone/
ethanol mixture to give yellow-green crystals, m.p. 121-125° (with 
osoftening at 80 ). Although several attempts were made, it was 
not possible to satisfactorily recrystallize the product (424).
^ 3,400; 1,650; 1,600; 1,560; 1,140 cm"^.
™^( liquid paraffin)
nmr à 9.0-9.3(IH,m,C«-H); 7.7-8.8(4H,m,aromatic(CD ) .SO '
protons); 3.5-4.1(4H,m,-CH2-CH2-); 2.8-2,9 
9 /CH 
(6H,d,)N( ^) ppm.
Mass Spec. 200 m/e.




10.9 Michael reaction of 4-(2-dimethylaminoethyl)quinazoline(424).with 
2-methylcyclonentane-l.3-dione
The Mannich base hydrochloride(424) (l.Og) and 2-methylcyclo- 
pentane-1,3-dione (0U5g) were added to t-butylalcohol (freshly 
distilled, 20 ml) containing potassium (0.2g). The grey suspension 
was heated under reflux for 24 h., under a steady stream of nitrogen. 
The resulting blue solution was carefully poured into water (40 ml), 
then extracted with chloroform (100 ml). The chloroform extract
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was washed with water (2x10 ml), dried over anhydrous magnesium 
sulphate, and the solvent removed under reduced pressure to afford 
a brown oily solid. The product was then extracted with boiling 
petroleum ether (b.p. 60-80°). After removal of solvent under 
reduced pressure, an impure yellow solid was obtained in very low 
yield. Recrystallization from acetone, ethanol, etc. was not 
successful.
V 1,710; 1,685 cm'l.
®^( Nujol)
Mass Spec. 268(M'*‘); 253 m/e.
10.10 Michael addition of methyl vinyl ketone to the diester(421)
Tb a solution of 4-(g ,g-diethoxycarbonyl)raethylquinazoline(421)
(1.05g) in anhydrous ethanol (30 ml), freshly prepared sodium ethoxide
I sodium (O.lg) in ethanol (1 ml)j was added at 0°, under an
atmosphere of nitrogen. After stirring the pale yellow solution 
ofor 0.5 h. at O , methyl vinyl ketone (l.Og) was added and the
oresulting yellow-green solution stirred for a further 0.5 h, at O .
The temperature was then raised to 25° and stirring continued under 
an atmosphere of nitrogen for ca. 24 h. (Reaction was allowed to 
proceed at 25° until complete loss of starting material was observed, 
by withdrawing small aliquots of the mother liquor and examining by 
thin layer chromatography.) After the addition of water (5 ml) to 
the reaction mixture, the solvents (ethanol/water) were removed under 
reduced pressure at 50°. The product was extracted into diethyl 
ether from the resulting dark yellow oil, washed with water, dried 
(magnesium sulphate), and finally the ether removed under reduced
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pressure to afford a yellow oily solid (0.28g). The product (427)
could not be crystallized satisfactorily.
nmr 6 6.8-8.1 (5H,m,aromatic protons); 3.5-3.9(4H,q,2x-CDClg
C H g - C H g ) ;  2 . 1 - 2 . 3 ( 3 H , C H 3 * C O ) ;  1 . 5 - 1 . 9 ( 4 H , m , - C H ^ - C H ^ - );
1.0-1.4(6H,t,2x-CH3); 4.0-4.4(broad,water?); 2.3-3.0 
(broad, soIvent?) ppm.
Mass Spec. 358(M^); 343; 298 m/e.
10.11 N-Methylation of 4-(0t-ethoxvcarbonyl)methvlquinazollne(420)
Methyl iodide (10 ml, large excess) was added dropwise to a 
solution of the ester(420) (O.lOOg) in acetone (15 ml) at 0°. The
resulting lemon-coloured solution was stirred at 25° for 48 h. 
(Reaction followed by Tic until loss of starting material observed.) 
The excess methyl iodide was removed under reduced pressure. Diethyl 
ether (3 ml) was added to the cream suspension thus obtained*, cooling 
of which at 0° for 2 h. afforded a pale-yellow precipitate. The 
precipitate was isolated by filtration, washed sparingly with cold 
water, then dried, to give the N-methylated product(428). Recryst­
allization from acetone/ethanol furnished almost colourless needles 
(0.092g, 87%), m.p. 168-170°.
1,660(>C=0); 1,635; 1,620; 1,510; 1,360;
(liquid paraffin) ,1,320 cm-1.
nmr /(CD) -SO 8.98(lH,s,C2-H); 7.58-8.10(4H,m,aromatic
protons); 6.10(111, s,=CH-); 4.3( 2H, q,-CH2-) ;
3.95(3H,S,>N-CH3); 1.3(3H,t,-CH3) ppm.
Mass Spec. 230(M^) m/e.
Elemental Analysis;- ^13^14^302 requires C,67.8%; H,6.1%; N,12.2%
found C,67.9%; H,6.1%; N,12.3%.
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10.12 N-Benzoylation of 4-(g-et,hoxvcarbonvl)Tnethvlq;jinaLZOlineC420)
Tb a suspension of 4-(g-ethoxycarbonyl)raethylquinazoline(420) 
(0.500g, 1 equivalent) in sodium-dried benzene (20 ml), benzoyl 
chloride (0.33g, 1 equivalent) and freshly distilled triethylamine 
(0.53g, 2 equivalents) were added at 0°. The resulting yellow 
emulsion was stirred at 25° for ca. 24 h. (Reaction followed by 
Tic until loss of starting material(420) observed.) Solvent 
(benzene) and excess^triethylamine were removed under reduced 
pressure < 50°, to afford a yellow solid. The product was 
extracted into diethyl ether, washed with water, dried over 
anhydrous magnesium sulphate, and finally, removal of the solvent 
(diethyl ether) under reduced pressure gave a brown oily solid.
The solid was washed with benzene, then crystallized from diethyl 
ether to furnish a yellow-green microcrystalline product(429), 
(0.42g, 57%), m.p. 100-105°.
1,700()C=0); 1,620 cm'l.
"^(liquid paraffin)
nmr 6 8.1(lH,s,C«-H); 7.3-7.8(9H,m,aromaticCDCI3 » » 2 - » » *
protons); 5.92(IH,s,=CH-); 4 .2(2H,q,-CH^-);
1.35(3H,t,-CHg) ppm.
[also 3.2(q,-CH„-) and 1.4(t,-CH_) ppm. 
due to impurity - (C2H3)3*N«HC1 . ]
Mass Spec. (338), 320(M^) m/e.
Elemental Analysis:- ^19^16^2^3*^2° requires C,67.5%; H,5.3%: N,8.3%
found C,67.8%; H,5.4%; N,8.2%,
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10.13 N-Acetvlation of 4-ethoxvquinazoline(422)
lb a solution of 4-ethoxyquinazoline(422)(0.500g, 1 equiv.) 
in sodium-dried benzene (20 ml), acetyl chloride (0.23g, 1 equiv.) 
in sodium-dried benzene (5 ml) was added dropwise at 0° under an 
inert atmosphere of nitrogen. The resulting mixture was stirred 
for 72 h. at 25°. (Complete loss of starting material(422) was not 
achieved, as observed by Tic.) Reaction mixture was heated under 
reflux for a further 12 h., after which solvent (benzene) was 
removed under reduced pressure to afford a yellow-green impure 
solid (0,41g), m.p. 50-56°, containing the required product(430) 
and some starting material(422). Purification of product (430) 
by recrystallization from aqueous ethanol or diethyl ether was 
unsuccessful.
nmr ^ 8.7( IH, SjCo-H) ; 7,3-81(4H,m,aromaticCDC1_/(CD_)_.S0 t f z - .
protons); 4.5(2H,q,-CH2-> ; 2.05(3H,s, 
-CO'CHg); 1.4(3H,t,-CH3) ppm.
(m *)
Mass Spec. 217; 174 m/e.
K
10.14 N-Benzoylation of 4-(&.a-diethoxvcarbonyl)methvlquinazoline(421)
To a suspension of the diester(421) (0.5(X)g) in sodium-dried 
benzene (20 ml), benzoyl chloride (0.25g) in benzene (10 ml) and 
triethylamine (0 ,2g) were added dropwise at 0° under cin atmosphere 
of nitrogen. After stirring the mixture at 25° for ca. 18 h. 
(until complete loss of starting material(421) was observed with
Q  oTic), the white precipitate ((C2H^)g.N.HCl) which had resulted was 
removed by filtration. The yellow filtrate was carefully washed 
with water, dried over anhydrous magnesium sulphate and finally,
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removal of the solvent (benzene) under reduced pressure afforded 
a pale-yellow solid, (0.52g), m.p. 76-79° which was found to be 
the required product (435) contaminated with impurities (benzoic 
acid and triethylamine hydrochloride).
V 1,730(^C=0); 1,710()C=0); 1,680(>C=0) cm’ .̂
(liquid paraffin)
nmr 8.5(IH,s,C2”H) ; 7.4-8.2(9H,m,aromatic
protons); 4.2-4.5(2H,q,-CH2-); 3.9-4.2(2H, 
q,-CH2-); 1.2-1.4(3H, t ,-€113) ; 0.8-1.0(3H, 
t,-CH3) ppm.
Mass Spec. 392(M‘‘), 226, 198 m/e.
10.15 Preparation of Starting Materials
10.15.1 Pyrrolidine enamine(437) of cyclopentanone
A mixture of freshly distilled cyclopenteinone (8.4g, 1 equiv.)
and pyrrolidine (14.2g, 2 equiv.) in sodium-dried benzene (100 ml)
was boiled in a flask fitted with a Dean and Stark separator until
the calculated amount of water was azeotropically removed (ca. 5 h).
Removal of solvent from the resulting dark red solution under
reduced pressure, followed by distillation under nitrogen, furnished
a colourless liquid(437) (9.8g, 72% based on cyclopentanone), b.p. 40°
at 1 mm Hg P.
1H nmr 3.95(lH,-s,C7-H) ; 2.85-3.15(4H,m,C2^5-H*s) ;
2.15-2.55(4H,m,Cg ^g-H's); 1.50-2.00(6H,m, 
C3,4,9-2's) ppm.
Mass Spec. 137(M"^) m/e.
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10.15.2 2-HydroxYmethylenecvclopentcinone(438)^^^*
513Above was prepared as described in literature, in 16% yield, 
m.p. 74-76°.
V 3,700(-0H); 1,740(>C=0); 1,670()C=0) cm"^.
™^*KBr disc
nmr 6 5.10(lH,s,=CH-0H); 4.05(1H,broad,-OH); 1.8-3.0
3 2* (6H,m,C3 4̂ 5̂-H’s) ppm.
Mass Spec. 112(M^) m/e.
10.15.3 n-ButvllithiumP^^
515Prepared as described in literature ̂  and stored under 
nitrogen*
10.15.4 Triphenylmethvlphosphonium iodidetCC^HgJg.P.CHg] I®
Preparation of above similar to that described in liteiu^ure 
for the bromide.
(yield 82%, m.p. 167-169°)
Mass Spec. 277, 199 m/e.
10.16 Wittig reaction of 4-chloroquinazoline(417)
To a suspension of triphenylmethylphosphonium bromide (7.16g, 
20 mM) in anhydrous 1,2-dimethoxyethane (distilled from lithium 
aluminium hydride) (20 ml), under nitrogen, n-butyllithium (1.28g,
20 mM) in hexane was added at -65°. After allowing the pale 
yellow emulsion to stir at -65° for 2 h., 4-chloroquinazoline 
(1.64, 10 mM) dissolved in anhydrous,1,2-dimethoxyethane (5 ml), 
was added dropwise. The resulting mixture was stirred at -65° for 
3 h. then at 25° for 12 h. under an atmosphere of nitrogen.
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The quinazoline ylid thus formed, was ”worked-up” in situ. 
via three different procedures to obtain the various quinazoline 
derivatives:-
10.16.1 Hydrolysis of vlid to obtain 4-methvlquinazoline(423)
After the addition of a solution of sodium carbonate (2.12g,
20 mM) in water (5 ml) to the ylid (10 mM), the mixture was heated 
under reflux for 2 h., cooled, then extracted with diethyl ether.
The ether extract was washed with water, dried over anhydrous 
magnesium sulphate and finally, removal of solvent (diethyl ether) 
under reduced pressure gave a brown oil. Distillation of the crude 
*oily* product under reduced pressure (0.1 mm Hg) afforded an 
analytically pure product (423), 4-methylquinazoline (0.93g, 65%), 
m.p. 36°-37°. [See Ex. 10.7 for analytical data.]
10.16.2 Reaction of ylid with acetone to obtain 4-(2-methyl-1-propenvl) 
quinazoline(439)
lb the ylid (10 mM) under an atmosphere of nitrogen, freshly 
distilled anhydrous acetone* (2.3g, 40 mM) in 1,2-dimethoxyethane 
(10 ml) was added dropwise at 0°. The resulting mixture was stirred 
for 24 h. at 25° under an atmosphere of nitrogen. After removal of 
the solvent (1,2-dimethoxyethane) and excess reagent (acetone) under 
reduced pressure, the product was extracted with hot diethyl ether. 
The combined ether extracts were dried (anhydrous magnesium sulphate), 
. Removal of solvent under reduced pressure afforded a brown solid, 
treatment of which with excess mercuric chloride in aqueous ethanol 
(25%) resulted in precipitation of a bright yellow mercuric chloride 
salt of the product. The salt was isolated by filtration, washed
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carefully with aqueous ethanol and finally, the product was freed 
by treating the salt with hydrogen sulphide followed by sodium 
carbonate in aqueous ethanol (10%). The mixture was filtered 
through a *Celite* bed to give a yellow filtrate, removal of 
solvents from which, under reduced pressure afforded a pale 
yellow solid (0.61g) m.p. 48-52°, Attempts to purify product 
(439) by recrystallization from aqueous ethanol or acetone/ether 
were unsuccessful. Distillation under reduced pressure resulted 
in decomposition of product.
V 1,670; 1,620; 1,570; 1,495 cm"^.
"*^(KBr disc)
nmr <5^^^ 8.8(lH,s,C2-H); 7.4-8.4(4H,m,aromatic protons);
6.2(lH,m,olefinic proton); 2.l(3H,m,-CH3);
1.9C3H,s,-CHg) ppm.
Mass Spec. 184(M^) m/e.
10.16.3 Reaction of ylid with benzaldehyde to obtain 4-styrylquinazoline(440) 
Procedure for Ex.10.16.2 was repeated, but freshly distilled, 
anhydrous benzaldehyde* (4.2g, 40 mM) in 1,2-dimethoxyethane (10 ml) 
was added in place of acetone* to the ylid.
Finally, a yellow solid was obtained, recrystallization of 
which from diethyl ether/ethanol afforded almost colourless crystals 
of product (440), (0.27g, 12%) m.p. 97-99° (lit.^^® 94-95°).
(Also see Ex. 10.19.
^"^( liquid paraf fin) 1,635, 1,610; 1,540 cm
nmr 8.8(IH,s,C2-H); 7.3-8.4(llH,m,9 aromatic
protons and 2 olefinie protons) ppm.
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M c L S S  Spec, 232(M^).
Elemental Analysis:- requires C,82.7; H,5.2; N,12.0%
found C,82.9; H,5.1; N,12.1%
10 .17 Attempted reduction of 4-(a-ethoxvcarbonvl)methvlquinazoline(420) 
and 4-(g.a-diethoxycarbonvl)methvlquinazoline(421)
10 .17.1 With sodium borohvdride(NaBH^)
To the raonoester(420) (l.Og) or the diester(421) (l.Og) dissolved.
in aqueous ethanol (80%) (20 ml), an excess of NaBH^ (2g) was added
slowly at 0°. The resulting mixture was stirred at 25° and the
reaction followed by UV spectroscopy until no further change was
observed (ca. 6 hJ. Sodium hydroxide (5 ml, 5M) and hydrogen
peroxide (5 ml, 50%) were carefully added to the reaction mixture 
oat O . Stirring of the mixture was continued for a further 4 h. at 
25° to effect decomposition of the borate complex. After the 
addition of sodium chloride (5g) to the yellow emulsion, the product 
was extracted with chloroform. The chloroform extract was washed 
with water, dried (anhydrous magnesium sulphate), and finally, 
removal of solvent (chloroform) under reduced pressure gave a yellow 
solid which was found to be a mixture of several products, none of 
which were the required products (441) or (442). Attempts to 
separate the components of the mixture by column (neutral alumina) 
chromatography led to decomposition of product(s). The crude 
mixtures were therefore discarded.
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10.17.2 Catalysed hydrogenations
10.17.2.1 At atmospheric pressure
10.17.2.1.1
The monoester(420) (2.0g) dissolved in absolute ethanol 
(50 ml) was added to Adam’s catalyst (PtOg) (0.2g). After the 
removal of air, hydrogen was introduced into the reaction vessel 
connected to a gas burette (so that hydrogen uptake by starting 
material [420] could be quantitatively measured). The mixture 
was stirred at 25° for 72 h. Filtration of the black suspension 
through a ’Celite’ bed (3 cm depth), followed by removal of solvent 
(ethanol) from the filtrate under reduced pressure, resulted in 
recovery of starting material(420). No reduction had occurred.
10.17.2.1.2
Ex. 10.17.2.1.1 was repeated, but palladium/charcoal (10%) 
(0 .2g) was employed in place of platinum dioxide as catalyst.
Again, starting material(420) was recovered; no reduction had taken 
place.
10.17.2*2 At a pressure of 6 atmospheres
10.17.2.2.1
A solution of the monoester(420) (l.Og) in absolute ethanol 
(30 ml) was added to Adam's catalyst (O.lg)* contained in a 
stainless steel flask. The flask was fitted to the hydrogenation 
apparatus. After removal of air, hydrogen was introduced into the 
flask and the pressure increased to 6 atmospheres. The flask was
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then shaken at 25° for 24 h, at this pressure. The resulting 
black suspension was filtered through a 'Celite* bed (2.5 cm depth) 
After removal of solvent (ethanol) from the yellow filtrate, the 
pale yellow solid (0.94g) obtained, was found to be a mixture of 
starting material(420) and the required product(441). Isolation 
and purification of the reduced product(441) by recrystallization 
from aqueous ethanol and ether/ethanol was unsuccessful.
V 3,450(>N-H); 1,735()C=0); 1,660 cm"^.
"^(Nujol)
Mass Spec. 218(M‘*‘), 216(M^) m/e.
10.17.2.2.2
A solution of the diester(421) (l.Og) in absolute ethanol
(30 ml) was added to Adam's catalyst (0.15g) and the procedure*
+described for Ex. 10.17.2.2.1 followed. After removal of
solvent (ethanol) from the yellow filtrate, the solid obtained was
recrystallized from ether/ethanol to afford almost colourless
crystals of the reduced prodUct(442), (0.89g, 88%), m.p. 59-62°.
V 3,500(>NH); 1,725()C=0); 1,665 cm"^.
“^(Nujol)
nmr 6 6.7-8.0(5H,m,aromatic protons); 4.6-4.9(lH,CDCI3 ' -
broad,)m); 4 .0-4.4(5H,m,2x-CH2 'CH3 and -CH-NO; 
3.5-3.8(lH,m,CH<); 1.1-1.4(6H,t,2x-CH3) ppm.
Mass Spec. 290(M'*'), 288 m/e.
1 0 . 1 8  4 - A m i n o q u i n a z o l i n e ( 4 4 3 ) 5 2 0
A mixture of 4-hydroxyquinazoline (2.92g, 20 mM) and phenyl 
phosphorodiamidate (4.30g, 25 mM) was heated to 230-240° in an oil
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bath and the temperature maintained for 1.5 h. After cooling, the 
fused melt was crushed then added to n-butylamine (200 ml). The 
resulting suspension was heated under reflux for 3 h. The 
insoluble yellow/green residue was filtered off cind discarded.
Treatment of the brown filtrate with decolourizing charcoal, 
followed by removal of solvent (n-butylamine) under reduced pressure 
afforded a yellow oil, crystallization of which from n-butylamine 
furnished pale yellow needles of 4-aminoquinazoline(443), (1.98g, 68%), 
m.p. 267-269° (lit.519 267-268°).
V 3,360(NH); 1,635(CN); 1,590; 1,560 cm"^.
“"(Nujol)
nmr 6. . 7.2-8.5(5H,m,aromatic protons); 4.6-6.0(2H,
3 2 * broad,-Ngg) ppm.
Mass Spec. 145(M""') m/e.
10.19 Condensation reactions with benzaldehyde
10.19.1 Reaction of 4-aminoquinazoline(443) with benzaldehyde
To a stirred suspension of 4-ciminoquinazoline (0.73g, 5 mM) in 
sodium-dried, freshly distilled benzene (30 ml), freshly distilled 
benzaldehyde (2.1g, 20 mM) was added.* The mixture was boiled in 
a flask fitted with a Dean and Stark separator for 18 h. After 
removal of solvent (benzene) under reduced pressure, the product 
was extracted with chloroform. The chloroform extract was washed 
with a cold saturated aqueous solution of sodium bisulphite, then 
with water and finally, dried with anhydrous magnesium sulphatet 
Removal of solvent (chloroform) under reduced pressure afforded a 
pale yellow solid, recrystallization of which from aqueous ethanol.
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furnished an almcst colourless microcrystalline productC444),
(0.13g, 11%), m.p. 195-198°.
V 1,685; 1,640; 1,585 cm .
® ^ K C 1 disc
nmr 8.52 (IH,S,aromatic proton); 7.2-8.2(10H,
m,9 aromatic protons and 1 olefinie proton) ppm.
Mass Spec. 233(M^) m/e.
Elemental Analysis:- requires C,77.3; H,4.7; N,18.0%
found C,77.6; H,4.6; N,17.9%.
10.19.2 Reaction of 4-methylquinazoline(423) with benzaldehyde
Freshly distilled benzaldehyde (2.1g, 20 mM) was added to a 
stirred emulsion of 4-methylquinazoline (0.72g, 5 mM) in sodium- 
dried benzene (20 ml), ajid the procedure described for 10.19.1 
♦repeated^.
After removal of solvent (chloroform) under reduced pressure, 
the yellow 'oily' solid obtained was crystallized from petroleum 
ether (b.p, 40-60*) to afford pale green crystals of product, 
4-styrylquinazoline(440), (0.34g, 29%), m.p. 96-98° (lit.^l® 94-95°) 
Mass Spec. 232(M^) m/e.
(Analytical data similar to that given for Ex. 10.16.3J
10.20 Attempted Diels-Alder reactions 
General procedure
To a solution or suspension of the diene(440) (4-styrylquin- 
azoline) or (444) (4-cizastyrylquinazoline) (10 mM) in acetonitrile 
(30 ml), the dienophile (maleic anhydride or N-phenylmaleimide)
(30 mM) was added. The reaction mixture was heated under reflux
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for 24-72 h. (until loss of starting material [440] or [444] was 
observed by Tic, elution solvent I). After removal of solvent 
(acetonitrile). under reduced pressure, the crude reaction mixture 
was examined by proton magnetic resonance spectroscopy and mass 
spectrometry.
10.20.1 Reaction of 4-stvrvlquinazoline with maleic anhydride
10.20.2 Reaction of 4-azastyrylquinazoline with N-phenylmaleimide
10.20.3 Reaction of 4-azastyrylquinazoline with maleic anhydride
Preliminary investigations suggest that complete loss of 
starting material (440) or (444) does not sometimes occur, even 
after a reaction time of 72 h. However some adduct formation 
may be occurring, together with several decomposition products. 
Mass Spec. Reaction 10.20.3 360; 331(M+); 197 m/e.
Reaction 10.20,2 422; 406(M^) m/e.
Reaction 10.20.1 330(M+); 252 m/e.
Analytical data - inconclusive.
10.21 Attempted reaction of 4-acetylenoquinazoline(451) with maleic
anhydride to obtain adduct(452)
A solution of dried 4-chloroquinazoline (3.28g, 20 mM) in 
freshly distilled, anhydrous dimethylsulphoxide (10 ml) was added 
dropwise to a suspension of lithium acetylide ethylenediamine 
complex (2.76g, 30 mM) in dimethylsulphoxide (5 ml) at -30°, 
under an atmosphere of nitrogen. The resulting black suspension
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was stirred at 0° for 2 h., then stirring continued at 25° for 
a further 0.5 h. under nitrogen. After the dropwise addition 
of water (10 ml), the product was extracted with chloroform.
The yellow chloroform extract was dried (anhydrous magnesium 
sulphate).
V 3,300(C5C); 1,655; 1,625; 1,600 cm"^.
™^(neat film)
After reducing the solvent to low volume (under reduced pressure), 
maleic anhydride (3.92g, 40 mM) was added to the yellow solution. 
The resulting mixture was heated under reflux for 12 h. Removal 
of solvent under reduced pressure furnished a brown 'oily* solid, 
which was crystallized from petroleum ether (b.p. 40-60°) to give 
an impure product (0.87g), m.p. 66-87°. Further attempts to 
purify the product by recrystallization were unsuccessful.
O2,500(=NH?); 1,760(>C=0); 1,700()C=0);
™^(neat film) ^1,635(CN) cm"^.
Mass Spec. 252; 247; 206 m/e.
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PART III EXPERIMENTAL (CONTINUED)
C H A P T E R  E L E V E N  
AZASTEROIDS FROM BENZO [f]QUINAZOLINES
11.1 1.4-Dlhydroxynaphthalene(455)
Crude 1,4-naphthaquinone (33g) was stirred with water (30 ml)
and sodium hydrosulphite (67.5g). The suspension was diluted to
2.25 & with hot water and then heated under reflux for 3 h. with
addition of decolourizing charcoal. Filtration of the hot solution
followed by cooling of the filtrate, furnished yellow crystals which
were washed with sodium, hydrosulphite (10% aqueous solution) and
finally, dried in a vacuum in the absence of light.
Recrystallization of product from aqueous ethanol (50%) afforded
colourless crystals, (17g, 50%), m.p. 175-176° (lit.5^1 176°).
(Tic. on silica: solvent C elution; R^ = 0.61»)
V 3,200(-0H); 1,6250C=CC); 1,580 cm"^.
“^(Nujol)
nmr  ̂ 8.25(2H,s,2x-0H)(2H,q,aromatic protons);
^ 7.45(2H,q,aromatic protons); 6.79(2H,q,
aromatic protons) ppm.
Mass Spec. 160(M'*') m/e.
11.2 1.4-Dimethoxynaphthalene(456)
Dimethyisulphate (15 ml) was added in methanol (15 ml) to a 
solution of 1,4-dihydroxynaphthalene (6g) in methanol (45 ml) 
under nitrogen. Potassium hydroxide (18g) in water (45 ml) was 
then added dropwise over 1 h., under an atmosphere of nitrogen.
The mixture containing colourless crystals was allowed to stand 
for 24 h. The crystalline solid was isolated by filtration, 
washed with aqueous methanol (30%), then recrystallized from
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methanol to furnish colourless needles (6,5g, 95%), m.p. 86-87°
(lit.^^^ 86*). (Tic on silica: solvent A elution, = 0.81).
V  1 , 6 2 5 ;  1 , 5 8 0  c m " ^ .
"^(Nujol)
nmr “(003)2 »C0 8.18(2H,q,aromatic protons); 7.50(2H,q,
aromatic protons); 6.80(2H,s,aromatic protons); 
3.95(6H,s,2x-CH3) ppm.
Mass Spec. 188(M^) m/e.
11.3 2-Chloromethvl-l.4-dimethoxynaphthalene(457)
1,4-Dimethoxynaphthalene was dissolved in a warm solution of
monochloromethylether (6.6 ml) in glacial acetic acid (16.6 ml).
After stirring the solution at 25° for 20 h., water (10 ml) was
added and the product extracted with benzene. The benzene extract
was washed with sodium carbonate solution ( 10%,aqueous ̂ 3x20 ml),
then with water (2x40 ml) followed by saturated sodium chloride
solution (Ix). After drying (anhydrous magnesium sulphate),
solvent (benzene) was removed under reduced pressure and the
brown residue distilled under re.JlucAjcL . The yellow
crystalline distillate, recrystallized from petroleum ether 
o(b.p. 40-60 ) furnished pale-yellow crystals (4c2g, 56%);
m.p. 63-64 (lit.^ 62-63°). (Tic on silica: solvent A elution,
R^ = 0.78J
''"-(Nujol) l.eOOOCaCO
nmr  ̂ 8.15(2H,q,aromatic protons); 7.55(2H,q,aromatic
^ ^ protons); 6.91(lH,s,aromatic proton); 4.89(2H,s,
Sf-CHg'Cl); 3,95(6H,s,2x-CH^) ppm.
Mass Spec. 237(M*^) m/e.
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11.4 1.4-Dimethoxv-2-naphthaldehvde(458)
To a solution of hexamine (5.5g) in chloroform (35 ml), 
2-chloromethyl-l,4-dimethoxynaphthalene (7.5g) was added. The 
mixture was heated under reflux on a steam bath for 4 h. during 
which time a precipitate separated out. The reflux condenser 
was replaced by a condenser set for distillation and heating 
continued until solvent (17.5 ml) had distilled over. After the 
addition of acetone (17.5 ml), the mixture was cooled in an ice- 
bath. The precipitate was isolated by filtration, then dried 
in air to yield salt, m.p. 193°.
nmr 8.25(lH,q,-CH-N^); 7.9(lH,q,aromatic proton);
7,60(2H,q,aromatic protons); 7.40(lH,s,aromatic 
proton); 7.28(lH,s,aromatic proton); 4.72(6H, 
s , 2 x - C H 3 ) ;  4.09(3H,s,-0.CH3); 3 . 9 8 ( 3 H , s , - O . C H 3 )  
ppm.
The salt was heated under reflux for 1 h. with acetic acid 
(50 ml, 50% aqueous solution). Water (50 ml) and concentrated 
hydrochloric acid (12.5 ml) were added, then boiling continued for 
a further 0.2 h. Cooling of mixture in an ice-bath furnished pale- 
yellow crystals of the aldehyde (4.2g, 61%), m.p. 117-118°. 
Recrystallization from aqueous ethanol (J0'7<,) gave almost colourless 
needles, m.p. 117° (lit,5^4 117°).526
(Tic on silica: solvent A elution, R^ = 0.62J
V 1,680(:C=0); 1,590 cm"^.
“^(Nujol)
H nmr 5 10.80(IH,s,-CHO); 8.25(2H,q,aromatic protons);CDCI3
7.60(2H,q,aromatic protons); 7.15(lH,s,aromatic 
proton); 4.15(3H,s,-OCÜ3); 4.05(3H,s,-0CH3) ppm. 
Mass Spec. 216(M^) m/e.
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Elemental Analysis:- ^13^12^3 f^^uires C ,72.2%; H,5.5%
found C,72.3%; H,5.5%.
11.5 1-Hydroxy.4-methoxy.2-naphthaldehyde(459)
l,4-Dimethoxy-2-naphthaldehyde (5.7g) in anhydrous dichloro- 
methane (20 ml), and boron trichloride (114 ml, 5 equivalents) in 
dichloromethane, were mixed at -70° and the fladcwas stoppered.
The intense red coloured solution was stirred at 25° for 2.5 h. 
(Reaction was followed by Tic until loss of starting material(458) 
was observed.) Water (100 ml) was added suid stirring continued 
for a further 12 h. at 25°. The product was extracted with 
dichloromethane, washed with water (2x20 ml), dried with anhydrous 
magnesium sulphate, and finally, removal of solvent under reduced 
pressure furnished pale-green crystals of 1-hydroxy,4-methoxy,
2-naphthaldehyde (5.Ig, 96%), m.p. 85-86°. The product was 
recrystallized from aqueous ethanol. (Tie on silica: solvent A 
elution, R^ = 0.58.)
3,400(-0H); 1,650()C=0) cm”^.
*’™^(Nujol)
^H nmr 6 10.98(lH,s,-CH0); 9.88(lH,s,-0H); 8.40CÜCI3
(lH,d,aromatic proton); 8.20(2H,d,aromatic 
protons); 7.65(lH,q,aromatic proton); 6.71 
( 1H,S,aromatic proton) 98 ( 5Hf s ,-OCH^ ) 
ppm. ,
Mass Spec. 202(M^) m/e.
Elemental Analysis:- ^12^10^3 requires C,71.3%; H,5.0%
found C,71.1%; H,4.9%.
(See Appendix II for Carbon-13 spectral data)-
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11.6 1.4-Dihvdroxv-2-naphthaldehvde(460)
1,4-Dimethoxy-2-naphthaldehyde (3.8g) in anhydrous dichloro- 
methane (10 ml) was added to a solution of boron trichloride in 
dichloromethane (76 ml, 5 equivalents) at -70°, and the flask was 
stoppered. The intense red coloured solution was stirred at 25° 
for 6 h. Water (60 ml) was added to the mixture, and stirring 
continued for 24 h. ^ product was extracted with dichloromethane, 
dried with anhydrous magnesium sulphate and finally, removal of 
solvent under reduced pressure furnished the required product,
l,4-dihydroxy-2-naphthaldehyde (3.2g, 97%), m.p. 190-192° (lit.^^^ 
190°). (Tic on silica: solvent A elution, = 0.34J 
Recrystallization of product (460) from aqueous ethanol (40%) gave 
yellow needles, m.p. 190-191°.
^**=(Nujol) 3,3 50 (-0H); 1,670()C=0) cm
nmr 6™ ,  12.4(lH,s,-OH); 9.8( IH, s,-OH) ; 10.8(lH,s,XDCI3
-CHO); 8.3(2H,q,aromatic protons); 7.7(2H,q, 
aromatic protons); 7.0(lH,s,£iromatic proton) ppm.
Mass Spec. 188(M^); 160 m/e.
Elemental Analysis:- C^^HgOg requires C,70.2%; H,4.3%
found C,69.6%; H,4.5%
11.7 3-Aminobenzo f f1quinazoline(463)
A mixture of 2-hydroxy-l-naphthaldehyde (6 .88g, 40 mM) and 
guanidine carbonate (10.8g, 60 mM) in n-octanol (20 ml) was heated 
under reflux for 4 h. at 160° (oil-bath), under an atmosphere of 
nitrogen. Benzene (100 ml) was added to the cooled mixture and 
stirring continued for 3 h. The dark red solid was isolated by
256.
filtration, washed several times with cold water and then 
carefully with dichloromethane. Crystallization of the crude 
product from n-butanol (with decolourizing charcoal), followed 
by drying in a oven (110°, 0,05 mm Hg P) afforded pale
yellow crystals of 3-aminobenzo[f]quinazoline(463) (1.94g, 25%), 
m.p. 257-259° (lit.52? 258-259.5°).
3,420()NH); 3,350()NH); 3,100; 1,660; 1,590; 
1,480; 1,330 cm"^“^(KCl disc)
Si nmr 6 9.75(IH,s,C.-aromatic proton); 8.60-8.80(lH,d,(0 0 3 )2 * 8 0
aromatic proton); 7.80-8.20(2H,m,aromatic 
protons); 7.40-7.80(3H,m,aromatic protons); 
7.00(2H,broad,I^2) PP®*
Mass Spec. 195(M^); 179; 168 m/e.
Elemental Analysis:- ^12^9^3 0,73.8%; H,4.6%; N,21.5%
found 0,74.2%; H,4.8%; N,21.8%.
11.8 Reaction of 1-hydroxy.4-methoxy.2-naphthaldehvde(459) with 
guanidine carbonate
Guanidine carbonate (1.08g, 6 mM) was added to a solution of 
1-hydroxy,4-methoxy,2-naphthaldehyde(449) (0.61g, 3 mM) in 
n-octanol (10 ml), under an atmosphere of dry nitrogen. The 
mixture was heated under reflux at 150-160° (oil-bath) for 2 h. 
under nitrogen. After cooling the red emulsion to 25°, benzene 
(10 ml) was added, and stirring continued for 2 h. The yellow 
solid was isolated by filtration, washed several times with cold 
water, recrystallized from ethanol, then dried in a vacuum 
(0.1 mm Hg P) oven at 100° to furnish a yellow-green product(461), 
(0.13g, 19%), m.p. 293-296°.
257
n*r <5̂ 8.8-9,0(lH,m,C.-aromatic proton); 7.2-8.4(0 0 3)2 - 3 0 ^
(5H,m,aromatic protons); 6.7(2H,broad,-N[i2) ;
4.0(3H,s ,-0CH3) pim.
Mass Spec. 225(M^) m/e.
11.9 3-Hvdroxvbenzo [f Iquinazoline (466) from 3-aminobenzo [f Iquinazoline 
via the diazonium intermediate
To a cooled (0°) mixture of 3-aminobenzo [f ]quinazoline (0.20g) 
and hydrochloric acid (5M, 10 ml), sodium nitrite (l.Og, large 
excess) was added portionwise. The resulting cold emulsion was 
added dropwise to an aqueous solution of sulphuric acid (5M, 20 ml). 
After allowing to boil under reflux for 2 h., the mixture was 
basified with aqueous sodium hydroxide solution and then boiled 
vigorously for 0.5 h. without a reflux condenser in order to expel 
any volatile impurities. The white suspension was then neutralized 
by the dropwise addition of hydrochloric acid (2M). The product 
was isolated by filtration, washed several times with cold water, 
then recrystallization from dilute acetic acid (50%) furnished
3-hydroxybenzo[f]quinazoline(466) (0.15g, 75%), m.p. 328-331°
(lit.527 330-332°).
^max^jj 3,500 ; 3,400; 1,680; 1,655; 1,630 cm” .̂
n m r f y gg 10.05(lH,s,-OH); 9.85(lH,s,C^-aromatic proton);
^ 8.7(lH,d,aromatic proton); 7.4-8.3(5H,m,
aromatic protons) ppm.
Mass Spec. 196(M^) m/e.
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11.10 N-Acetylation of 3-aminobenzo[f]quinazoline
To a suspension of 3-aminobenzo[f]quinazoline (0.20g, 1 mM) 
in sodium-dried toluene (20 ml), acetyl chloride (0.24g, 3 mM) in 
toluene (5 ml) was added, under an atmosphere of nitrogen. After 
the dropwise addition of triethylamine (0.3g, 3 mM) in toluene 
(5 ml) at 0° under nitrogen, the resulting mixture was stirred at 
25° for 6 h. then heated under reflux for 3 h, (Reaction followed 
by Tic on silica, solvent H elution; until complete loss of 
starting material [463] observed.) After removal of solvent 
(toluene) under reduced pressure, the product was extracted with 
diethyl ether, washed with water, dried (anhydrous magnesium 
sulphate) and finally, removal of solvent (diethyl ether) under 
reduced pressure furnished a yellow 'oily* solid. Crystallization 
from ether/ethanol afforded a pale-yellow microcrystalline solid 
(467), (O.llg, 45%), m.p. 210-214°.
V_-„ 3,300(-NH); 1,650 ( *>C=0) ; 1,570;
(KCl disc) ,1,520 cm-1.
nmr  ̂ 9.80(lH,s,C^ -aromatic proton); 8.60-8.80
(lH,d,aromatic proton); 7.40-8.40(5H,m, 
aromatic protons); 6.93(lH,s,-NH); 2.35(3H* 
s,-CHg) ppm.
Mass Spec. 237(M**’), 222 m/e.
Elemental Analysis;- C^^H^^NgO requires C,70.9%;H,4.6%; N,17.7%
found C,71.3%;H,4.7%; N,17.6%
11.11 N-Chloroacetylation of 3-aminobenzo[f]quinazoline(463) fo l l o w e d  by 
cvclization of intermediate(468)
To a suspension of 3-aminobenzo [f]quinazoline (0.39g, 2 mM)
in sodium-dried toluene (30 ml), freshly distilled, anhydrous
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pyridine (0.32g, 4 mM) in toluene (5 ml) was added, under an 
atmosphere of nitrogen at 0°. Chloroacetyl chloride (0.9g, 8 mM) 
was then added with a yl syringe over 10 minutes at 0°. The 
reaction mixture was stirred at 0° under nitrogen for 10 minutes, 
then stirring was continued for 2 h. at 25°. After heating the 
yellow suspension under reflux for 6 h. the product was isolated 
by filtration, washed several times with cold water and finally, 
dried in a vacuum oven (0.1 mm Hg P) at 100° to afford a yellow 
microcrystalline product(469) (0.23g, 43%), m.p. 283-285° (with 
darkening at 170°).
""-(liquid paraffin) 1.660(.C=0) cm'l.
^H nmr 6 10.38(IH,s,C.-aromatic proton); 8.60-8.95CFg.COgH » » 1
(2H,m,8Lromatic protons); 7.95-8.35(5H,m,
4 aromatic protons and -I#); 4.60(2H,s,-CH2)
ppm.
Mass Spec. 271; 236(M*) ; 221; 195 m/e.

































































Acetone - dried with anhydrous calcium sulphate or
potassium carbonate
- dried with sodium wire, then distilled. 
Stored over Linde 4X molecular sieve.
- dried with calcium chloride. Distilled 
from phosphorus pentoxide, then passed 
down an alumina column.
- dried with sodium wire, then distilled 
from lithium aluminium hydride.
- dried with sodium, then distilled from 
lithium aluminium hydride.
N,N-Dimethyl formamide - dried with anhydrous magnesium sulphate,
then distilled under reduced pressure.
- dried with calcium hydride, then distilled 
from calcium hydride. Stored over Linde 
4A molecular sieve.
- dried with anhydrous calcium sulphate, 
then distilled. Stored over Linde 4A 
molecular sieve.
- see procedure for Ethanol.
• dried with molecular sieve, then distilled
under reduced pressure through a column 
packed with glass helices.
■ dried with potassium hydroxide,then 
distilled from potassium hydroxide. Stored 
over Linde 4A molecular sieve.
■ dried over calcium hydride, then distilled 
from lithium aluminium hydride after heating 









in the absence of light.
- dried for 36h. with linseed oil, then 
distilled.
- dried with sodium wire, then distilled.
- dried, then distilled from potassium 
hydroxide, stored over molecular sieve.
APPENDIX II
Although Carbon-13 nuclear magnetic resonance (^^C-nmr) spectro­
scopy is an invaluable technique for the study of organic 
compounds , it was not of significant value in this project, 
since many of the compounds concerned were large, complex 
structures. Also, in several cases, poor solubility of the 
nitrogen-containing steroidal molecules in the usual solvents, 
hindered any attenpts to record the spectra. The few ^^C-nmr 
spectra that were recorded, were found to be ambiguous and 
extremely difficult to interpret as standard reference data 
to these compounds was not available (see Plate 6).
^^C-nmr spectra were obtained for the less-complex inter­
mediates involved in this project, the data for some of which 
are given below:-
Intermediate Carbon-13 nmr (ôppm from TMS standard )
CHO
OH
ôcDci 192.97(C-ll,d); 164.70(s),132.73 (s) , 
127.64(s), 124.33(s),(C-l,C-2,C-9,C-10); 





O C H 3
ôcDci 195.68(C-12,d) ; 156.5KC-1 , s) ; 
148.44(C-4,s); 130.24(s), 130.02(s), 
(C-9,C-10); 126.61(C-8,d); 124.17 (C-6, 
C-7,d); 122.11 (C-5,d); 113.17(C-2,s); 
10l.79(C-3,d); 55.53(C-11,q) ppm




133.27(C-7,d); 127.85(C-6,d); 126.77(d), 





142.53(d), 132.84(d), 128.07(d), 124.98(d), 
(C-5,C-6,C-7,C-8); 126.99 (C-lO, s) ;
79.47 (C-ll,t); 59.48(C-13,t);
14.52(C-14,q) ppm
ôcDci 170.32(0-2,0-5,8); 136.30(0-7,8); 
134.14 (0-3,0-4,d); 127.80-128.66 
(0-8,0-9, 0-10,0-11,0-12,m); 41.39 
(0-6,t) ppm
N-CH
6odoi 176.72(0-2,0-5,8); 135.98 (0-7,s); 
127,91-128.88(0-8,0-9,0-10,0-11,0-12, 
m); 42.36 (0-6,t); 28.22(0-3,0-4,t) ppm
- C H 2C H 3
60D01 170.60 (0-2,0-5,8); 134.20(0-3,
0-4,d); 32.72 (0-6,t); 13.81(0-7,q) ppm
6 (od ) .so 174.88(0-2,8); 156.13(0-4,8); 
139.82(0-6,0-6',8); 126.55-128.45 (10 
aromatic carbons, m); 70.37 (0-5,s) ppm
Intermediate Carbon-13 nmr (<Sppm from t mS standard)
c a .0
^cDci 198.54(C-1,s ); 162.47(C-9,s); 
137.22(0-10,s); 126.06-132.52(m), 
125.90(d), (C-3,C-4,C-5,C-6, C-7, 
C-8); 36.73 (C-11, q) ppm
APPENDIX III
A Procedure for Biological Evaluation of Potentially Active Compounds. 
Selection Procedure for Psychotropic Compounds*
Phase O: Toxicity-lethality study
mice : 100 and 320 mg./Kg. 
rats: 46 mg./Kg.




After Phase 1 testing the ccxnpound can be categorised 
in one of the five following possible "profiles":
A. General CNS depressant profile.
Activity in all tests is similarly decreased, 
even if compound is retested at lower doses.
B. "Neuroleptic" profile.
Apomorphine-induced climbing is inhibited at 
dose-levels not interfering with spontaneous 
locomotor behaviour.
C. "Antidepressant" profile.
Muricidal behaviour is depressed at dose-levels 
lower than those affecting spontaneous motor and 
exploratory behaviour.
D. "Anxiolytic" profile.
Spontaneous motor behaviour of mice is depressed 
whereas that of rats is increased. No further effects.
E. Unknown.
The compound either has no effects(El), or has 
a profile not falling into one of the four classes 
mentioned above (E2).
Phase 2: (A): The compound is tested in the "sleeping test" (rats)
(B): 1. Dopamine turnover in selected rat-brain areas.. .
2. Motor coordination
3. Central anticholinergic properties (yawning 
test in rats).
4. Duration of action (time-response curve).
5. Ambulation-exploration (rats).
(C): 1. Shuttle box performance (rats).
2. Swimming test (rats or mice).
3. Uptake of noradrenaline and 5-hydroxytrypfamine 
into rat synaptosomes.
4. Uptake of 5-hydroxytryptamine in human 
(preferably also depressed patient) platelets.
5. MAO inhibition.
6. Anti-appetite.
(D): 1. Anxiety test (rats).
2. Isolation-induced aggression (mice).
3. Stairway-test (rats).
4. GSP conflict test.
(El): 1. High dose in shuttle box performance (to see
whether compound is affecting CNS). If this is 
positive:-
at lower doses: 2. Appetite suppression (rats).
3. Sleeping test (rats).
4. Shuttle box acquisition (rats). 
(E2): All phase 2 tests available.





3. Peripheral and central anticholinergic activity test >
yawning test (rats).
skin resistance test (mice).
4. Motor coordination (rat rotarod).
5. Combined CNS-screen.
6. Peripheral profile.
Phase 4: 1. Haematological profile.
2. Endocrine profile.
3. Brain excitability tests.
4. Alcohol interaction.








*The above details are as obtained from ORGANON LABORATORIES-.
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